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Malignant brain tumors such as glioblastoma multiforme (GBM) and 
oligodendroglial tumors can arise from a subpopulation of cells with stem-like 
properties, commonly called glioma-propagating cells (GPCs). GPCs exhibit 
resistance to conventional therapies, hence are the likely culprits of tumor 
recurrence. These cells are controversial largely because their identity depends 
on the context of animal assays designed to measure the tumor-initiating cell 
frequency. Our study describes the derivation of GPCs from a patient with 
anaplastic oligoastrocytoma, NNI-8. We show that these GPCs displayed 
stem-like characteristics with extensive self-renewal capability, and preserve 
the karyotypic integrity of the primary tumor. Importantly, the glioma 
xenograft phenocopied the patient‟s original tumor histopathology. We 
explored if GPCs derived from these glioma variants can serve as reliable in 
vitro culture systems for studies. We utilized gene expression analyses, since 
GBM and oligodendrogliomas can be molecularly classified. Accordingly, we 
derived a gene signature distinguishing oligodendroglial GPCs from GBM 
GPCs collated from different studies, which was enriched for the Wnt, Notch 
and TGFβ pathways. Using a novel method in glioma biology, the 
Connectivity Map, we mapped the strength of gene signature association with 
patient gene expression profiles in 2 independent glioma databases. Our gene 
signature consistently stratified survival in glioma patients. This data would 
suggest that in vitro low passage GPCs are similarly driven by transcriptomic 
changes that characterize the favorable outcome of oligodendrogliomas over 
GBM. Additionally, the gene signature was associated with the 1p/19q co-
deletion status, the current clinical indicator of chemosensitivity. Our gene 
ix 
 
signature detects molecular heterogeneity in oligodendroglioma patients that 
cannot be accounted for by histology or the 1p/19q status alone, and highlights 
the limitation of morphology-based histological analyses in tumor 
classification, consequently impacting on treatment decisions. Furthermore, 
these findings highlight the clinical contribution of GPCs to disease 
progression and survival outcome; thus linking for the first time, the 
controversial “cancer stem cells” to the primary tumor. 
We identified GSK3β as a possible target of GPCs in a collaborative 
small molecule screen with Eli Lilly. Utilizing a well-known GSK3 inhibitor, 
BIO, together with shGSK3β knockdown, we show that GSK3β maintains 
GPC survival, preferentially in the CD133
+
 population that is frequently 
associated with tumor-initiating potential. Reduced GSK3β triggers apoptosis 
and a reduction in c-Myc oncoprotein, with concomitant differentiation. 
Interestingly, we observed increased proliferation in the CD133
-
 non-tumor 
stem cell population. While GSK3β may be crucial to maintain the tumor-
propagating fraction, these data indicate that tumor cells interact with their 
microenvironment, and one needs to target both cellular fractions for an 
effective therapeutic approach. Our findings thus challenge the “cancer stem 
cell hypothesis” that only the tumor-initiating fraction is relevant for 
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CHAPTER 1 - INTRODUCTION 
1.1 BRAIN TUMORS 
1.1.1 Classification of Gliomas  
 Brain tumors of the astrocytic lineage predominate the spectrum of 
adult malignant central nervous system disorders. Variants such as 
glioblastoma multiforme (GBM) portend poor prognosis despite advanced 
surgical interventions, accompanied by adjuvant radiation therapy and 
chemotherapy
1, 2
. Gliomas are classified according to the World Health 
Organization (WHO) scheme
1, 3
 which is based upon the absence or presence 
of 4 criteria; namely nuclear atypia, mitoses, endothelial cell proliferation, and 
necrosis (Table-1). Importantly, the classification scheme is based on 
morphology which can be subjective. Clinically, tumor grade is a major factor 
influencing the type of therapy administered. The designation of grade III 
describes neoplasms with histological evidence of malignancy, such as nuclear 
atypia and brisk mitotic activity. Grade IV describes cytologically malignant, 
mitotically active and necrosis-prone neoplasms, which are usually associated 
with rapid pre- and postoperative disease progression leading to fatal outcome. 
Extensive infiltration of surrounding tissue also typifies some grade IV 
neoplasms
1
. Among the gliomas of better prognosis are the oligodendroglial 
tumors. These tumors typically respond better to chemotherapies and possess 
genetic indicators such as the 1p/19q co-deletion status which predicts its 
chemosensitivity
4
. Traditional anatomic/pathologic categorization of tumors 
has very limited ability to completely stratify patients into meaningful 




Table-1. WHO grading of glial tumors is based on histology. WHO grading of 
glial tumors into grades I-IV is based upon the presence or absence of 4 criteria; 
namely nuclear atypia, mitoses, endothelial cell proliferation, and necrosis. Adapted 





Type of glial tumor Criteria 
WHO I Pilocytic astrocytoma Low cellularity 
Rosenthal fibres 
May have microvascular proliferation 
WHO II Diffuse astrocytoma Well differentiated neoplastic astrocytic 
cells 
Cellularity moderately increased 
Mitotic activity absent 
No microvascular proliferation or 
necrosis 
WHO III Anaplastic 
astrocytoma 
Distinct nuclei atypia 
Cellularity increased 
Marked mitotic activity 
No microvascular proliferation or 
necrosis 
WHO IV GBM Pleomorphic astrocytic tumor cells, 
marked nuclei atypia 
Cellularity increased 
Brisk mitotic activity 
Microvascular proliferation OR 
necrosis 
 
1.1.2 Molecular Stratification of Gliomas 
 In 2006, the National Cancer Institute, USA, initiated a public effort 
(The Cancer Genome Atlas, TCGA) to collate genomic and clinical data from 
patients of selected cancers
6
. GBM was one of these cancers because of its 
poor prognosis and impact to healthcare. The effort was predicated on 
increasing evidence that showed that the patient's gene expression and genetic 
makeup drive disease progression and consequently survival outcome
7
. 
Indeed, recent work highlighted that GBM tumors, despite being histologically 
3 
 
similar, can be subtyped into 4 molecular classes: Proneural, Classical, Neural 
and Mesenchymal
7
. Each class is distinguished by unique gene expression as 
well as genetic aberrations. Importantly, GBM tumors are driven by mutations 
frequently occurring in the 3 key signaling pathways: p53, retinoblastoma 
(Rb) and Receptor Tyrosine Kinases (RTKs)
6
. These molecular subclasses 
could thus account for the frequently observed inter-patient variability to 
treatment response. Similar molecular heterogeneity has been observed in 
other glioma variants, as well as within oligodendrogliomas
8-10
. These findings 
thus support a patient-tailored approach to designing effective medicines.  
 One of the important implications of TCGA is patient heterogeneity. 
This presents challenges in scientific endeavors, particularly in the lab where 
cellular systems and animal models must reflect the patient's uniqueness. 
These challenges form the basis for our investigations described in this thesis.  
 
1.2 ANIMAL MODELS OF GLIOMA 




1.2.1 Somatic Cell Gene Transfer Models 
Somatic cell gene transfer methods make use of viral vectors to 
transfer genes to a specific subset of somatic cells postnatally. These methods 
utilize the replication competent Moloney Murine Leukemia Virus 
(MMLV)
12
, an avian leukosis virus (ALV)-based replication competent virus 
(RCAS) and its receptor tumor virus-A (tv-a)
13
, and a replication-incompetent 
adenovirus engineered to carry Cre recombinase (Ad-Cre)
14
. Somatic cell 
mouse models involving key genes have been described; the neurofibromin 1 
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(NF1), epidermal growth factor receptor (EGFR) and Platelet-derived growth 
factor receptor (PDGFR) classes
7
. While these models serve as very good 
tools for preclinical studies, they lack the ability to trace the etiology of the 
disease. 
1.2.2 Transgenic Models 
Transgenic models utilize genetic manipulation of signal transduction 
pathways involved in the development of gliomas, through germline genetic 
modification techniques, which recapitulate the mechanism of glioma 
initiation more closely than do transplantation or somatic cell gene transfer 
models targeting generally diverse cell types. Further refinement of disease 
etiology can be derived from gene deletions mediated through cell type-
specific Cre, which allows for characterization of the cell-of-origin alongside 
its differentiated progeny, as has been elegantly shown in intestinal cancers
15
. 
Recent works have highlighted the importance of neural stem cells as the 




, as opposed to 
arising from the more mature progeny such as astrocytes, in contributing to 
GBM formation. In addition, the clever use of color cassettes tracing different 
proliferating progeny upon sporadic induction of mutations in the neural stem 
cell compartment allowed for visualization of the transformation process prior 
to tumor growth
17
, thus challenging for the first time that mutations in 
initiating cells may confer only transformational powers but may not 
eventually be the cells forming the tumor bulk. Transgenic models are 





1.2.3 Orthotopic Transplantation Models 
 One of the important findings of TCGA was the demonstration that 
orthotopic xenograft tumors established from surgical material recapitulated 
the GBM molecular subtypes and patient heterogeneity
7, 18
. Moreover, 
xenograft models have reliably maintained serially-transplanted, human-
derived glioma-propagating cells (GPCs), with preservation of primary tumor 
transcriptomic and karyotypic hallmarks
19
. Although this model cannot 
identify the cell-of-origin, and lacks in providing suitable tumor 
microenvironment interactions and host immune responses, it remains 
important for several reasons: Implantations of GPCs grown under serum-free 
condition form tumors that recapitulate the gene expression, phenotypic and 
karyotypic profiles of their primary tumors
19
, these xenografts are thus 
important “replicas” of human tumors that can be prospectively tested with 
new candidate compounds, yet have retrospective clinical history, gene 
expression, and paraffin tissue blocks for mining prognostic indicators. This is 
an important endeavor as small molecule candidates cannot be currently tested 
in truly treatment-naïve patients, because doctors do not deny the patient the 
standard care of drugs (e.g. temozolomide). The mouse “replicas” will thus 
provide the alternative to testing tumor response to drugs, mirroring as closely 
as possible the biology of the patient‟s original tumor.  
 
1.3 GLIOMA STEM CELLS OR -PROPAGATING CELLS 
In recent years, the distinction between glioma stem cells, glioma-
initiating or –propagating cells has been highlighted. Elegant transgenic 
models have shed light on the role of neural stem cells as the transformational 
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cells in GBM formation, hence their accurate terminology as glioma stem cells 
or -initiating cells
14, 16, 17
. Traditionally, the similar identification of these cells 
in clinical specimens has followed the studies involving first, leukemic stem 
cells
20
 and now several other tumor systems
21-24
; namely, tumor-initiating 
capacity was defined as cells which conferred significant tumor initiation in 
xenografted animals. However, recently, Quintana et al.
25
 challenged the 
definition of the tumor-initiating cell by showing that tumor initiation could be 
altered based on 3 parameters: Addition of matrigel, varying the severity of 
immune-compromised mice depending on strains used, and extending the time 
to formation of the tumor. This study thus demonstrated that the tumor-
initiating capacity is an artifactual consequence of the conditions employed in 
the xenograft model. Despite the lack of ability of in vitro cultured stem cell-
like GPCs to reflect the actual transformational cell in tumorigenesis, these 
cells remain valuable for several reasons: First, they have been shown to retain 
transcriptomic and karyotypic features commonly found in the primary tumor, 
compared to commercially procured serum-grown glioma cells which often 
contain additional genomic aberrations
19, 26
. Second, only GPCs establish 
xenograft tumors that recapitulate the patient‟s original histopathology19. 
Finally, transcriptomic analyses suggest that the stemness properties of GPCs 
and other cancer stem cells are enriched in high grade, malignant tumors, and 
contributes to disease progression and survival outcome
27
. These reasons 
underscore the importance of GPCs as a relevant cellular system to study. The 
terminology of “glioma-propagating cells” has now been assigned to these in 
vitro passaged cells to illustrate their properties in the context of an animal 
model (Fig. 1). 
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Our earlier work described the isolation and characterization of 
patient-derived GPCs
28
. Two important observations were made: (1) 
Histologically similar GBM tumors yielded GPCs with very different 
transcriptomic profiles, suggesting that these underlying differences may 
account for the frequently observed inter-patient variability to treatment 
response. In support, Shats et al.
27
 has shown that a stemness signature derived 
from embryonic stem cells could predict the breast cancer patient cohort 
sensitive to small molecules linked to this signature using the Connectivity 
Map
29
, demonstrating the clinical contribution of cancer stem cells to patient 
outcome; (2) Many investigators have repeatedly derived new GPC lines or 
serially propagated the cells in animals to maintain their lines. What this 
means is that GPCs are constantly treated as reproducible entities, even though 
they're really derived from different patients. In addition, serial propagation in 
animals has been shown to result in a genetic drift towards highly proliferating 
genes
18
. The end result is that the original features of these lines are lost. With 
our novel cryopreservation technique, we have essentially resolved the 
bottleneck in maintaining these cells. That is, we now have a reliable 
repository of different patients‟ lines which can be thawed upon experimental 
needs, and we have characterized them so we know what each patient's 
phenotypic and transcriptomic profiles looks like. This greatly enhances any 
projects that deal with larger patient numbers that addresses the patient 
stratification hypothesis. Collectively, these findings form the foundation of 
our work described here: We have suitable xenograft models that recapitulate 
the patient‟s original histopathology, and we have GPCs which reflect the 




Figure-1. Cancer stem cells (CSCs) are defined by functional characteristics. 
CSCs are defined by their capacity for sustained self-renewal, persistant proliferation 
and tumor initiation/propagation. Some characteristics which are commonly but may 
not be necessarily associated with CSCs are that CSCs constitute only a minority 
population, can be isolated by cell surface markers, and display multipotency upon 
induction of differentiation. Adapted from Rich and Eyler
30
.      
 
1.3.1 Assays to Define Functional Activity of Glioma-Propagating Cells 
 In recent years, several markers have been proposed to represent the 
tumor-initiating or stem cell in brain tumors. These include complementarity 
determinant 133 (CD133)
31





, aldehyde dehydrogenase (ALDH)
33
 and the Side Population (SP)
34, 
35
. Many of these markers are also present on normal cellular counterparts, 
hence do not present the best targeting candidates in any therapeutic strategy. 
Furthermore, markers such as CD133 are debatable as tumors have also been 
shown to arise from CD133-negative cells in a subset of GBM tumors
36, 37
. In 
addition, CD133 expression changes with surface sialylation according to 
disease state and progression
38, 39
, further complicating its definition as a 
marker of bona fide tumor-initiating capacity. Thus, the field of cancer stem 
cells is moving away from heavy reliance on surface markers, to 
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complementing findings by adopting assays which measure the functional 
activities of tumor stem cells. 
 The neurosphere assay is often used to approximate neural stem cell 
frequency in normal biology
40
. Neurospheres are heterogeneous and comprise 
long-term, self-renewing neural stem cells, as well as short-term, transiently-
amplifying progenitors. Thus, sphere frequency is typically scored over 3-4 
generations to measure the activity of bona fide neural stem cells, compared to 
transient progenitors which cease sphere formation typically after 1-2 
generations
41
. This sphere frequency has often been shown to translate to in 
vivo animal survival outcome
2, 42
. Sphere size which is also measured 
represents proliferation. This readout of individual spheres is important 
because it distinguishes proliferation arising from the stem cell population, 
which is masked if general 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)-based viability tests are carried out that 
also measure the proliferation of progenitors. We utilized these functional 
assays to complement our current studies and conclusions. 
 
1.4 GAP IN KNOWLEDGE 
Our effort described here comprises the following: 
1. We derived and characterized GPCs from a high grade oligodendroglial 
tumor. GPCs have routinely been isolated from such tumors, and more 
commonly, from GBM. Our oligodendroglial GPCs, NNI-8, established 
tumor xenografts that were distinct from GBM tumors, and illustrated 
typical features of oligodendroglial tumors. It is tempting to speculate that 
such tumor phenotypes are driven by transcriptomic programs residing in 
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GPCs. By inference, different patients‟ GPCs would be unique 
phenocopies of their primary tumors. If so, such a repository of GPCs 
would be very valuable for recapitulating the tumor profiles of patients 
and be amenable to preclinical drug compound testing. In addition, we 
would also be able to study signaling pathways distinguishing GPC 
subtypes, and therefore possibly targeting more primary tumor subtypes. 
2. We embarked on a small molecule screen to look for candidate 
compounds targeting GPC survival. Several known targets were 
identified, thus validating our screen. Novel targets included glycogen 
synthase kinase 3 (GSK3), which was selected for our subsequent studies 
because of its dual role in cell death and cell fate. 
3. We show that GSK3 regulates GPC maintenance and survival. Depletion 
of GSK3 activity impairs proliferation, triggers apoptosis and reduces 
tumor stem cell frequency. A pro-differentiation response is also 
observed. 
 Collectively, our approach conveys important information that GPCs 
capture the molecular heterogeneity of primary tumor subtypes and can be 
effectively targeted by GSK3 inhibition. We further show the importance of 
a tight balance between cell death and cell fate in maintaining GPCs. 
 
1.5 GSK3 REGULATION AND SIGNALING 
Physiological regulation of GSK3 activity by a number of upstream 
kinases
43-46
 in various physiological and pathological conditions has been 
reported
47
. The activity of GSK3 is controlled by an activating Tyr279/Tyr216 
phosphorylation or an inhibitory Ser21/Ser9 phosphorylation. GSK3 is 
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phosphorylated constitutively and essentially stoichiometrically at a single 
tyrosine residue (Tyr279 in GSK3α and Tyr216 in GSK3β)48, and the 
dephosphorylation of this residue ablates activity in vitro
48
.  Evidence from 
mammalian cells has shown that an intramolecular autophosphorylation event 
may play an important role in stabilizing GSK3
49
.  However, tyrosine 
phosphorylation of GSK3 does not seem to be greatly influenced by 
extracellular signals
49
. Instead, it is now well published that the activity of 
GSK3 is inhibited in response to a variety of agonists resulting from the 
phosphorylation of a single serine residue (Ser21 in GSK3α and Ser9 in 
GSK3β)50, 51. Fig. 2 shows a schematic representation of mammalian GSK3α 
and GSK3β with the tyrosine and serine phosphorylation sites pointed out by 
arrowheads (adapted from Doble and Woodgett
47
). 
 Insulin stimulation of cells results in inactivation of GSK3 through a 
phosphoinositide 3-kinase (PI 3-kinase)-dependent pathway. PI-kinase-
induced activation of protein kinase B (PKB), also known as Akt, results in 
PKB phosphorylation of Ser9 in GSK3β and Ser21 in GSK3α, thereby 
inhibiting GSK3 activity
44
. Inhibition of GSK3 activity results in 
dephosphorylation of substrates such as glycogen synthase and eukaryotic 
protein synthesis initiation factor-2B (eIF-2B), leading to activation of their 
functions, with a subsequent enhanced glycogen and protein synthesis
52
. In 
addition, growth factors like epidermal growth factor (EGF), platelet-derived 
growth factor (PDGF) and brain-derived neurotrophic factor (BDNF) also 
inactivate GSK3 through Ser9/Ser21 phosphorylation. These growth factors 
stimulate the GSK3-inactivating kinase p90 ribosomal S6 kinase (p90RSK) 
(or MAPKAP-K1) through mitogen-activated protein (MAP) kinases, 
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activators of p70 ribosomal S6 kinase (p70S6K), activators of cAMP-activated 
protein kinase (PKA) and PKC activators
47
. Wnt-induced inhibition of GSK3 
also occurs but GSK3 does not become phosphorylated at Ser9 upon induction 
of Wnt signalling. Instead, phosphorylation of proteins in the Wnt pathway 
such as axin, adenomatous polyposis coli (APC) and β-catenin might involve 




 Recent work has demonstrated two possible candidates for kinases that 
might contribute to tyrosine phosphorylation of GSK3, namely the proline-rich 
tyrosine kinase 2 (PYK2), a calcium-sensitive enzyme and the Fyn tyrosine 
kinase
47. GSK3 phosphorylates several transcription factors, such as β-catenin, 
c-Jun, c-Myc, and cyclic AMP response element binding protein (CREB)
53
. 
Upon GSK3 phosphorylation, most of these transcription factors transcription 
factors subsequently undergo proteosomal degradation. Other substrates of 
GSK3 include the microtubule-associated protein Tau, involved in the control 
of neuronal polarization and axon growth, and the pro-apoptotic protein Bax
53
.  
In addition, many proto-oncogenic or tumor suppressing transcription 
and translation factors are substrates of GSK3β. Tumor suppressor 
transcription factor p53 is a substrate of GSK3β where the levels as well as 
intracellular localization of p53 are modulated
54
. Moreover, the activity of 
transcription factors, activator protein 1 (AP-1) and nuclear factor-κB (NF-κB) 
are also directly regulated by GSK3β55-57. These transcription factors possess a 
vital role in neoplastic transformation and tumor formation. An illustration of 
the GSK3 signalling pathway is shown in Fig. 3, while Fig. 4 shows a 
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Figure-2. Schematic representation of GSK3α and GSK3β in mammals. The blue 
arrowheads indicate sites of tyrosine phosphorylation, Tyr279 (GSK3α)/ Tyr216 
(GSK3β), and sites of serine phosphorylation, Ser21 (GSK3α)/ Ser9 (GSK3β). 





Figure-3. An illustration of the GSK3 signalling pathway. GSK3 inhibition 
through Ser21/Ser9 phosphorylation occurs upon insulin, growth factor stimulation or 
via Wnt-induction, leading to the inhibition of phosphorylation of downstream 







Figure-4. Representative GSK3 substrates involved in various cellular functions.  
GSK3 phosphorylates several transcription factors including β-catenin, c-Jun, c-Myc, 
SMAD1, CREB, nuclear factor of activated T cells (NFATc) and neurogenin 2. Upon 
GSK3 phosphorylation, these transcription factors subsequently undergo proteasomal 
degradation. GSK3 phosphorylation also influences proteasomal targeting and 
degradation of other proteins such as cyclin D1 and cyclin E. Microtubule-associated 
proteins, which are also substrates, include adenomatosis polyposis coli (APC), 
CLIP-associated protein 1 (CLASP1) and CLASP2, collapsing response mediator 
protein 2 (CRMP2), microtubule-associated protein 1B (MAP1B) and Tau. Molecules 
involved in signalling, such as phosphatase and tensin homologue (PTEN) and Wnt 
co-receptor low-density lipoprotein receptor-related protein 6 (LRP6), are also 
phosphorylated by GSK3. Other substrates of GSK3 are kinesin light chain (KLC), 
which function to regulate selective transport, and important elements of the 
translational machinery, such as eukaryotic initiation factor 2B (EIF2B) and tuberous 




1.5.1 GSK3 in Tumorigenesis 
 The dysregulation of GSK3β has been associated with tumorigenesis 
and cancer progression. However, it remains controversial as to whether 
GSK3β is a “tumor suppressor” or “tumor promoter”59. In certain types of 
tumors, GSK3β may function as a “tumor suppressor”, but enhances the 
growth and development of yet other kinds of tumors. Reports have shown 
GSK3β to be a negative regulator of skin tumorigenesis. In a study that 
utilizes a mouse epidermal multistage carcinogenesis model, it was shown that 
inactivation of GSK3β takes place during mouse skin carcinogenesis, in that 
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there was a stark elevation in phosphorylation of Ser9 (inactive form of 
GSK3β) and drastic drop in Tyr216 phosphorylation (active form of GSK3β) 
in late papillomas and squamous cell carcinomas
60
. Moreover, a study 
conducted using human skin cancer tissues showed high pGSK3β(Ser9) 
expression in squamous cell carcinoma cells
61
. These and other studies 
indicate that GSK3β plays a role in tumor development during skin 
carcinogenesis, and inactivation or down-regulation of GSK3β would make it 
oncogenic for epidermal cells
62
. 
 The role of GSK3β as a tumor suppressor is also evident in mammary 
tumors. Studies have shown that kinase-inactive GSK3β in mouse mammary 
glands promotes mammary tumorigenesis, mediated by dysregulation of the 
Wnt/β-catenin pathway63. On the other hand, studies have also provided 
evidence of GSK3β as a promoter of tumorigenesis and cancer progression. 
Overexpression of the GSK3β protein has been reported in human ovarian, 
colon and pancreatic carcinomas
57
. It has been shown that in a mouse model of 
hepatic carcinogenesis, elevated levels of GSK3β correlating with positive 
regulation of the proliferation and survival of human ovarian cancer cells both 
in vivo and in vitro are observed
64. In colon cancer cell lines, GSK3β 
expression has also been demonstrated to be elevated, and ablation of GSK3β 
by pharmacological inhibition or RNA interference led to a decrease in 
survival and proliferation of colon cancer cells both in vitro and in vivo
65
. In 
addition, GSK3β inhibition reduces pancreatic cancer cell survival and 
proliferation
66
, and studies conducted in hepatocellular, prostate and 
lymphocytic leukemia cancer cells have also reported that proliferation and 
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survival is enhanced upon GSK3β activation67-70, thereby validating GSK3β 
inhibition as an attractive therapeutic target. 
 Studies have been conducted to implicate the role of GSK3β in GBMs. 
Kotliarova et al.
71
 has shown that GSK3 inhibition reduced glioma cell 
survival and clonogenicity, through the effects of c-Myc, decrease in NFκB, 
and alteration of glucose metabolism, leading to apoptosis and cytotoxicity. In 
addition, Korur et al.
72
 has demonstrated that Bmi1, the polycomb group gene 
needed for neural stem cell self-renewal is highly expressed in GBMs, and 
Bmi1 downregulation led to a concomitant reduction in GSK3β levels, also 
found to be overexpressed in GBMs. GSK3β inhibition further induced tumor 
cell differentiation, apoptosis and reduction in clonogenicity. Many of these 
studies were carried out in commercially procured, serum-grown glioma cells. 
It remains to be investigated if GPCs, the tumor-initiating cells, can be 
effectively targeted by GSK3β inhibition. 
 
1.5.2 Investigating the Role of GSK3β in GPCs 
In collaboration with Eli Lilly, we carried out a small molecule screen 
targeting various oncologic pathways, and discovered GSK3β as a potential 
drug target in our GPCs. Utilizing the GSK3 specific inhibitor BIO as well as 
lentiviral shGSK3β, we observed the effects of GSK3β inhibition on cell 
viability, levels of the apoptotic protein cleaved poly (ADP-ribose) 
polymerase (PARP), oncoprotein c-Myc, as well as the neuronal marker β-
tubulin (TuJ1), to assess for pro-differentiation effects upon GSK3β inhibition. 
The pro-differentiation effect induced by GSK3β inhibition was also validated 
through immunofluorescence analyses. Subsequently, flow-cytometric 
17 
 
analysis revealed a decrease in the levels of the stem cell marker CD133, and 
NFκB, and an increase in PARP. We also utlized the neurosphere assay and 
soft agar assay, and observed an abrogation of self-renewal capability as well 
as in vitro tumorigenic potential. The implication of the GSK3β pathway in 
regulation of GPCs should provide new insights into the generation of 






















CHAPTER 2 - MATERIALS AND METHODS 
 
GPC cell lines from this study, “Gunther”73 and “Pollard”74; gene expression 
data processing and the derivation of the oligodendroglial GPC gene signature 
are described in supplementary methods in the appendix section. 
 
2.1 Tissue Collection and Primary Oligoastrocytoma Neurosphere 
Culture 
Graded brain tumor specimens were obtained with informed consent, as part 
of a study protocol approved by the institutional review board. In this study, 
NNI-8 was from a patient with primary anaplastic oligoastrocytoma who was 
treatment-naive. NNI-1 was from a patient with recurrent GBM (grade IV) 
who had received radiation therapy, and NNI-4, NNI-5, and NNI-11 were 
from patients with primary GBM who were treatment-naive. Tumors were 
processed using methods established in our previous work
28
. Cells were 
seeded at a density of 2,500 cells per cm
2
 in chemically defined serum-free 
selection growth medium consisting of basic fibroblast growth factor (bFGF; 
20 ng/ml; PeproTech, New Jersey), epidermal growth factor (EGF; 20 ng/ml; 
PeproTech), human recombinant leukemia inhibitory factor (LIF; 20 ng/ml; 
Chemicon, Temecula, CA), heparin (5 g/ml; Sigma-Aldrich, St. Louis), and 
serum-free supplement (B27; 1; Gibco, Grand Island, NY) in a 3:1 mix of 
Dulbecco‟s modified Eagle‟s medium (DMEM; Sigma-Aldrich) and Ham‟s F-
12 Nutrient Mixture (F-12; Gibco). The cultures were incubated at 37°C in a 
water-saturated atmosphere containing 5% CO2 and 95% air. To maintain the 
undifferentiated state of neurosphere cultures, growth factors were replenished 
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every 2 days. Differentiation was carried out over 14 days in DMEM/F12 
without growth factors, supplemented with 5% fetal bovine serum (FBS; 
Invitrogen, Carlsbad) and B27. Successful neurosphere cultures (1–2 weeks) 
were expanded by mechanical trituration using a flame-drawn glass Pasteur 
pipette, and cells were reseeded at 100,000 cells per milliliter in fresh medium. 
 
2.2 GSK3 inhibitor Treatment in Vitro   
Compound 14 was kindly provided by Eli Lilly (Indianapolis, IN, USA). The 
small molecule of 6-bromoindirubin-3‟-oxime (BIO), a specific inhibitor of 
glycogen synthesis kinase-3 (GSK-3), was purchased from Calbiochem (San 
Diego, CA, USA). All drugs were dissolved in 100% DMSO and used at the 
concentrations specified in our study. 
 
2.3 Cell Proliferation and Viability Assays 
To assess cellular proliferation rates, cells were harvested and plated into 96-
well plates at 5000 cells per well. Wells containing media only without cells 
were used as a background control. Cytotoxicity assay to measure viability of 
cells after drug treatment was carried out by plating 5000 cells per well into 
96-well plates. Wells containing cells and treated with dimethyl sulfoxide 
(DMSO) (Merck & Co., Whitehouse Station, NY) were used as a control. 
Cells were then incubated in 10% alamarBlue
®
 (Serotec, Oxford, UK) diluted 
in normal culture media for 16 hours before each reading was taken. 
Proliferation rates and cell viability were determined at various timepoints and 
absorbance readings were measured at 570 and 600nm using the Tecan 
microplate reader Sunrise
TM 
(Tecan Trading AG, Switzerland). 
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2.4 Immunofluorescence Analyses 
Neurospheres were dissociated into single cells using Accutase
TM
 
(eBioscience Inc., San Diego; non-trypsin-based) and seeded at a cell density 
of 2 104 cells per well (stemness markers)/ 1 104 cells per well 
(differentiation markers) of laminin-coated (Sigma-Aldrich) eight-well culture 
slides (BD Biosciences, San Diego). Plated cells were fixed with 4% 
paraformaldehyde (Sigma-Aldrich) for 10 minutes, permeabilised with 0.1% 
Triton X-100 (Sigma-Aldrich) for 10 minutes, blocked with 5% FBS for 1 
hour, all at room temperature and stained for the following markers. 
Stemness Markers. The undifferentiated cells (stem state) were stained for 
Nestin (Chemicon), Oct4 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), 
Musashi-1 (Chemicon), and Ki-67 (Chemicon). Incubation with a secondary 
antibody conjugated to Alexa-Fluor-488 or -594 (Molecular Probes, Eugene, 
OR) was carried out. The cells were then counterstained with 4‟6-diamidino-
2-phenylindole (DAPI, 100 mg/ml, Sigma-Aldrich) to visualize the nuclei. 
Differentiation Markers. Induction of differentiation was carried out with 
DMEM/F12 in the absence of growth factors and supplemented with 5% FBS 
and 1 B27. After 14 days, differentiated cells were stained for neurons 
(neuron-specific class III beta-tubulin, TuJ1; Chemicon), astrocytes (glial 
fibrillary acidic protein, GFAP; Dako, Glostrup, Denmark), and 
oligodendrocytes (O4; Chemicon).  
 
2.5 Limiting Dilution Assay and Primary Sphere Formation Assay 
Limiting dilution assay was performed as previously described
75, 76
. After 





 and plated into 96-well plates in 100 μl of GPC medium. Final 
cell dilutions ranged from 100 cells/well to 5 cells/well in 100 μl volumes. 
Growth factors were replenished every 2 days. After 7 days, the percentage of 
wells not containing spheres for each cell plating density was calculated and 
plotted against the number of cells per well. Regression lines were plotted and 
x-intercept values calculated, which represent the number of cells required to 
form at least 1 tumor sphere in every well.  
 
2.6 Secondary Sphere Formation Assays 
Tumor neurospheres were dissociated into single cells by treatment with 
Accutase™. The cells were then dispensed into each well of a 96-well plate at 
30 cells per well. Primary sphere size was scored at day 7 after seeding. To 
carry out serial passaging, the primary spheres were similarly dissociated into 
single cells and then dispensed into each well of a 96-well plate at similar cell 
numbers. Secondary sphere size was scored at day 7 after seeding. This 




2.7 Flow Cytometry 
Neurospheres were dissociated with Accutase™ and blocked with FcR 
blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany). For 
stemness analysis, cells were stained with anti-CD133/2-allophycocyanin 
(Miltenyi Biotec, Bergisch Gladbach, Germany), anti-CD15 (BD Biosciences, 
San Diego), anti-neuroglial chondroitin sulfate proteoglycan 4 (NG2, 
Millipore AB5320, Bedford, MA), anti-Nestin (Chemicon) and detected for 
aldehyde dehydrogenase activity (ALDH, Stem Cell Technologies, 
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Vancouver, Canada) according to the manufacturers‟ instructions. For cleaved 
PARP and NF-κB expression analysis, cells were stained with PE mouse anti-
cleaved PARP (Asp214) (BD Biosciences) and 488 mouse anti-NF-κB p65 
(BD Biosciences) according to the manufacturers‟ instructions and 
subsequently co-stained with anti-CD133/2-allophycocyanin. A total of 
10,000 events were acquired on a FACSCalibur instrument (BD Biosciences). 
Data were plotted using FlowJo software (Tree Star, Ashland, OR). 
 
2.8 Immunohistochemical Staining of Tumor Tissues 
Specimens from the human tumor and from tumors of mice that presented 
with neurological deficits were fixed in 4% paraformaldehyde, embedded in 
paraffin wax (Microm AP280-2, Zeiss), and sectioned (4 μm) using the 
microtome (Microm HM360, Zeiss). Hematoxylin and eosin (H&E) staining 
was carried out as described in our previous work
28
. For antibody staining, we 
adapted protocols from Gritti et al.
78
. Briefly, sections were mounted on poly-
L-lysine-coated slides, and subsequently processed for heat-induced epitope 
retrieval. The sections were incubated with 5% goat serum for 1 hour at room 
temperature and then stained with rabbit polyclonal anti-CD133 (Abcam), 
anti-NG2 (human tissue using Invitrogen 372300, mouse tissue using 
Millipore AB5320
79
) or mouse anti-Nestin (Chemicon) antibodies overnight, 
followed by incubation with HRP-conjugated secondary antibody (goat anti-
rabbit or anti-mouse IgG). Detection was carried out using the ChemMate 
Detection Kit (Dako); a positive reaction was indicated by brown color using 
DAB, and was counterstained with hematoxylin. ALDH activity was detected 
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according to the manufacturer‟s instructions (ALDH, Stem Cell Technologies, 
Vancouver, Canada). 
 
2.9 Stereotaxic Intracranial Implantations of NOD/SCID gamma (NSG) 
Mice 
Mice were treated according to the guidelines of the Institutional Animal Care 
and Use Committee, National Neuroscience Institute, Singapore. NNI-8 cells 
from dissociated neurospheres were injected orthotopically into non-obese 







, The Jackson Laboratory, 
Maine) mice. Five hundred thousand cells in 2 µl of phosphate-buffered saline 
were delivered into the right frontal lobe (0.1 µl/minute) by stereotaxic 
injection through a glass electrode connected to a Hamilton syringe 
(Narishige, Tokyo). The coordinates used were +2 mm mediolateral, +1 mm 
anteroposterior and -2.5 mm dorsoventral. Mice were euthanized by means of 
transcardiac perfusion with 4% paraformaldehyde upon presentation of 
neurological deficits with ataxia, cachexia, lethargy, or seizure
28
. Where 
secondary cultures were generated, non-perfused tumors were surgically 
removed, avoiding mouse tissue and dissociated into single cells using 
Accutase™ and treated as described in our previous work28. 
 
2.10 Karyotypic Analysis of Tumor Neurospheres (Conducted by SH 
Leong and OL Kon, National Cancer Centre)
 
Two million cells from dissociated neurospheres were cultured in a T-25 flask 
(BD Biosciences). The cells were then treated within 3–5 days with 0.1 g/ml 
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colcemid (Invitrogen) for 24 hours. Metaphase-arrested cells were pelleted 
(180g for 10 minutes) and hypotonic-treated with 0.075 M potassium chloride. 
Chromosomes were fixed in methanol:acetic acid (3:1), re-centrifuged and 
resuspended in fixative. Twelve µl of the fixed cell suspension was dropped 
on a clean, moistened glass slide and placed on a hot plate at 48
o
C to obtain 
chromosome spreads. Spectral karyotyping (SkyPaint; Applied Spectral 




2.11 Microarray Data Acquisition of Tumor Neurospheres  
Total RNA was isolated from neurosphere cells using TRI Reagent
®
 
(Molecular Research Center, Cincinnati, OH) and purified with the RNeasy 
Mini Kit (Qiagen, Hilden, Germany). Reverse transcription and cRNA 
amplification were performed using an RNA Amplification kit (Ambion, 
Austin, TX). Microarray hybridization was performed using the Illumina Gene 
Expression BeadChip (Illumina Inc., San Diego). 
 
2.12 Connectivity Map Analysis (Conducted by F.S.L. Ng, Singapore 
Institute for Clinical Sciences, A*STAR)
 
We utilized the Connectivity Map, a method originally used to define the 
strengths of association of a biological state (represented by a gene signature) 
to the action of small molecule therapeutics (a database of reference 
profiles)
29
. Since then, this method has successfully been used to determine 
the degree of oncogenic pathway activation in gastric cancer
80
. We adapted the 
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method to score glioma gene expression databases based on the extent of 
pathway activation associated with our GPC gene signature. (i) First, we 
defined a “GPC signature” – a set of genes exhibiting altered expression 
between 2 cell states (oligodendroglial GPC versus GBM GPC), (ii) Second, 
we generated databases of reference gene expression profiles from 2 major 
public glioma databases – REMBRANDT and “Gravendeel”9, 81.  (iii) Third, 
using a non-parametric, rank-based pattern matching procedure, we mapped 
the GPC signature onto each patient gene expression profile and calculated 
activation scores based on the strength of association to the GPC signature, 
and finally, (iv) The patients were sorted according to their pathway activation 
scores.  Two groups of patients were identified, (+) and (-), where a positive 
activation score indicates that the patient gene expression profile is positively 
associated to the gene signature and vice versa.  Kaplan-Meier and Cox 
regression analysis of (+) and (-) groups were done in R using the survival 
package
168
. The two-tailed test p-values associated with each activation score 
were calculated as described in Lamb et al. 
29
.  Samples with p-value ≤ 0.1 
were considered significant. 
 
2.13 Western Blot Analysis 
Cells were harvested and pelleted prior to lysis with RIPA buffer (1% sodium 
deoxycholate (ionic detergent), 1 Triton X-100 (non-ionic detergent), 0.1% 
SDS (sodium dodecyl sulfate) (ionic detergent), 0.15 M NaCl, 50 mM Tris 
HCl pH7.2 in deionised water) in the presence of a cocktail of protease 
inhibitors (1 mM phenylmethylsulphonyl fluoride (PMSF) (Sigma-Aldrich), 
10 µg/ml aprotinin (Sigma-Aldrich), 10 µg/ml pepstatin (Sigma-Aldrich) and 
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10 µg/ml leupeptin (Sigma-Aldrich)). Protein lysates were resolved on 
denaturing 8% sodium dodecyl sulphate (SDS)-polyacrylamide gel, 
transferred to a polyvinylidene difluoride (PVDF) membrane (Invitrogen), and 
probed with the following antibodies: anti-GSK-3α/β (1:300, Santa Cruz 
Biotechnology Inc.); anti-phospho-GSK3 (Tyr279/Tyr216) (1:1000, 
Millipore); anti-phospho-GSK3α/β (Ser21/9) (1:1000, Cell Signaling 
Technologies, Beverly, MA); mouse anti-cleaved PARP (#9546 used to detect 
both full length and cleaved PARP) (1:2000, Cell Signaling Technologies); 
rabbit anti-cleaved PARP (#9541 used to detect only cleaved PARP) (1:1000, 
Cell Signaling Technologies); anti-c-Myc (1:300, Santa Cruz Biotechnology 
Inc.); anti-tubulin, beta III isoform (TuJ1, 1:1000, Millipore) and β-actin 
antibody (1: 10,000, Santa Cruz Biotechnology Inc.). Goat anti-mouse 
horseradish peroxidise (HRP)–conjugated secondary antibody (1: 10,000, ECL 
Amersham Biosciences, Buckinghamshire, UK), donkey anti-rabbit HRP-
linked secondary antibody (1: 10,000, ECL Amersham Biosciences), or goat 
anti-mouse IgG-HRP (1: 10,000, Santa Cruz Biotechnology Inc.) were used. 
All antibodies were diluted in blocking buffer [5% w/v bovine serum albumin 
(Sigma), 10 mmol/L Tris-HCl, 100 mmol/L NaCl, 0.1% (v/v) Tween 20]. 
Membranes were visualized using the chemiluminescence detection kit ECL 
plus (Amersham Biosciences), SuperSignal West Pico (Thermo Scientific, 
Rockford, USA) or  SuperSignal West Pico (Thermo Scientific) according to 
the manufacturer‟s instructions. Protein bands were quantified with Quantity 
One
®









 GPC Cell Populations 
GPCs were harvested, blocked with FcR blocking reagent (Miltenyi Biotec) 
and stained with allophycocyanin (APC)-conjugated anti-CD133/2 (Miltenyi 
Biotec) and mouse IgG2b-APC isotype control antibody (Abcam, Cambridge, 
UK). Cells were subsequently sorted with a FACS Aria
TM
 (BD Biosciences).  
 
2.15 Colony Formation Assay 




 and total 
populations as described in section 2.14
 
and plated in triplicate into 96-well 
plates containing 100µl of DMEM/F12 culture medium supplemented with 
growth factors. Cells were treated with BIO after a recovery period of 4 days 
post-sorting. Cells were grown for up to 21 days at 37
0
C and 5% CO2, during 
which period the drugs were topped up and growth factors were supplemented 
twice a week. Cells were then scored for number of colonies formed and 
colony size under a Nikon
®
 microscope (Nikon Instruments Inc., Melville, 
USA) at days 7, 14 and 21.  
 
2.16 Lentiviral Infections 
Human GIPZ lentiviral shRNAmir target gene set was obtained from Open 
Biosystems (Huntsville, AL) consisting of a set of 3 clones (Clone ID. 
V2LHS_114290, V2LHS_114293 and V2LHS_114291). Non-silencing-GIPZ 
lentiviral shRNAmir control (Open Biosystems) and the lentiviral vectors 
targeting GSK3β were transfected into HEK-293T cells together with 
plasmids encoding the packaging (psPAX2) and envelope proteins (pMD2-
VSV-G) (Addgene, Cambridge, USA) using FuGENE
® 
6 transfection reagent 
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(Roche Applied Biosciences, Indianapolis, IN, USA). The concentration of 
infectious particles in the supernatant was titred using the Lenti-X
TM
 p24 
Rapid Titer Kit (Clontech, CA, USA) according to the manufacturer‟s 
instructions. Glioma cells were transduced with infectious viral particles. 
Stably transfected clones were selected with 2 µg/ml puromycin. 
 
2.17 Soft Agar Assay 
Equal volumes of melted 1% Agar (DNA grade) (Vivantis, CA, USA) and 2× 
DMEM/F12, supplemented with growth factors were mixed to give 0.5% 
Agar, 1× DMEM/F12 and added into each of the wells in a 24-well culture 
plate (Nunc, Denmark). The agar was allowed to set to constitute the base 
agar.  Following that, equal volumes of melted 0.8% Agar (DNA grade 
agarose) and 2× DMEM/F12 supplemented with growth factors was prepared 
to give a final dilution of 0.4% Agar, 1× DMEM/F12; and 2,000 cells were 
resuspended and immediately plated into each of the wells in the 24-well 
culture plate precast with the base agar.  Cells were incubated at 37
0
C and fed 
weekly by overlaying the soft agar with 0.4% Agar, 1× DMEM/F12 
supplemented with growth factors. The colonies were counted after 14 days of 
plating and the colony sizes determined under phase contrast.   
 
2.18 Statistical Analysis 
Data are expressed as means ± SEM of at least three independent experiments. 
Student‟s t test or the Mann-Whitney U test was used where appropriate. 





CHAPTER 3 – A NOVEL METHOD TO INTERROGATE THE 
CONTRIBUTION OF STEM-LIKE GLIOMA-PROPAGATING CELLS 
TO MOLECULAR HETEROGENEITY AND SURVIVAL OUTCOME 
IN GLIOMAS 
Gliomas are heterogeneous and can arise from neural precursors such 
as stem cells
14, 16
 or oligodendrocyte progenitor cells (OPCs)
79, 82
, depending 
on the initial cell type-specific mutations created in transgenic mouse models. 
As lineage-tracing studies can be performed, transgenic mouse models allow 
us to identify the cell-of-origin, its subsequent progeny and consequently 
pinpoint events in the etiology of gliomas. Although these mouse models 
demonstrate tumor formation that resembles the patient‟s original 
histopathology, we now know that they often do not recapitulate the diverse 
molecular heterogeneity characterizing human specimens. This highlights the 
limitation of using transgenic mouse models for glioma studies
83
. Recent work 
by The Cancer Genome Atlas (TCGA)
6, 7





 illustrate the complexity of human gliomas. Accordingly, 
these studies defined molecular sub-groups distinguished by gene expression, 
genetic aberrations and clinical profiles. These findings indicate that gene 
expression drives disease progression and survival outcome. In addition, the 
different sub-groups could be distinguished by recurring mutations in key 
signaling mechanisms such as the RTK, p53 and Rb pathways
6
. An important 
observation from the TCGA effort was the ability of xenografted surgical 





Such findings underlie the foundation of our current study. We had 
previously characterized GPCs derived from GBM
28, 84
, and demonstrated 
their extensive self-renewal and multi-lineage potential, accompanied by their 
ability to form orthotopic xenograft tumors that recapitulate the patient‟s 
original pathophysiology. Importantly, we showed that histologically similar 
tumors yielded GPCs with very different transcriptomic profiles, thus offering 
a possible explanation for the frequently observed inter-patient variability to 
treatment response. Here, we characterized NNI-8 GPCs derived from a 
different high grade glioma variant with oligodendroglial features. 
Oligodendroglial tumors are well-documented to have better prognosis than 
GBM
14
; in particular, the presence of the 1p/19q co-deletion status predicts 
their sensitivity to chemotherapy
4
. We thus explored the following: (1) We 
asked if NNI-8 GPCs displayed stem cell-like properties, and could re-
establish xenograft tumors that mirrored the patient‟s original histopathology, 
which would be expected to differ from GBM tumors. This information would 
shed light on whether GPCs represent a reliable cellular model for 
recapitulating the tumor class; (2) By collating oligodendroglial GPCs and 
GBM GPCs from different investigators
28, 73, 74
, we asked if differentially 
regulated genes characterized these tumor classes. Next, we derived clinical 
relevance of this gene signature by mapping its strength of association with 
gene expression profiles of patients from major public glioma databases, 
REMBRANDT
81
 and “Gravendeel”9. We utilized a novel method in glioma 
biology, the “Connectivity Map”29 to draw these associations. This method has 
the advantage of allowing us to make connections between different data 
platforms and biological information through the common vocabularly of 
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genome-wide expression profiling.  Our question was to ascertain if the gene 
signature could stratify patients for survival outcome, and thus highlight the 
clinical contribution of GPCs to disease outcome. 
 
3.1 An Anaplastic Oligoastrocytoma, NNI-8, Expresses Stemness Markers, 
Displays Extensive Self-Renewal and Multipotentiality 
3.1.1 Patient magnetic resonance imaging (MRI) and histopathology 
The patient from which the tumor specimen and subsequent GPC line was 
derived, was a 49 year old Chinese man who presented with progressive 
headaches over 3 months. The magnetic reasonance (MR) images were 
consistent with that of a high grade glioma – specifically, there was a 
lobulated left temporal intra-parenchymal mass lesion with irregular rim-
enhancing borders which demonstrated inhomogeneous contrast enhancement 
accompanied by surrounding vasogenic edema and local mass effect (Fig. 5A-
C). In addition, a satellite lesion with similar morphology could be seen in the 
posterior temporal lobe. On histopathological analysis following surgical 
resection, it was revealed to be a highly cellular neoplasm with juxtaposed 
regions of astrocytic and oligodendroglial differentiation. The astrocytic 
component was fibrillary in nature and the oligodendroglial component 
showed the typical dense network of branching capillaries and also tumor cells 
with clear cytoplasm, well-defined plasma membranes, hyperchromatic nuclei 
and peri-nuclear halos. Features of malignancy such as increased cellularity, 
marked cytologic atypia and high mitiotic activity were present as well. There 
was extensive hemorrhaging and the tumor exhibited a “fried egg” 
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morphology with “chicken wire” patterning of the stroma, typical of tumors 




Figure-5. Magnetic resonance images, histopathology and 
immunohistochemistry of a case of anaplastic oligoastrocytoma. (A) Coronal, (B) 
Axial, and (C) Sagittal sections. White arrows denote tumor mass. (D) Representative 
H&E staining of primary tumor tissue, exhibiting the characteristic clear halo “fried-
egg” appearance of oligodendroglial cells with “chicken wire” patterning of the 
stroma, and extensive haemorrhaging. Scale bar = 50 μm. Abbreviations: H&E, 




3.1.2 Anaplastic oligoastrocytoma-derived GPCs (NNI-8) display stemness 
expression and extensive self-renewal capability 
GPCs from GBM, ependymoma and medulloblastoma have previously been 
characterized
86-88
. Here, we investigated the expression of common GPC 
surface markers based on our hypothesis that similar cells exist in anaplastic 
oligoastrocytoma. We evaluated the appearance of CD133, CD15 (SSEA-1), 
ALDH and Nestin, all frequently associated with the brain tumor stem cell
2, 31, 
33, 89
. NNI-8 GPCs doubled in approximately 5 days (Fig. 6A) and displayed 
~80% CD133, ~0.4% CD15, ~5% ALDH and ~100% Nestin expression (Fig. 
6Bi, ii). To assess in vitro self-renewal potential, we utilized the neurosphere 
assay adapted from normal neural stem cell biology which approximates the 
tumor stem cell frequency
40
. As neurospheres are heterogeneous, we carried 
out long-term serial passage (up to 3 generations) to measure self-renewal 
capacity originating from bona fide tumor stem/propagating cells which can be 
distinguished from short-term, transit amplifying progenitors
41
. We show that 
the GPC frequency was maintained at ~1.25% for up to 3 generations (Fig. 
6Ci). Sphere size, which is an indication of GPC cell proliferation, remained 
constant at ~54.16 ± 1.44 µm for up to 3 generations (Fig. 6Cii)90. A slight but 
significant increase was observed in passage 2 compared to passage 1. Our 
data suggests that NNI-8 GPCs possess common brain tumor stem cell surface 
markers and their abundance can be reliably maintained in vitro for up to 3 
passages. In support, we previously demonstrated that by mechanical 
trituration, we were able to expand GPCs for up to 10 passages with 
preservation of transcriptomic profile, stemness/differentiation expression, key 
karyotypic hallmarks and tumorigenicity
28
. This method of mechanical 
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expansion without the use of harsh enzymatic dissociation solution is 
analogous to expansion of normal neural stem cells as a batch colony and best 










Figure-6. NNI-8 glioma propagating cells exhibit stemness expression and 
extensive self-renewal. (A) Proliferation curve measured by alamarBlue®, showing 
a doubling time of about 5 days. (Bi) Graphical representation for the percentages of 
CD133, CD15, ALDH and Nestin expressions. (Bii) Representative flow cytometric 
plots of data shown in (Bi). (Ci) Limiting dilution analysis of GPCs at first, second 
and third passages, illustrating the maintenance of GPC frequency. (Cii) Sphere sizes 
at first, second and third passages indicating a constant proliferation rate. 
Abbreviations: CD133, complementarity determinant 133; CD15, complementarity 






 3.1.3 NNI-8 displays stem-like cell phenotypes and are multipotent 
We evaluated NNI-8 GPCs for cell type-specific phenotypes 
previously demonstrated in GPCs of other brain tumor types. The GPC 
neurospheres were dissociated into single cells and seeded on to laminin-
coated wells mounted on glass slides. After a recovery phase of 2-3 days was 
allowed, the cells were stained for various antigens. GPCs grown as adherent 




 We observed that nearly all GPCs displayed Nestin, Musashi-1 (Msi-1) 
and octamer-binding transcription factor 4 (Oct4) expression, with ~30% Ki-
67-positive cells (Fig. 7A, B). Nestin is expressed in neural precursors; Msi-1 
is a marker for self-renewal and Oct4 is a transcription factor essential for the 
maintenance of an undifferentiated state
94-97
. Ki-67 marks actively dividing 
cells
98
. These data suggest that NNI-8 GPCs are actively-dividing and possess 
stemness markers commonly associated with pluripotency and self-renewal 
ability.  
Next, we subjected our GPCs to growth factor withdrawal, 
accompanied by serum addition over a period of 14 days. As cell morphology 
changes accompany the induction of differentiation of neural stem cells, we 
assessed multipotentiality by scoring for neurons (neuron-specific class III 
beta-tubulin, TuJ1), astrocytes (glial fibrillary acidic protein, GFAP) and 
oligodendrocytes (O4). In addition, we scored for differentiated cells staining 
positive for Nestin and Msi-1 stemness markers. Our data indicate that upon 
induction of differentiation, most cells retained Nestin and Msi-1 positivity, 
suggesting the preservation of a primitive neural precursor state with 
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continued self-renewal, otherwise distinct from normal terminally 
differentiated neural cells (Fig. 7A, C). The differentiated cells also nearly all 
stained positive for the astrocytic and oligodendroglial lineages, with ~20% 
staining positive for the neuronal lineage. Interestingly, ~10% of cells stained 
positive for both TuJ1 and GFAP, reflecting an aberrant developmental 
pathway otherwise absent in normal terminally differentiated neurons or 
astrocytes (Fig. 7A, C). Our data suggest that NNI-8 GPCs are multipotent and 
retain some degree of self-renewal potential, however, the extent of self-




Figure-7. NNI-8 expresses stem-like cell phenotypes and multipotentiality. (A) 
Graphical representation of GPCs stained with stemness markers Nestin, Msi-1, Ki-
67, Oct4, and assessed for neurons (TuJ1), astrocytes (GFAP) and oligodendrocytes 
(O4) before (stem) and after (differentiated for 14 days) the addition of serum. Cells 
co-stained for TuJ1 and GFAP were also assessed as well as neural precursor cells 
marked by Nestin and cells staining for Msi-1 after serum addition, indicating self-
renewal potential. Abbreviations: Msi-1, Musashi-1; Ki-67, antigen identified by 
monoclonal antibody Ki-67; Oct4, octamer-binding transcription factor 4; TuJ1, 
neuronspecific class III beta-tubulin; GFAP, glial fibrillary acidic protein. **p < 0.01, 






Figure-7. NNI-8 expresses stem-like cell phenotypes and multipotentiality. (B) 
Representative immunofluorescent images of data shown in (A), before serum 





Figure-7. NNI-8 expresses stem-like cell phenotypes and multipotentiality. (C) 
Representative immunofluorescent images of data shown in (A), after serum addition. 











3.2 NNI-8 Orthotopic Xenograft Recapitulates Original Patient Tumor 
Pathophysiology and Retains Key Karyotypic Hallmarks upon 
Serial Passage 
3.2.1 NNI-8 orthotopic xenograft phenocopies original patient tumor 
pathophysiology 
One of the cardinal features of tumor-propagating cells is their ability 
to reform serially transplantable tumors which phenocopy the original primary 
tumor morphology
99
. Such tumor sustaining capacity reflects the extensive 
self-renewal capability of stem-like cells whereas the more committed, transit-
amplifying cells such as progenitors tend to form tumors that cannot be 
serially transplanted with time
100
. In addition, the ability of GPCs to give rise 
to all neural lineages (that is, multipotency); namely astrocytes, 
oligodendrocytes and neurons, is important in reconstituting the tumor 
phenotype. We stereotaxically implanted 500,000 dissociated GPC single cells 
into the right frontal cortex of NOD-SCID gamma mice and monitored the 
time to development of neurological deficits. NNI-8 GPC cells typically 
formed large tumors within 4.5-6 months (Fig. 8Ai-iii). These tumors were 
highly invasive and infiltrated along white matter tracts such as the corpus 
callosum (Fig. 8Ai). Extensive hemorrhaging was common, and microscopic 
analyses revealed cells with a “fried egg” morphology and “chicken wire” 
patterning of the stroma, typical of tumors with an oligodendroglial 
component
85
. The morphology of the mouse tumor xenograft was identical to 
the human primary tumor; in addition, its molecular expression profile 
associated it with the oligodendroglial lineage
101
, thus confirming the initial 
diagnosis (Fig. 5D, Fig. 8Ai-iii, Fig. 9). To assess self-renewal capacity, we 
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derived secondary GPC cultures from these first generation xenografts, and re-
implanted a second set of animals. We were able to obtain similar tumors in 
comparable time periods in the second generation mice, suggesting that our 
GPCs possessed self-renewal capability (Fig. 8B). In addition, we noted that in 
both human and xenografted tumors, the expressions of CD133 and Nestin 
were maintained (Fig. 8C, Fig. 9). The strong ALDH “positive” staining in the 
primary tumor was confirmed by the pathologist to arise from reactive 
astrocytes, a reaction not seen in the immune-compromised mouse xenograft 
model. Neuroglial chondroitin sulphate proteoglycan 4 (NG2) expression has 
recently been implicated as the marker for progenitor cells-of-origin in a 
mouse model of oligodendroglioma
102
. NG2 staining was negligible in both 
human and xenografted tumors (Fig. 9). Furthermore, primary GPCs derived 
from patient material and GPCs derived from xenografted tumors both 
maintained similar levels of expression of ALDH and Nestin, while CD133 
and CD15 were slightly but significantly elevated in xenografted GPCs (Fig. 
8Di, ii). While it is attractive to postulate that in vivo serial passaging 
positively enriches for CD133 and CD15-expressing GPCs, this would require 
further robust clonality assays to be carried out. In contrast, we observed a 
significant increase in abundance of NG2-positive cells in primary GPCs (Fig. 
10)
102
. We noted that this pattern was reversed in GPCs cultivated in serum-
free medium supplemented with leukemia inhibitory factor (LIF), another 
culture condition frequently used by several teams (Fig. 10)
103
. Thus, NG2 
expression, at least in vitro, appears to vary in accordance with the presence of 
LIF, explaining the discrepancy with results obtained from the tumor 
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immunohistochemistry data. This indicates that in vitro cultures cannot be 
used to assess the enrichment of NG2-expressing tumor-propagating cells. 
 
Figure-8. NNI-8 orthotopic xenograft recapitulates patient tumor 
pathophysiology. (Ai-iii) Tumor xenograft section showing extensive hemorrhaging, 
“fried egg” morphology and “chicken wire” patterning of the stroma via H&E 
staining. Scale bar = 50 μm. (B) Tumorigenicity and animal survival arising from 
implanted primary and secondary GPCs. (C) Graphical representation of CD133, 
ALDH and Nestin expressions in the primary and xenografted tumors derived from 
immunohistochemical staining; *, p < 0.05. NG2 had negligible expression. Note that 
CD15 expression was not evaluated as the anti-CD15 antibody cross-reacts strongly 
with mouse tissue, thereby confounding analysis. (Di) Graphical representation of 
CD133, CD15, ALDH and Nestin expressions in primary and secondary GPCs; *, p < 
0.05. (Dii) Representative flow cytometric plots of data illustrated in (Di). 
Abbreviations: H&E, hematoxylin and eosin; GPCs, glioma-propagating cells; 
CD133, complementarity determinant 133; ALDH, aldehyde dehydrogenase; NG2, 





Figure-9. Xenografted tumor maintains common stemness marker expressions 
compared to the primary tumor. (A) Immunohistochemical staining detecting for 
the presence of ALDH in primary tumor (B) Immunohistochemical staining detecting 
for the presence of CD133, Nestin, ALDH and NG2. Note that the “positive” staining 
pattern of ALDH in the primary tumor was confirmed by the pathologist to arise from 
reactive astrocytes, a reaction not seen in the immunecompromised mouse xenograft 
model. Scale bar = 50 μm. Abbreviations: CD133, complementarity determinant 133; 





Figure-10. Leukemia inhibitory factor (LIF) influences the level of NG2 
expression. (A) The addition of LIF in the culture medium leads to a significant 
reduction in NG2 expression; ***, p < 0.001. (B) Representative flow cytometric 
plots of data illustrated in (A). Abbreviations: LIF, leukemia inhibitory factor; NG2, 










3.2.2 In vivo serial passage maintains key karyotypic hallmarks 
(Conducted by SH Leong and OL Kon, National Cancer Centre)
 
We previously showed that we were able to maintain key karyotypic 
hallmarks of GPCs derived from patients with GBM that were in vitro 
expanded for 10 passages
28
. To our knowledge, no work exists that has studied 
the progression of GPC karyotypes when the cells have been serially 
transplanted in animals. Work by Lee et al. has suggested that GPCs cultured 
under serum-free condition supplemented with growth factors contained 
karyotypic patterns similar to the primary tumor, however, their preservation 
through in vivo passaging remains to be verified
19
. We thus evaluated 
karyotypes of NNI-8 GPCs within 10 passages after derivation from clinical 
material (“primary GPCs”), and within 10 passages after harvesting from the 
first generation animal implantations (“secondary GPCs”). Our motive was to 
ascertain if any karyotypic hallmarks were preferentially selected for or 
obliterated upon in vivo tumor propagation. This is an important endeavor as it 
addresses the reliability of in vivo serial transplantation to maintain such GPCs. 
 Our data are illustrated in Fig. 11A, B. The structural rearrangements 
in black font in the figure legend were retained in both primary and secondary 
GPCs, indicating that the majority of chromosomal rearrangements were 
preserved in first generation mouse transplantations. The structural 
rearrangement, i(7q), and the diploid Y chromosome status (both shown in red 
font) were obliterated in the secondary GPCs. Whether these obliterations 
occurred as a result of selection of tumor-propagation activity, or accidental 
clone loss remains to be followed up in subsequent work. Interestingly, the 
translocation at t(5;10) was no longer balanced, suggesting that the copy 
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numbers of 5p and 10q were likely to be altered. Our data suggest that in vivo 
serial passage maintains the overall karyotypic integrity of NNI-8 GPCs. 
 
Figure-11. Majority of karyotypic hallmarks in GPCs are maintained upon 
serial transplantation. (A) Primary GPCs derived from clinical material. Karyotype: 
93~102, XXYY[10], +1x2[10], +2[10], +3x3~4[8], +4[9], +t(10;5)(10qter →
q23::5p13 → 5qter;10pter → 10q23:5p13 → pter)x3[9],, +6x2~3[8], +7x1~2[10], 
+i(7q)[5], +t(7;12)(7pter → 7q31::12?)x3[9], +8x2~3[10], +9x2[8], +t(6;11)(6qter
→ ?6q22::11p23→ 11qter)[9], +12[10], +13[10], +14[10], +15x2~3[9], +16x3[9], 
+17x2[9], +18x3[9], +19x2~3[9], +20x4~5[9], +21x3[7], +22x3[7], cp10. 
Parentheses indicate number of metaphases with observed structural rearrangement; 
cp10 indicates total number of 10 metaphases scored. (B) Secondary GPCs derived 
from first generation tumor xenograft showed similar karyotype except for 
obliteration of structural rearrangements in red font above; Y and +i(7q)[5]. Note that 
the translocation at t(5;10) was also no longer balanced, suggesting that the copy 








3.3 An Oligodendroglial GPC Gene Signature Stratifies Patient Survival 
in Gliomas (Conducted by F.S.L. Ng, Singapore Institute for Clinical 
Sciences, A*STAR) 
3.3.1 An oligodendroglial GPC gene signature is defined 
 We first determined genes differentially regulated between 2 cell 
groups: Oligodendroglial GPCs (NNI-8, GS-2, G174) and 17 GBM GPCs 





previously described (Fig. 12). We used a linear model that selected for 
differentially expressed genes while batch variation was normalized. A log2 
fold change of 0.8 with p-value of 0.05 were maintained. Eighty-four genes 
corresponding to 95 probes were selected as the top-ranking candidates. We 
called this the “oligodendroglial GPC gene signature” which was enriched in 




Figure-12. Study flowchart for derivation of oligodendroglial GPC gene 
signature.  Oligodendroglial GPCs (NNI-8, GS-2, G174) and 17 GBM GPCs were 




. The number of 





3.3.2 The oligodendroglial GPC gene signature stratifies patient survival 
in all gliomas 
Next, we analyzed the strength of association of this gene signature 
with patient gene expression data from 2 public glioma databases – 
REMBRANDT and Gravendeel
9, 81
. We assigned positive "(+)" and negative 
"(-)" activation scores with significant p-values where (+) refers to a strong 
enrichment of the gene signature in similar direction in the clinical database, 
while an inverse correlation is defined as (-) (Table S2 in appendices). We 
observed that the gene signature separated (+) and (-) patient cohorts with 
approximately 30-50% in each category (Table 2). Importantly, the gene 
signature stratified patient survival (Fig. 13). Patients with better survival 
comprised of (+) association (more oligodendroglial GPC association) 
whereas poorly surviving patients tended to be (-) (i.e. more GBM GPC 
association) (REMBRANDT p-value, 1.93E-05; Gravendeel p-value, 0.0082). 
The (+) activation score also contained more low grade gliomas, especially 
enriched for oligodendrogliomas, while the (-) activation score enriched for 
high grade gliomas with mainly GBMs. A univariate Cox regression model 
indicated that the gene signature could serve as an alternate indicator of patient 
prognosis in addition to age, histology and tumor grade (Tables 2, 3; 
REMBRANDT p-value, 2.90E-05; Gravendeel p-value, 0.009). In the larger 
database REMBRANDT, the gene signature predicted survival better than age, 
histology and grade (Table 3; p-value, 2.22E-05). 
 Next, we attempted to strengthen our findings that tumor grade 
inversely correlates with the oligodendroglial GPC gene signature. We applied 
the "Phillips" classification of gliomas
10
 which molecularly categorizes the 
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tumors into 3 sub-classes: Proneural, Proliferative and Mesenchymal. We 
found that the (+) activation score enriched for the Proneural sub-class, while 
the (-) activation score tended to be Proliferative or Mesenchymal (Fig. 13). 
Proneurals are typically lower grade gliomas with oligodendroglial features, 
frequently associated with better prognosis; in contrast, the Mesenchymal sub-
class characterizes highly aggressive, recurrent gliomas such as GBM. 
Interestingly, recent work has suggested that oligodendrogliomas are more 
chemosensitive because their cells-of-origin are OPCs, compared to the more 
resistant neural stem cells in GBM
102
. Although this conclusion arose from 
transgenic mouse models, we find it intriguing that all in vitro cultured GPCs 
from different studies maintained the phenotypes of these purported cells-of-
origin; however, we are not able to definitively pinpoint the identity of GPCs 
due to its human origin. Furthermore, to eliminate the possibility that we were 
biasing the gene signature selection towards better surviving oligodendroglial 
tumors by our filtering procedure, we additionally derived a gene signature by 
comparing NNI-8 GPCs to its primary tumor (Tables S3, S4, S5 in 
appendices). This gene signature similarly stratified patient survival, with the 
(+) class enriching for lower grade tumors of Proneural classification, while 
the (-) class enriched for higher grade tumors with Mesenchymal features (Fig. 
S2 in appendices). The data collectively suggest that oligodendroglial GPCs 
contribute to a favorable prognosis, likely mediated by more chemosensitive 









Table-2. Summary of results from Connectivity Maps, Logrank and Cox Regression Analysis for all patient samples.  
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Log Rank 
p-value 
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Multivariate Cox Regression: 
REMBRANDT:  coxph(formula = Surv(survival, status) ~ age + grade + class, data = dat) 
Gravendeel:  coxph(formula = Surv(survival, status) ~ age + grade + class, data = dat) 
 
Table-3B. Univariate cox regression model for all patient samples. 
Dataset variable coef exp(coef) exp(-
coef) 
lower .95 upper .95 se(coef) z Pr(>|z|) Significance 
REMBRANDT class -0.7715 0.4623 2.163 0.322 0.6638 0.1845 -4.181 2.90E-05 *** 
Gravendeel class -0.6252 0.5351 1.869 0.3344 0.8563 0.2399 -2.607 0.00914 ** 
 
 
Univariate Cox Regression: 
REMBRANDT:  coxph(formula = Surv(survival, status) ~ class, data = dat) 




Dataset variable coef exp(coef) exp(-
coef) 
lower .95 upper .95 se(coef) z Pr(>|z|) Significance 
REMBRANDT 
age 0.019326 1.0195 0.9809 1.007 1.032 0.00628 3.076 0.0021 ** 
grade 0.710044 2.0341 0.4916 1.393 2.97 0.19307 3.678 0.00024 *** 
class -0.82114 0.4399 2.2731 0.301 0.643 0.19359 -4.242 2.22E-05 *** 
Gravendeel 
age 0.04299 1.044 0.9579 1.0235 1.065 0.01008 4.267 1.98E-05 *** 
grade 1.02668 2.792 0.3582 1.5974 4.879 0.28485 3.604 0.00031 *** 




Figure-13. Oligodendroglial GPC gene signature stratifies patient survival. 
Patient survival is shown in all glioma patients. Tumor grade (“Grade”) and 
molecular classification (“Phillips”10) distribution corresponding to (+) and (-) classes 
is shown below the activation score graphs. Patients with better survival comprised of 
+ association (more oligodendroglial GPC association) whereas poorly surviving 
patients tended to be - (i.e. more GBM GPC association). The + activation score also 
contained more low grade gliomas, especially enriched for oligodendrogliomas; and 





3.3.3 The oligodendroglial GPC gene signature defines molecular 
heterogeneity within oligodendrogliomas 
We next interrogated this GPC gene signature in oligodendroglioma 
patients. The (+) class enriched for lower tumor grades associated with 
patients exhibiting the 1p/19q co-deletion (Fig. 14). Interestingly, patients 
without loss-of-heterozygosity at 1p/19q were spread throughout the (+) and (-) 
classes, indicating that the gene signature detected molecular heterogeneity 
that cannot be accounted for by the 1p/19q co-deletion status alone.  
 
 
Figure-14. Oligodendroglial GPC gene signature is associated with lower tumor 
grade and 1p/19q co-deletion. Tumor grade („Grade”) and 1p/19q co-deletion 







Following the characterization of GBM GPCs in our previous manuscript
28
, 
we describe the derivation of GPCs from a patient with anaplastic 
oligoastrocytoma, NNI-8. These GPCs displayed stem cell-like characteristics; 
notably, extensive self-renewal capacity and multi-lineage potential. 
Importantly, orthotopically implanted cells formed tumors that phenocopied 
the patient‟s original tumor histopathology. These data suggest that NNI-8 
GPCs do preserve the ability to reform tumors that mirror the original primary 
tumor pathological diagnosis. To address the clinical relevance of GPCs, 
transcriptomic analyses were carried out on 2 major groups of GPCs derived 
from GBM and oligodendroglial tumors. Our data show that tumor classes and 
their survival outcome can be predicted by transcriptomic information residing 















CHAPTER 4 – IDENTIFICATION OF GSK3β AS A DRUG 
CANDIDATE FROM ELI LILLY SCREEN 
4.1 Identification of GSK3β as a Possible Drug Candidate in GPCs 
4.1.1 Drug screening from 50 Eli Lilly compounds reveals key signaling 
pathways in gliomas 








molecularly heterogeneous among patients even if their tumor histologies are 
similar. These findings underscore the limitation of morphology-based 
histological analyses in diagnosing tumor class/grading and consequently 







 suggest that gene expression 
drives disease progression and survival outcome. These public efforts show 
that brain tumors such as GBM can be classified into 4 subtypes based on gene 
expression, with each class containing unique genetic aberrations and clinical 
outcome
7
. In addition, TCGA efforts mapped the 3 major signaling 
mechanisms most frequently altered in GBM: RTKs, p53 and Rb tumor 
suppressor pathways. 
Accordingly, to identify the mechanisms promoting self-renewing and 
tumorigenic GPCs (i.e. to target the relevant tumor-propagating fraction in the 
heterogeneous tumor mass), we selected 50 small molecules (Table S7 in 
appendices) targeting common oncologic pathways. Each pathway was 
targeted by more than 1 compound to ensure that data implicating specific 
pathways could be reproduced. We screened these small molecules in 4 GPC 
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lines: NNI-1, 4, 5 (previously published
28, 84
) and NNI-8 (this study). From our 
previous work, we showed that NNI-1 and NNI-5 GPCs clustered together in a 
Principal Component Map (PCA) analysis (S cluster); while NNI-4, a semi-
adherent sphere subtype clustered away, closer to the primary tumor, thus 
confirming that it also differs transcriptomically from the S cluster spheres, 
and may contain more differentiated progeny found in the primary tumor (T 
cluster))
3, 28
. Interestingly, all 3 spheres were derived from histologically 
similar GBM primary tumors, once again confirming the inadequacy of 
morphological approaches in tumor grading. In contrast, NNI-8 which 
represents GPCs derived from a high grade glioma with oligodendroglial 
features remained transcriptomically distinct from all others, consistent with 
our earlier findings that the transcriptomic changes driving the primary tumor 
phenotype are “hardwired” into the GPCs (Fig. 15). Our choice of GPC lines 
reflects our rationale for identifying small molecules that inhibit all glioma 
GPCs irrespective of morphology and transcriptomic differences. Intuitively, 
the inability of certain molecules to target different GPC subtypes may reflect 
underlying differences that regulate these subtypes. 
 We adapted our screening protocol from previous investigators
105, 106
. 
Briefly, we carried out the small molecule screen with suspension GPC 
spheres and assayed for their viability upon drug treatment. Viability rather 
than functional sphere formation assays which reflect GPC frequency was 
used initially due to its relative ease in screening 50 compounds quickly. We 
used two criteria: First, we winnowed down candidate compounds that 
reduced viability by at least 2-fold. Second, we selected only compounds that 





. Ideally, the use of normal human neural stem cells 
or astrocytes would offer better alternatives but ethical issues may preclude 
their use. This is because (i) Bioinformatics data in this thesis carried out by 
bioinformaticians at Eli Lilly and company do not approve the use of human 
fetal cell-related research (ii) Normal human neural stem cells are 
immortalized and not entirely representative of the stem cells we are studying 
(iii) Normal human astrocytes (NHA) or human neural stem cells procured 
commercially are of higher passages, thus these cells might possess in-vitro 
passage artifacts. 
The specificity of compounds was assessed using the following 
“selectivity ratio”: % viability (astrocytes) / % viability (GPCs). Thus, a good GPC 
inhibitor would be reflected as a high selectivity ratio. Using this approach, we 
grouped our data to show compounds that are consistent with GPC literature, 
and compounds that are novel in GPC sustenance that may potentially 
represent areas of exploration (Fig. 16). Interestingly, inhibitors targeting the 
PI3K/Akt/mammalian target of rapamycin (mTOR)
3
, transforming growth 
factor beta receptor 1 (TGFR1)42, 107 and Jak2/Stat3108, 109 pathways identify 
signalling elements existent in GBM GPCs. These data validate our screening 





, likely because their regulation involves 
paracrine feedback which is not present in our screening system
111, 112
. 
Inhibitors against Polo-Like Kinase (PLK), Aurora A/TAK1 (AURKA), 
Cyclin-Dependent Kinase (CDK) and Glycogen Synthase Kinase 3 beta 
(GSK3 were identified in this screen and their roles in GPC maintenance are 
currently unknown. We thus focused on investigating the GSK3 signalling 
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pathway for 3 reasons: Firstly, inhibitors against PLKs, CDKs and AURKA 
tend to target the proliferative aspects of tumor growth (i.e. cell cycle 
machinery)
113, 114
. We rationalized that GPC self-renewal and tumorigenic 
properties would comprise more than proliferation alone; for example, cell 
fate (aberrant stem cells versus lineage-committed progenitors in the 
transformation process) determines tumorigenic potential
100
. Consequently, 
targeting these unique properties would more likely be specific towards tumor 
cells than targeting cell cycle machinery as normal cells would be similarly 
affected. Secondly, previous work suggested that GSK3 inhibitors may target 
primary glioma cells via a novel apoptotic machinery, but its impact on tumor-
initiating GPCs is unknown
71
. Thirdly, recent work has implicated GSK3 
regulation with cell fate
72
. We thus hypothesized that GSK3 specifically, 
may control GPC self-renewal and consequently tumor growth by regulating 
cell fate. We focused on the beta isoform since GSK3-null mice exhibited no 










Figure-15. GBMs exhibit different phenotypic and genotypic subtypes. PCA of 
NNI-1, NNI-4, NNI-5 and NNI-8 showing the distinct genetic profiles of S, D, and T 
clusters. NNI-4 tumor spheres associated with the T cluster. NNI-8 shows a distinct 
transcriptome profile from the S cluster. Abbreviations: D, differentiated; PCA, 
























Figure-16. Compound groups from Eli Lilly screen published and novel in GPCs. 
Consistent with literature, the mTOR/PI3K/Akt, TGFβR1 and JAK2 pathways were 
identified. The roles of PLKs, AURKA, CDKs and GSK3β are currently unknown in 
GPCs. 
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4.1.2 Investigation of GSK3β as a Drug Target in GPCs 
The GSK3β inhibitor accessed from Eli Lilly is designated as 
Compound 14 (Table S7, Fig. 17), selected based on its ability to reduce cell 
viability by at least 2-fold at 10µM and exhibiting a selectivity ratio of 2-fold 
or more across the 4 GPC lines. Compound 14 further demonstrated an 
interesting toxicity profile in the free-floating neurospheres (NNI-1, NNI-5 
and NNI-8), demonstrating cell viabilities of 28.64%, 59.57% and 13.92% 
respectively; but displayed little toxicity towards NNI-4, a semi-adherent 
GBM sphere subtype with 85.51% cell viability (Fig. 17). Interestingly, this 
data would be consistent with Compound 14 targeting the relatively more 
undifferentiated NNI-1, 5 and 8 GPCs compared to the more differentiated 
NNI-4 GPCs as predicted by the PCA map (Fig. 15), further strengthening its 
mechanism through cell fate.  
 
Figure-17. Compound 14 reduces cell viability of free-floating neurospheres by 
2-fold or more and displays a selectivity ratio greater than 2. Compound 14 
(boxed in red) demonstrates greater toxicity in the free-floating neurospheres (NNI-1, 
NNI-5 and NNI-8) as compared to the semi-adherent neurosphere (NNI-4). 
Preferential targeting of GPCs over mouse astrocytes is also observed.  
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4.1.3 Half Maximal Inhibitory Concentration (IC50) of Compound 14 in 
Relation to Kinase Selectivity Profiles of Well-Published GSK3β 
Inhibitors  
To further characterize Compound 14 effects on GPCs, we established 
dose response curves to determine the half maximal inhibitory concentrations 
(IC50) needed to reduce viability by 50%. We observed that NNI-1, 5 and 8 
showed IC50 values of 8.4, 14.3 and 15.8M respectively (Fig. 18). In contrast, 
the more resistant GPC line, NNI-4 showed an IC50 value of 25.4M. These 
data suggest that Compound 14 effectively targets the relatively 
undifferentiated, free-floating sphere subtype. 
We referenced these concentrations to well-published GSK3β 
inhibitors to generate an understanding of whether these concentrations reflect 
the potency of Compound 14 (Table 4). The kinase selectivity profile of 6-
bromoindirubin-3‟-oxime (BIO), a potent GSK3 inhibitor, revealed an IC50 of 
0.005µM for GSK3 kinase activity, indicating a strong selectivity of BIO for 
GSK3α/β116. In vitro experiments involving BIO utilized concentrations 
ranging from 5nm-5µM BIO116-118, exhibiting a greater specificity than lithium 
chloride (LiCl). LiCl is the most frequently used pharmacological inhibitor of 
GSK3, despite its effects being in the 10-20mM range in cell-based assays
119
. 
Under conditions that approximate the intracellular environment (free 
concentration of Mg
2+
 0.5mM and isotonic KCl 150mM), lithium exhibits an 
IC50 of 2mM
120
. Korur et al.
72
 utilized another GSK3 inhibitor, SB216763, at 
20µM in commercially procured, serum-grown glioma cell lines. Taken 
together, our data suggests that Compound 14 may target GSK3 selectively in 
our GPCs but that its relatively weaker potency precludes its utility as an 
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investigational tool in further work. We further substantiate this conclusion 
below. 
 
Figure-18. Dose-response curves of GPCs treated with Drug 14 over 5 days. 
NNI-4 displays higher IC50 value of 25.4µM as compared to 8.4µM, 14.3µM and 
15.8µM in NNI-1, NNI-5 and NNI-8 respectively. 
 
 
Table-4. Inhibitory concentrations (IC50) of well-published GSK3β inhibitors in 
biochemical and cell-based context.  IC50 values of commonly used GSK3β 
inhibitors in published literature, with LiCl being the most frequently used but least 
specific inhibitor.   
 


















4.1.4 Compound 14 Acts as an Initial Lead in Exploration of GSK3β 
Modulation of GPCs  
GSK3 exists as two isoforms – GSK3α and GSK3β. GSK3α is an 
enzyme originally isolated from tissues as a 51kDa protein, while GSK3β is a 
46kDa polypeptide exhibiting similar catalytic properties as GSK3α121. 
Studies have shown that GSK3 is highly phosphorylated on tyrosine in vivo, 
which is functionally essential. The activating phosphorylation occurs on 
Tyr279 of GSK3α and Tyr216 of GSK3β48. Phosphorylation by protein 
kinases such as PKB/AKT leads to inhibitory phosphorylation of GSK3 at a 
serine residue near its amino terminus, which is serine 21 (Ser21) in GSK3α 
and Ser9 in GSK3β, hence inhibiting GSK3 activity51.  
 We assessed of the levels of Tyr279/Tyr216 and Ser21/Ser9 
phosphorylation after treating the GPCs with Compound 14 at their IC50 
concentrations. We rationalized that such changes in phosphorylation would 
have to occur for Compound 14 to act specifically through GSK3-related 
mechanisms. We observed a slight decrease in Tyr216 of GSK3 in the GPCs, 
and a drastic increase in Ser21 of GSK3 phosphorylation for NNI-4, which 
has the highest IC50 of 25.4µM (Fig. 19). This difference is due to NNI-1, 
NNI-4 and NNI-8 representing different patient-specific cell lines. This 
specific assay for GSK3 activity suggests that Compound 14 is a weak GSK3 
inhibitor and could have likely reduced cell viability by additional off-target, 
toxic effects. Nevertheless, we obtained consistent viability-reducing data with 
other compounds in the cluster targeting GSK3 (Table S7, Fig. 17), thus we 
believe that its initial value at implicating this pathway in GPCs is valid. We 
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thus focused on the use of well-published and more specific GSK3 inhibitors 




Figure-19. Compound 14 exhibits slight effects in modulation of GSK3β activity 
in GPCs. Assessment of activating Tyr279/Tyr216 and inhibitory Ser21/Ser9 
phosphorylations revealed only a slight decrease in Tyr216 in GPCs and increase in 
Ser21/Ser9 phosphorylation in NNI-4 and NNI-8.  
 
SUMMARY 
Small molecule inhibitor screening with Eli Lilly compounds revealed drug 
targets in our GPCs consistent with previously characterized pathways such as 
the mTOR/PI3K/Akt, TGFβR1 and JAK/STAT signaling pathways, thus 
aligning our cells with international brain tumor stem cell efforts. GSK3β was 
identified as an interesting potential drug target due to a reduction in cell 
viability in our GPCs that was selective over normal mouse astrocytes, and a 
purported role in regulation of cell fate. Compound 14, however, was not the 
best candidate to elucidate GSK3β modulation of GPCs and therefore, we 
relied on the well-published and more specific inhibitor BIO as a probing tool 





CHAPTER 5 – BIO IS A SELECTIVE GSK3 INHIBITOR 
5.1 BIO (6-bromoindirubin-3’-oxime) selectively inhibits glycogen  
synthase kinase-3 (GSK3)  
Studies have recently shown that 6-bromoindirubin derived from 
Tyrian purple, a natural dye produced by the gastropod mollusks, is a potent 
GSK3 inhibitor. Its synthetic derivative, 6-bromoindirubin-3‟-oxime (BIO), 
constitutes a cell-permeable, potent and selective inhibitor of GSK3
116
. The 
kinase selectivity profile of BIO indicates a biochemical IC50 value of 
0.005µM for GSK3 activity (Table 5)116. Specifically, the study showed that as 
much as 1µM BIO significantly reduced tyrosine phosphorylation (at Tyr279 
and Tyr216) levels of both GSK3α/β isoforms respectively. We thus 
proceeded to assess BIO effects on our GPCs with a range of 5nM to 1M. 
We treated all GPC lines with increasing concentrations of BIO from 
5nM to 1µM for 48 hours, and assessed the phosphorylation status of 
activating Tyr279 (GSK3α), Tyr216 (GSK3β) and inhibitory Ser21 (GSK3α), 
Ser9 (GSK3β) (Fig. 20). Previous work implicates the role of these 
phosphorylation sites at regulating GSK3 activity
51
. We observed a dose-
dependent decrease in the levels of Tyr279/216 phosphorylation with as little 
as 50nM BIO treatment. Conversely, no dose-dependent increase in Ser21/9 
phosphorylation was observed in NNI-1, 4 and 8 (Fig. 20A-C), implying that 
BIO inhibits GSK-3 activity by suppressing the activating Tyr279/216 
phosphorylation sites. The inhibitory phosphorylation of GSK3α Ser21 was 
upregulated in NNI-11, suggesting additional GSK3 inhibition by this mode 
(Fig. 20D).  
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 We thus utilized 500nM BIO for our subsequent experiments because 
significant ablation of Tyr279/216 phosphorylation of GSK3α/β was observed 
(Fig. 20).  Following, we observed a time-dependent reduction in cell viability 
with 500nM BIO (Fig. 21). Interestingly, by day 15, viability decreased by 
approximately 20% in all GPC lines, suggesting that the process of cell death 
and cell proliferation must be balanced to maintain this small change upon 
BIO treatment. Accordingly, we explored 2 possible mechanisms previously 
associated with GSK3 inhibition
71, 72
: apoptosis (cell death) and induction of 




Table-5. Biochemically-derived kinase selectivity profile of BIO, showing strong 
selectivity of BIO for GSK3α/β. Kinases were assayed using various concentrations 
of each compound. IC50 values, generated from the dose-response curves, are 
expressed in µM. Data from Meijer et al.116.  
 
Protein Kinases BIO 
GSK3α/β 0.005 
CDK1/cyclin B 0.32 
CDK2/cyclin A 0.30 
CDK4/cyclin D1 10 
CDK5/p35 0.08 
erk1 > 10 
erk2 > 10 
MAPKK 10 
protein kinase C α 12 
protein kinase C β1 > 10 
protein kinase C β2 > 10 
protein kinase C γ > 10 
protein kinase C σ > 10 
protein kinase C ε > 10 
protein kinase C η > 10 
protein kinase C ξ > 10 
cAMP-dependent PK > 10 
cGMP-dependent PK > 10 
casein kinase 2 > 10 








Figure-20. BIO selectively inhibits GSK3α/β by suppressing Tyr279/216 
phosphorylation. BIO causes a dose-dependent decrease in activating Tyr279/216 
phosphorylation in NNI-1, NNI-4, NNI-8 and NNI-11, while also promoting 
inhibitory Ser21 phosphorylation in NNI-11. 500nM BIO was utilized for subsequent 
experiments due to significant ablation of Tyr279/216 observed. (Right Panel) 
Quantitation using Quantity One of protein levels in Western blot (Left Panel) 
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Figure-21. GSK3 inhibition by BIO treatment decreases GPCs cell viability. 
Treatment of GPCs at increasing timepoints leads to a significant decrease in cell 
viability in NNI-8 and NNI-11 by 5 days BIO treatment; and in NNI-1 and NNI-4 by 














5.2 GSK3 inhibition by BIO specifically targets the stem cell population 
defined by the CD133 marker 
5.2.1 GSK3 inhibition depletes clonogenicity in GPCs and preferentially 
targets towards the CD133
+ 
population 
The study of tumor stem cells is complicated by the fact that 
conventional assays tend to reflect the activity of majority cells, thus masking 
that of a fractional population. GPCs are grown as spheroid structures and 
recent work highlights their heterogeneous make-up
77, 122
. To determine the 
activity of specific cellular populations, we utilized flow cytometry to evaluate 
the sphere-forming ability of CD133-expressing cells, a marker frequently 
associated with tumor-initiating capacity in certain GBM subtypes
36, 37
. The 
neurosphere assay estimates bona fide tumor stem cell frequency, while sphere 
size indicates proliferative capacity
123
. This assay provides an in vitro readout 









seeded at clonal densities that distinguish true stem cell-originated spheres 
from cell aggregations
90
. Thirty cells per well were seeded into 96-well plates 
and the percentage of neurospheres formed, as well as neurosphere size were 
assessed. Colonies greater than 20µm were scored as spheres124. In all GPC 
lines, we observed the following trends (Figs. 22A-D; Tables 6A, B): (1) 
Sphere number in unsorted cells decreased by day 21 post-BIO treatment (Figs. 
22A-Di), indicating that the tumor stem cell frequency was diminished; (2) 
BIO treatment reduced sphere number in specifically CD133
+
 cells compared 
to CD133
-
 cells (Figs. 22A-Di), suggesting that bona fide tumor stem cells 
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were effectively targeted; (3) Sphere size, an indicator of proliferation, was 
diminished in BIO-treated CD133
+
 cells, whereas CD133
-
 spheres tended to 
increase in size (Figs. 22A-D,ii-iv). These data suggest that GSK3 inhibition is 
effective against tumor stem cells, causing cellular disintegration, leading to 
the appearance of more small spheres; while CD133
-
 cells were unaffected and 
continued to proliferate. This underscores the importance of designing 
therapies that target both tumor-initiating and other majority cells to 
completely eradicate tumor growth. The data challenges that while the “cancer 
stem cell hypothesis” accurately pinpoints the etiology of the tumor, targeting 
the supporting cells may also be crucial to remove the microenvironmental 
niche
125
. Interestingly, recent evidence supports that CD133
+
 GBM cells are 
capable of differentiating into endothelial cells which in turn provide the 
vasculogenic niche to maintain the tumor stem cell fraction
24, 126, 127
. Such 
findings highlight the delicate interplay between various cellular fractions in 















Table-6A. Average percentage neurospheres formed normalized to DMSO control for GPCs treated with BIO. GPCs were seeded at 




-flow sorted fraction CD133
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Table-6B. Average neurosphere size normalized to DMSO control for GPCs treated with BIO. GPCs were seeded at 30 cells per well 
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Figure-22A. GSK3 inhibition by BIO depletes self-renewal potential of GPCs 
preferentially in the CD133
+ 
population in NNI-1. (i) BIO treatment reduces 
average percentage neurospheres formed and (ii) average neurosphere size in the 
CD133
+ 
subpopulation. (iii) Distribution of neurosphere size showing a reduction in 
spheres of larger sizes and increase in spheres exhibiting smaller sizes in the CD133
+ 
subpopulation as compared to the total and CD133
- 
subpopulations upon BIO 
treatment. (iv) Representative colonies at days 7, 14 and 21 in the DMSO-control and 




Figure-22B. GSK3 inhibition by BIO depletes self-renewal potential of NNI-4 
GPCs preferentially in the CD133
+ 
population. (i) BIO treatment reduces average 
percentage neurospheres formed and (ii) average neurosphere size in the CD133
+ 
subpopulation. (iii) Distribution of neurosphere size showing a reduction in spheres 
of larger sizes and increase in spheres exhibiting smaller sizes in the CD133
+ 
subpopulation as compared to the total and CD133
- 
subpopulations upon BIO 
treatment. (iv) Representative colonies at days 7, 14 and 21 in the DMSO-control and 
BIO-treated NNI-4 GPCs. Disintegration of neurospheres was observed upon BIO 
treatment in the CD133
+ 
and total populations at days 14 and 21. Scale bar = 100µm. 




Figure-22C. GSK3 inhibition by BIO depletes self-renewal potential of NNI-8 
GPCs preferentially in the CD133
+ 
population. (i) BIO treatment reduces average 
percentage neurospheres formed and (ii) average neurosphere size in the CD133
+ 
subpopulation. (iii) Distribution of neurosphere size showing a reduction in spheres 
of larger sizes and increase in spheres exhibiting smaller sizes in the CD133
+ 
subpopulation as compared to the total and CD133
- 
subpopulations upon BIO 
treatment. (iv) Representative colonies at days 7, 14 and 21 in the DMSO-control and 
BIO-treated NNI-8 GPCs. Disintegration of neurospheres was observed upon BIO 
treatment in the CD133
+ 
and total populations at days 14 and 21. Scale bar = 100µm. 




Figure-22D. GSK3 inhibition by BIO depletes self-renewal potential of NNI-11 
GPCs preferentially in the CD133
+ 
population. (i) BIO treatment reduces average 
percentage neurospheres formed and (ii) average neurosphere size in the CD133
+ 
subpopulation. (iii) Distribution of neurosphere size showing a reduction in spheres 
of larger sizes and increase in spheres exhibiting smaller sizes in the CD133
+ 
subpopulation as compared to the total and CD133
- 
subpopulations upon BIO 
treatment. (iv) Representative colonies at days 7, 14 and 21 in the DMSO-control and 
BIO-treated NNI-11 GPCs. Disintegration of neurospheres was observed upon BIO 
treatment in the CD133
+ 
and total populations at days 14 and 21. Scale bar = 100µm. 




5.2.2 GSK3 inhibition leads to an increase in cleaved PARP-positive cells 
specifically in the CD133
+ 
population 
 Due to apparent cell death from data in our sphere assays, we explored 
the possibility of apoptosis occurring upon BIO treatment. Previous literature 
implicates the role of GSK3 inhibition in triggering apoptosis of common 
serum-grown glioma cells
71
. We explored this phenomenon in GPCs by 
capitalizing on the ability of flow cytometry to detect multiple parameters in 
single cell populations. Accordingly, we evaluated cleaved poly(ADP-ribose) 
polymerase (PARP) in CD133
+/-
 GPC fractions. PARP has been implicated in 
DNA repair
128
 and is the main cleavage target of caspase-3, thereby separating 
the 24kDa PARP amino-terminal DNA binding domain from the 89kDa 
carboxy-terminal catalytic domain
129
. PARP is required for maintenance of 
cell viability, and its cleavage aids in cell disassembly, thus serving as a 
marker of apoptotic cells
130
. 
 We observed in all GPC lines the following trends (Figs. 23A-H): (1) 
Apoptosis as measured by cleaved PARP-expressing cells increased by 1.5 to 
3-fold after 5 days of treatment with 500nM BIO; (2) This increase in cleaved 
PARP-expressing cells coincided with CD133-marked cells. In contrast, the 
changes in cleaved PARP levels in CD133
-
 cells were insignificant. These data 
suggest that GSK3 inhibition by BIO triggers apoptosis in specifically CD133
+
 
tumor-initiating cells, further supporting that GSK3 regulation may be more 








Figure-23A-D. GSK3 inhibition induces a significant increase in cleaved PARP-
positive cells, preferentially targeting the CD133
+ 
fraction. Graphs showing 
percentage of cleaved PARP-positive and CD133-positive cells in GPCs treated with 





Figure-23E. GSK3 inhibition induces a significant increase in cleaved PARP-
positive cells, preferentially targeting the CD133
+ 
fraction in NNI-1. 
Representative FACS plots of the data in (A) showing changes in CD133 percentage, 




fraction in NNI-1. (i, ii, iv, v)(Bottom panels) Percentages of CD133 and cleaved 
PARP-positive cells gated on their respective isotype controls (i, ii, iv, v)(Top 





subpopulations of DMSO and BIO-treated cells respectively. (viii) 






Figure-23F. GSK3 inhibition induces a significant increase in cleaved PARP-
positive cells, preferentially targeting the CD133
+ 
fraction in NNI-4. 
Representative FACS plots of the data in (B) showing changes in CD133 percentage, 




fraction in NNI-4. (i, ii, iv, v)(Bottom panels) Percentages of CD133 and cleaved 
PARP-positive cells gated on their respective isotype controls (i, ii, iv, v)(Top 





subpopulations of DMSO and BIO-treated cells respectively. (viii) 






Figure-23G. GSK3 inhibition induces a significant increase in cleaved PARP-
positive cells, preferentially targeting the CD133
+ 
fraction in NNI-8. 
Representative FACS plots of the data in (C) showing changes in CD133 percentage, 




fraction in NNI-8. (i, ii, iv, v)(Bottom panels) Percentages of CD133 and cleaved 
PARP-positive cells gated on their respective isotype controls (i, ii, iv, v)(Top 





subpopulations of DMSO and BIO-treated cells respectively. (viii) 





Figure-23H. GSK3 inhibition induces a significant increase in cleaved PARP-
positive cells, preferentially targeting the CD133
+ 
fraction in NNI-11. 
Representative FACS plots of the data in (D) showing changes in CD133 percentage, 




fraction in NNI-11. (i, ii, iv, v)(Bottom panels) Percentages of CD133 and cleaved 
PARP-positive cells gated on their respective isotype controls (i, ii, iv, v)(Top 





subpopulations of DMSO and BIO-treated cells respectively.  
 






5.2.3 GSK3 inhibition depletes NF-B-positive cells, preferentially in the 
CD133
+ 
fractions in NNI-8 and NNI-11 
Reports have implicated nuclear factor-kappaB (NF-κB) in pro-
survival activities of glioma: NF-B activation protected against tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL)–induced cell death 
in glioma cells
131
; NF-κB inhibition induced apoptosis in GBM cell lines and 
primary cultures and inhibited tumor growth in nude mice brains
132
; and 
overexpression of mitogen-activated protein kinase/extracellular-regulated 
kinase kinase kinase-3 (MEKK3) conferred resistance to apoptosis through 
NF-κB activation133. Furthermore, GSK3 ablation was shown to inhibit NF-κB 
activity, leading to reduced glioma cell survival in vitro and extended tumor 
latency
71
.   
 We sought to investigate the effects of BIO treatment on changes in 
levels of NF-κB specifically in CD133+/- cells. We show that GSK3 inhibition 
significantly decreased NF-κB-expressing cells, preferentially in the CD133+ 
fractions (Figs. 24C, D, G, H). NNI-1 and NNI-4 however did not show this 
trend in the CD133
+
 fraction (Figs. 24A, B, E, F), indicating that GSK3 
inhibition of CD133
+
 cells was likely occurring through a NFB-independent 
mechanism. This is not unexpected because CD133 as a marker of tumor-
initiating capacity has been controversial and shown to vary according to the 
state of disease progression
134
. Furthermore, tumor-initiating capacity has been 
found in CD133
-
 cells as well
36, 37
, highlighting the complexity of relying on 
surface markers to assign tumorigenic properties to populations of cells. This 
emphasizes the need to adopt complementary assays to measure the functional 




Figure-24A-D. GSK3 inhibition induces a significant decrease in NF-κB-positive 
cells, preferentially targeting the CD133
+ 
fraction in NNI-8 and NNI-11. Graphs 
showing of percentage NF-κB-positive and CD133-positive cells in GPCs treated 





Figure-24E. GSK3 inhibition induces a significant decrease in NF-κB-positive 
cells, preferentially targeting the CD133
+ 
fraction in NNI-8 and NNI-11.  
Representative FACS plots of the data in (A) showing changes in CD133 percentage, 
NF-κB percentages and NF-κB expression in the CD133+ and CD133- fraction in 
NNI-1. (i, ii, iv, v)(Bottom panels) Percentages of CD133 and NF-κB-positive cells 
gated on their respective isotype controls (i, ii, iv, v)(Top panels). (iii, vi) Percentage 
of NF-κB-expressing cells in the CD133+ and CD133- subpopulations of DMSO and 





Figure-24F. GSK3 inhibition induces a significant decrease in NF-κB-positive 
cells, preferentially targeting the CD133
+ 
fraction in NNI-8 and NNI-11.  
Representative FACS plots of the data in (B) showing changes in CD133 percentage, 
NF-κB percentages and NF-κB expression in the CD133+ and CD133- fraction in 
NNI-4. (i, ii, iv, v)(Bottom panels) Percentages of CD133 and NF-κB-positive cells 
gated on their respective isotype controls (i, ii, iv, v)(Top panels). (iii, vi) Percentage 
of NF-κB-expressing cells in the CD133+ and CD133- subpopulations of DMSO and 





Figure-24G. GSK3 inhibition induces a significant decrease in NF-κB-positive 
cells, preferentially targeting the CD133
+ 
fraction in NNI-8 and NNI-11. 
Representative FACS plots of the data in (C) showing changes in CD133 percentage, 
NF-κB percentages and NF-κB expression in the CD133+ and CD133- fraction in 
NNI-8. (i, ii, iv, v)(Bottom panels) Percentages of CD133 and NF-κB-positive cells 
gated on their respective isotype controls (i, ii, iv, v)(Top panels). (iii, vi) Percentage 
of NF-κB-expressing cells in the CD133+ and CD133- subpopulations of DMSO and 






Figure-24H. GSK3 inhibition induces a significant decrease in NF-κB-positive 
cells, preferentially targeting the CD133
+ 
fraction in NNI-8 and NNI-11. 
Representative FACS plots of the data in (D) showing changes in CD133 percentage, 
NF-κB percentages and NF-κB expression in the CD133+ and CD133- fraction in 
NNI-11. (i, ii, iv, v)(Bottom panels) Percentages of CD133 and NF-κB-positive cells 
gated on their respective isotype controls (i, ii, iv, v)(Top panels). (iii, vi) Percentage 
of NF-κB-expressing cells in the CD133+ and CD133- subpopulations of DMSO and 






5.3  BIO causes GPC cell death through the effects of cleaved PARP, c-
Myc and leads to a pro-differentiation response 
5.3.1 BIO induces a time-dependent increase in cleaved PARP, and a 
decrease in c-Myc protein levels 
 The c-Myc oncoprotein has recently been implicated in the regulation 
of cell proliferation, differentiation and apoptosis and has been reported to be 
deregulated in various human tumors
135, 136
. c-Myc was previously reported to 
regulate GPC maintenance and self-renewal
137
. GPCs with reduced c-Myc 
levels showed diminished proliferation, increased apoptosis, and were unable 
to form neurospheres in vitro or generate tumors in mice. Accordingly, we 
explored the timing of events occurring after BIO treatment, specifically the 
induction of apoptosis, as well as the onset of differentiation (subsequent 
section). We treated the GPCs with BIO at increasing time-points of 48 hours, 
72 hours and 5 days and probed for levels of cleaved PARP and c-Myc. These 
time periods were chosen to reflect the average time needed for doubling as 
well as to allow other phenotypic changes such as differentiation to occur
28
 
(Fig. 25). As a positive control for apoptosis, GPCs were treated with 10µM 
etoposide for 72 hours. Etoposide, a chemotherapeutic drug, is a 
topoisomerase II inhibitor known to induce apoptosis by promoting DNA 
double strand breaks, thereby leading to p53 activation
138
. We noted a time-
dependent increase in cleaved PARP after 5 days, indicating an induction of 
apoptosis upon GSK3 inhibition by BIO (Fig. 26). This data mirrors the 
timing of the earlier flow-acquired data on PARP distribution in CD133
+/-
 
cellular fractions (Fig. 23). In addition, we also observed a decrease in c-Myc 
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after 5 days of BIO treatment (Fig. 26). These results provide evidence of 
apoptosis triggered by GSK3 inhibition. 
 
Figure-25. Proliferation curves of GPCs. (A) Proliferation curve of NNI-1 (B) 
NNI-4 and (C) NNI-8, showing doubling times of approximately 5 days (D) 


















Figure-26. GSK3 inhibition leads to a pro-apoptotic and pro-differentiation response. Treatment of GPCs with BIO showed a time-
dependent increase in levels of cleaved PARP and a decrease in c-Myc (except for NNI-1) protein levels. Protein levels of β-tubulin increased 
for NNI-1, NNI-8 and NNI-11 but this was not evident in NNI-4. (Bottom panel) Quantitation by Quantity One of Western blots (Top panel)
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5.3.2 GSK3 inhibition induces a pro-differentiation response 
 Recent findings implicate the role of cell fate in the tumorigenicity of 
GPCs
100
. Accordingly, relatively undifferentiated, bona fide tumor stem cells 
retain tumor-initiating and propagating activity; in contrast, the more 
differentiated progenitors exit mitosis and eventually cease cell division, 
resulting in tumor involution. Enforced differentiation of GPCs has thus been 
proposed as a viable therapeutic strategy. As GSK3 inhibition has been 
associated with changes in cell fate
72
, we explored this possible mode of 
regulation in our GPCs. 
 We first assessed the protein levels of -tubulin III (TuJ1) which 
marks neuronal cells, and then scored for the differentiated phenotypes by 
immunofluorescent analyses. We observed in all GPC lines a general trend of 
time-dependent, elevated TuJ1 expression upon BIO treatment for up to 72 
hours, except for NNI-4 at day 5 (explained below; Fig. 26). Etoposide which 
acted as a positive control for apoptosis similarly induced TuJ1 expression, 
consistent with its role at inducing differentiation
139
. This protein blot analysis 
allowed us to correlate the time of appearance of TuJ1 increase with the 
appearance of the apoptotic process, as illustrated by cleaved PARP and c-
Myc (Fig. 26). Our data suggests that BIO treatment induces apoptosis, a post-
mitotic event that accompanies cellular differentiation
72
.  
 To substantiate our initial findings, we carried out immunofluorescent 
analyses to document the induction of differentiated phenotypes after BIO 
treatment. We analyzed changes in the stemness markers, Nestin, Musashi-1 
(Msi-1), Oct4 and Ki-67; as well as changes in the differentiation markers, 





, Msi-1 is a marker for self-renewal
95
, Oct4 is a 
transcription factor involved in maintaining the pluripotency of stem cells
96, 97
 
and Ki-67 is a marker of dividing cells. TuJ1 marks neurons, GFAP is an 
astroglial marker, and O4 marks oligodendrocytes. Our data are summarized 
in Table 7; Fig. 27 (NNI-1); Fig. 28 (NNI-4); Fig. 29 (NNI-8) and Fig. 30 
(NNI-11). Briefly, we observed a slight but significant decrease in stemness 
markers of all GPCs except for NNI-4 (not significant). Nestin expression was 
decreased in NNI-1, NNI-8 and NNI-11 (Fig. 27, 29, 30); Oct4 expression was 
decreased in NNI-1 and NNI-11 (Fig. 27, 30); while Msi-1 expression was 
decreased in NNI-8 (Fig. 29). Ki-67 expression was also decreased in all 
GPCs except for NNI-4, and correlated with the drop in cell viability upon 
BIO treatment (Fig. 21). Analysis of differentiation markers revealed that in 
BIO-treated cells except for NNI-4, TuJ1 and GFAP were increased while O4 
was increased in only NNI-8 and 11 cells (Fig. 27-30). The differentiation 
capacity to various neural lineages can differ for patients‟ lines74, 140, 
consistent with our observations. Taken together, these data provide strong 
evidence for the pro-differentiation effect of GSK3 inhibition by BIO. 
Interestingly, NNI-4 did not demonstrate significant differentiation, likely 













Table-7. Immunofluorscent analysis of percent positive cells for stemness and differentiation markers in GPCs treated with BIO for 5 
days. Significant decrease in stemness markers Nestin, Msi-1 Oct4 and Ki-67 percentages and increase in differentiation markers TuJ1, 
GFAP and O4 was observed upon GSK3 inhibition.  
 
 % positive 
cells 
Nestin Msi-1 Oct4 Ki-67 TuJ1 GFAP O4 
NNI-1 
DMSO 97.42±0.20 99.14±0.20 97.83±0.45 37.09±0.43 2.81±0.28 21.54±1.15 6.04±1.34 
BIO 95.52±0.34 96.17±1.37 94.20±0.27 19.67±0.78 31.42±0.10 31.15±0.09 4.57±1.39 
p - value 0.00706 0.0914 0.00320 0.000930 0.00003 0.00608 0.264 
NNI-4 
DMSO 97.45±0.17 98.72±0.11 96.29±0.32 30.84±1.45 14.52±0.49 41.38±1.40 68.32±0.91 
BIO 96.58±0.23 98.58±0.14 96.40±0.16 30.59±1.35 14.92±0.61 39.69±0.85 68.33±0.84 
p - value 0.0762 0.192 0.419 0.449 0.289 0.252 0.497 
NNI-8 
DMSO 97.17±0.17 98.96±0.13 94.89±0.33 31.15±0.79 29.21±1.21 91.30±0.49 89.53±1.37 
BIO 94.81±0.63 97.39±0.07 92.73±0.86 18.39±3.62 55.98±3.84 93.98±0.50 94.52±0.14 
p - value 0.0326 0.000642 0.0975 0.0259 0.0167 0.0000430 0.0328 
NNI-11 
DMSO 56.19±0.42 98.24±0.44 96.87±0.11 65.29±1.23 2.75±0.70 13.12±0.56 86.76±0.26 
BIO 41.16±4.73 98.34±0.16 95.28±0.15 49.63±1.38 25.20±1.60 43.06±3.43 95.16±0.64 









Figure-27. GSK3 inhibition by BIO reduces stemness expression and induces 
differentiation in NNI-1. (A, B) Graphical representation of NNI-1 GPCs stained for 
stem and differentiation marker upon BIO treatment as compared to DMSO control. 
(C, D) Representative images of the graph in (A), showing changes in stemness 
marker expression in DMSO (C) and BIO-treated cells (D). Scale bar = 10µm; *p < 





Figure-27. GSK3 inhibition by BIO reduces stemness expression and induces 
differentiation in NNI-1. (E, F) Representative images of the graph in (B), showing 
changes in differentiation marker expression in DMSO (E) compared to BIO-treated 








Figure-28. GSK3 inhibition by BIO does not affect stemness and differentiation 
expression in NNI-4. (A, B) Graphical representation of NNI-4 GPCs stained for 
stem and differentiation marker upon BIO treatment as compared to DMSO control. 
(C, D) Representative images of the graph in (A), showing changes in stemness 




Figure-28. GSK3 inhibition by BIO does not affect stemness and differentiation 
expression in NNI-4. (E, F) Representative images of the graph in (B), showing 
changes in differentiation marker expression in DMSO (E) compared to BIO-treated 




Figure-29. GSK3 inhibition by BIO reduces stemness expression and induces 
differentiation in NNI-8. (A, B) Graphical representation of NNI-8 GPCs stained for 
stem and differentiation marker upon BIO treatment as compared to DMSO control. 
(C, D) Representative images of the graph in (A), showing changes in stemness 
marker expression in DMSO (C) and BIO-treated cells (D). Scale bar = 10µm; *p < 





Figure-29. GSK3 inhibition by BIO reduces stemness expression and induces 
differentiation in NNI-8. (E, F) Representative images of the graph in (B), showing 
changes in differentiation marker expression in DMSO (E) compared to BIO-treated 




Figure-30. GSK3 inhibition by BIO reduces stemness expression and induces 
differentiation in NNI-11. (A, B) Graphical representation of NNI-11 GPCs stained 
for stem and differentiation marker upon BIO treatment as compared to DMSO 
control. (C, D) Representative images of the graph in (A), showing changes in 
stemness marker expression in DMSO (C) and BIO-treated cells (D). Scale bar = 





Figure-30. GSK3 inhibition by BIO reduces stemness expression and induces 
differentiation in NNI-11. (E, F) Representative images of the graph in (B), showing 
changes in differentiation marker expression in DMSO (E) compared to BIO-treated 







We have chosen BIO as the probing tool of choice at elucidating GSK3 
regulation in our GPCs. We show that BIO targets preferentially CD133
+
 cells, 
inducing apoptosis with concomitant reduction in oncoprotein c-Myc and pro-









CHAPTER 6 – GENETIC MANIPULATION BY GSK3β shRNA 
ABOLISHES IN VITRO TUMORIGENIC POTENTIAL 
6.1 GPCs lentivirally transduced with shGSK3β exhibit high transduction 
efficiencies and diminished GSK3β activity 
6.1.1 High transduction efficiency  
 As GSK3-null mice are viable and GSK3cannot rescue the 
embryonically lethal GSK3-null mice115; along with the evidence that 
GSK3maintains the growth of several commercially procured serum-grown 
glioma cells
71, 72
, we explored if GPCs were similarly regulated. Our work is 
not merely a replication of GSK3‟s role in a different cellular context for the 
following reasons: (1) GPCs represent the tumor-initiating fraction in the 
heterogeneous tumor mass; consequently, their effective targeting is crucial; (2) 
Serum-grown glioma cells, in contrast with GPCs, have been shown to contain 
karyotypic aberrations not found in the primary tumor. Furthermore, they are 
transcriptomically very distinct from GPCs and the primary tumor
19
, 
suggesting that they may be driven by different signalling pathways. In 
addition, they form orthotopic xenograft tumors that exhibit well-delineated 
margins and are non-hemorrhagic
19
. These features are not reflective of the 
actual patient‟s tumor morphology. Thus, the validation of GSK3‟s role in 
GPCs would be important to ensure that these signalling mechanisms are 
indeed present. Importantly, we will specifically implicate GSK3‟s role in 
regulating GPCs by lentiviral knockdown of the gene. 
GPCs are slowly-dividing cells and thus amendable to genetic 
manipulation via lentiviral vectors
141, 142
. This method also yields stably 
transduced cells, necessary for our long-term in vitro assays to detect tumor 
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stem cell activity. We utilized the human pGIPZ lentiviral shRNAmir target 
gene set from Open Biosystems (Huntsville, AL) consisting of 3 clones which 
we termed clone 1 (V2LHS_114290), clone 2 (V2LHS_114293) and clone 3 
(V2LHS_114291). The microRNA-adapted shRNAs (shRNAmir) incorporate 
the gene-specific silencing sequence into a microRNA scaffold, leading to 
greater specificity due to endogenous processing of the hairpin and also 
exhibits lower cellular toxicity, hence is advantageous over classic stem-loop 
designed shRNAs
143, 144
. In addition, the pGIPZ vector contains turbo-GFP 
(tGFP), enabling visualization and quantification (Fig. 31). 
We carried out lentiviral transductions in NNI-4 and 8 because these 
GPC lines form tumor xenografts reproducibly
28, 84
 (NNI-8, this study), and 
therefore, would be crucial for future in vivo experimentation. GPCs were 
transduced for 4 days at a multiplicity of infection (MOI) of 50
2
, and then 
clonally selected at 5µg/ml puromycin for at least 2 passages. Stably 
transduced clones were further maintained in media containing 2µg/ml 
puromycin. Visual analysis showed green fluorescent cells (data not shown), 
with high transduction efficiencies confirmed by flow cytometry (Fig. 32). 
Briefly, in both GPC lines, we observed close to 95% GFP-positive cells, 
compared to non-transduced and non-silencing controls for all 3 shGSK3 
clones 1-3. 
 
Figure-31.  Vector map of pGIPZ lentiviral backbone. The vector is driven by a 
CMV promoter, a turbo GFP marker to track shRNAmir expression and a puromycin 




Figure-32. NNI-4 and NNI-8 GPCs transduced with GSK3β shRNA Clones 1 to 
3 and non-silencing control displays high transduction efficiencies. (Ai) NNI-4 
GPCs transduced with GSK3β shRNA and non-silencing construct exhibits 
transduction efficiencies greater than 95%. Non-transduced GPCs was used as a 
negative control. (Aii) Representative FACS plots of the data in (Ai). (Bi) NNI-8 
GPCs transduced with GSK3β shRNA and non-silencing construct displays 
transduction efficiencies greater than 95%. Non-transduced GPCs was used as a 
















6.1.2 GSK3β activity is diminished in shGSK3 cells 
Following lentiviral transductions, we observed that effective 
knockdown of GSK3was confirmed in all GPC lines (Fig. 33). Next, we 
assessed GSK3 activity by probing for the activating Tyr279()/Tyr216() 
and inhibitory Ser21()/Ser9() phosphorylation status. In both NNI-4 and 8 
GPC lines, we observed the following trends: (1) Phosphorylation at Tyr216 
() was significantly reduced while negligible change was seen with Tyr279 
(); and (2) Negligible change was observed at inhibitory Ser21()/9() 
phosphorylation sites (Fig. 33). BIO-treated cells were used as the positive 
control and displayed diminished GSK3 activity at both  and  
phosphorylation sites, consistent with its kinase selectivity profile of being 
non-selective over the  and  forms (Table 5). These data suggest that 
specific knockdown of GSK3 could be achieved. This is important as it 




Figure-33. Transduction of NNI-4 and NNI-8 GPCs with GSK3β shRNA results 
in an ablation of total GSK3β and activating phosphorylated Tyr216 (GSK3β) 
(Ai) Representative western blot showing reduction of total GSK3β and activating 
pTyr216 levels in NNI-4. (Aii-iv) Quantitation of total GSK3α/β, activating tyrosine 
279/216 phosphorylation and inhibitory serine 21/9 phosphorylation levels 
respectively for the data in (Ai). (Bi) Representative western blot showing reduction 
of total GSK3β and activating pTyr216 levels in NNI-8. (Bii-iv) Quantitation of total 
GSK3α/β, tyrosine 279/216 and serine 21/9 phosphorylation levels respectively for 
the data in (Bi). All values are normalized to the non-silencing control and non-
transduced cells for cells transduced with shGSK3β clones and cells treated with BIO 
respectively, and are performed in triplicates. *p < 0.05, **p < 0.01, ***p < 0.001 





6.2 GSK3β inhibition reduces cell viability and CD133 expression, 
mediated by PARP, c-Myc and a pro-differentiation response, leading 
to diminished soft agar colony formation  
6.2.1 shGSK3 knockdown reduces cell viability 
We assessed cell viability after lentiviral transduction of shGSK3 
clones 1-3. Generally, we observed reduced cell viability by 1.8-fold for up to 
10 days (NNI-4) and 1.4-fold for up to 15 days (NNI-8) (Fig. 34). The data 
suggest that GSK3 maintains GPC proliferation. 
 
 
Figure-34. Ablation of GSK3β reduces cell viability in NNI-4 and NNI-8. (A) Cell 
viability curve of NNI-4 showing reduced cell viability in cells transduced with 
shGSK3β clones 2 and 3 as compared to the non-silencing control. (B) Cell viability 
curve of NNI-8 demonstrating reduced cell viability for cells transduced with 











6.2.2 shGSK3 knockdown reduces CD133-expressing cells 
Next, we assessed the effects of shGSK3 knockdown on the 
frequency of CD133-expressing cells, bearing in mind that our previous 
experiments suggested that BIO preferentially targeted CD133
+
 tumor-
initiating cells. Accordingly, we observed up to 2-fold reduction in CD133 in 
NNI-4 for clones 2 and 3; while NNI-8 demonstrated ~ 2-3-fold CD133 
reduction for clones 1-3 (Fig. 35). It should be noted that the CD133% in NNI-
4 was already low (~3%) in initial cultures hence a clear reduction is less 
obvious. Nevertheless, other works have indicated that mere 2-fold changes in 
CD133% can result in significant differences in tumor latency
145
 due to 





Figure-35. GSK3β ablation depletes the CD133-expressing GPCs. (Ai) NNI-4 
transduced with GSK3βshRNA clones 2 and 3 showed a significant reduction in 
CD133-percentage when normalized to the non-silencing control. (Aii) 
Representative FACS plots of the data in (Ai). (Bi) NNI-8 transduced with 
GSK3βshRNA clones 1-3 displayed a significant decrease in CD133-percentage 
when normalized to the non-silencing control. (Bii)Representative FACS plots of the 










6.2.3 shGSK3β knockdown leads to increased cleaved PARP and 
correlates with decreased c-Myc, and the induction of differentiation 
 Next, we evaluated the levels of cleaved PARP, c-Myc and TuJ1 in 
shGSK3 knocked down GPCs. Although the result was less clear in NNI-4 
(Fig. 36A), we generally noted with shGSK3 clone 3 that cleaved PARP was 
increased, with concomitant decrease in oncoprotein c-Myc. In addition, TuJ1 
was induced. We noted that this clone also generated the most obvious 
phenotypic change in the soft agar colony assay described in a later section 
(Section 6.2.5). This would be accounted for by the extent of efficient GSK3 
knockdown. BIO- and etoposide-treated GPCs were included as positive 
controls of apoptosis. Our data further strengthens previous findings with BIO 
that GSK3 inhibition, specifically the  form, results in apoptosis with 





Figure-36. NNI-4 and NNI-8 GPCs transduced with GSK3β shRNA exhibitied 
an increase in cleaved PARP, correlated with a decrease in c-Myc and also leads 
to elevated TuJ1 expression levels. (A) NNI-4 GPCs transduced with GSK3β 
shRNA Clones 2 and 3 exhibitied an increase in cleaved PARP, correlated with a 
decrease in c-Myc and an increase in TuJ1 expression for clone 3. (Ai) Western blot 
analysis of NNI-4 transduced with GSK3β shRNA with etoposide as a positive 
control. (Aii) Quantitation of Western blot results by Quantity One. (B) NNI-8 GPCs 
transduced with GSK3β shRNA exhibitied an increase in cleaved PARP, correlated 
with a decrease in c-Myc and also leads to elevated TuJ1 expression levels. (Bi) 
Western blot analysis of NNI-8 transduced with GSK3β shRNA with etoposide as a 
positive control. (Bii) Quantitation of Western blot results by Quantity One.  







6.2.4 GSK3β inhibition leads to induction of differentiation 
 To substantiate our observation that shGSK3 (clone 3 in particular) 
knockdown leads to the induction of differentiation, we scored for 
differentiated cell types: Neurons (TuJ1), astrocytes (GFAP) and 
oligodendrocytes (O4). In addition, we examined the retention of stemness 
markers such as Nestin, Msi-1 and Oct4. Ki67 indicates dividing cells. In both 
GPC lines, we observed negligible changes in the levels of stemness markers 
(Figs. 37, 38), consistent with the notion that GPCs maintain self-renewal 
properties typical of bona fide stem cells, and may represent a state of de-
differentiation
146
. However, our studies with cells of human origin preclude 
that analysis. In NNI-4, significant increases were observed in O4 cells, while 
proliferation was diminished (Fig. 37A). On the other hand, NNI-8 displayed 
an increase in mainly TuJ1 cells, similarly with diminished proliferation (Fig. 
38A). The ability of patients‟ GPCs to give rise to varied lineages has been 
previously documented
28, 74
. Collectively, our data provides strong support that 
GSK3 inhibition leads to the induction of differentiation, with concomitant 
reduction in proliferation. This finding would be consistent with the notion 
that enforced differentiation of GPCs may be a way to blunt the tumorigenic 
potential of these cells
100
. By targeting GSK3 critically required for GPC 






Figure-37. GSK3β downregulation by shGSK3β reduces stemness expression 
and induces differentiation in NNI-4. (A) Graphical representation of NNI-4 GPCs 
stained for stem and differentiation markers upon shGSK3β transduction as compared 
to GPCs transduced with the non-silencing control construct. (B) Representative 
images of the graph in (A), showing changes in stemness and differentiation marker 
expression in non-silencing construct -transduced cells. Scale bar = 10µm; *p < 0.05, 




Figure-37. GSK3β downregulation by shGSK3β reduces stemness expression 
and induces differentiation in NNI-4. Representative images of the graph in (A), 
showing changes in stemness and differentiation marker expression in shGSK3β 




Figure-37. GSK3β downregulation by shGSK3β reduces stemness expression 
and induces differentiation in NNI-4. Representative images of the graph in (A), 
showing changes in stemness and differentiation marker expression in shGSK3β 














Figure-38. GSK3β downregulation by shGSK3β reduces stemness expression 
and induces differentiation in NNI-8. (A) Graphical representation of NNI-8 GPCs 
stained for stem and differentiation markers upon shGSK3β transduction as compared 
to GPCs transduced with the non-silencing control construct. (B) Representative 
images of the graph in (A), showing changes in stemness and differentiation marker 
expression in non-silencing construct -transduced cells. Scale bar = 10µm; *p < 0.05, 





Figure-38. GSK3β downregulation by shGSK3β reduces stemness expression 
and induces differentiation in NNI-8. Representative images of the graph in (A), 
showing changes in stemness and differentiation marker expression in shGSK3β 




Figure-38. GSK3β downregulation by shGSK3β reduces stemness expression 
and induces differentiation in NNI-8. Representative images of the graph in (A), 
showing changes in stemness and differentiation marker expression in shGSK3β 
Clone 3 (E) -transduced cells.  
 
6.2.5 shGSK3 knockdown diminishes colony formation in soft agar 
The soft agar assay is an in vitro correlate of transformation and 
detects malignant cell transformation
147, 148
. It is often an accurate prediction 
of in vivo tumorigenesis
147, 148
. Colony formation was measured to determine 
the anchorage-independent growth potential of GPCs following transduction 
with shGSK3.  
 We observed, except with clone 1 in NNI-4, that GSK3 knockdown 
in general led to reduced colony numbers and sizes (Fig. 39). Notably, clone 3 
which we earlier documented to show the greatest changes in PARP, c-Myc 
and TuJ1 proteins, significantly abrogated colony growth. Our data provides 
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strong evidence that GSK3 maintains GPC survival, and its ablation leads to 
diminished tumorigenic potential. 
 
Figure-39. GSK3β inhibition depletes in vitro tumorigenic potential in GPCs. (A) 
NNI-4 GPCs showed a (i) decrease in number of colonies and (ii) reduction in colony 
size when transduced with GSK3β shRNA clones 2 and 3 (iii) Representative soft 
agar images (4× magnification) illustrating the data in (Ai,ii). (B) NNI-8 GPCs also 
showed an inhibition in soft agar colonization with a (i) decrease in number of 
colonies as well as (ii) reduction in colony size when transduced with GSK3β shRNA 
clones 2 and 3 (iii) Representative soft agar images (4× magnification) illustrating the 




To definitively prove the role of GSK3β in GPC regulation, we employed 
lentiviral-mediated transduction of shGSK3β in our GPCs. We show that 
ablation of GSK3β activity depletes CD133 expression, leading to apoptosis 
with concomitant increase in PARP and reduction in c-Myc, further resulting 



















CHAPTER 7 – DISCUSSION 
Cancer stem cells are controversial because their definition as the cells-
of-origin of the tumor can be interpreted as an artifactual consequence of the 
animal model when prospectively isolated
25
. Thus, GPCs isolated from 
clinical specimens cannot reflect the etiology of the disease although they may 
contain characteristics that perpetuate the tumor. It is critical to realize that the 
molecular characteristics supporting the malignant traits of GPCs are not 
necessarily the same molecular alterations that permit transformation and thus 
generation of tumors de novo
149
. To reveal cellular compartments necessary 
for transformation, lineage-tracing models with suitable cell type-specific 
promoters would have to be utilized to identify the tumor-initiating cell, and 
its subsequent progeny which reconstitutes the tumor mass
14, 16
. This poses a 
question as to how reliable GPCs are as cellular models for investigations. 
Previous works have highlighted that GPCs grown in serum-free media 
supplemented with growth factors retain transcriptomic and karyotypic 
hallmarks typically found in the primary tumor
19
, whereas commercially 
procured serum-grown glioma cells contain many additional aberrations
19, 150
. 
In addition, their respective xenograft tumors differ with only GPCs capable of 
recapitulating the patient‟s original histopathology19. Such findings underscore 
the relevance of GPCs, but do not shed light on how these cells might 
contribute to disease outcome and patient survival profiles. The link between 
GPCs and the primary tumor thus remains unresolved.  
Our work initially described the isolation and characterization of GPCs 
from GBM and oligodendroglial tumors. These tumors are molecularly 
distinct; furthermore, have very different clinical profiles where patients with 
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oligodendrogliomas typically respond better to chemotherapy and survive 
longer
4
. We thus sought to establish if these phenotypic differences were 
driven at the gene expression level in GPCs. This is an important endeavor as 
it would suggest that GPCs retain similar properties to the primary tumor, and 
potentially mirror the primary tumor molecular classification systems 









. It would further suggest that to target a tumor 
effectively, the selective disruption of key signaling pathways predicted by 
gene expression would become imperative. Accordingly, we observed an 
enrichment of the oligodendroglial GPC gene signature in better surviving, 
lower grades of gliomas including oligodendrogliomas, while the GBM GPC 
signature predominated the higher grades. These data would strongly imply 
that neural precursor type differences underlie their survival outcome. In 
support, Persson et al. showed using transgenic mouse models that GPCs 
derived from oligodendrogliomas were more sensitive to chemotherapeutic 
agents than GPCs derived from GBM
102
. These oligodendroglioma GPCs 
exhibited features of oligodendrocyte progenitor cells (OPCs), as opposed to 
GBM GPCs which displayed neural stem cell features. Thus, our findings 
validate Persson et al.‟s conclusions in a clinical setting. Surprisingly when we 
looked at the performance of the gene signature within oligodendrogliomas, 
patients who fared better were enriched for this signature, which seemed to 
contradict the conventional belief that cancer stem cells drive the 
aggressiveness and grade of tumors as had been shown by a recent work that 
the abundance of CD133
+
 cells correlates with oligodendroglioma grade
151
. 
Our findings could be reconciled by recognizing that in our work, we were 
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observing entire transcriptomic changes related to the oligodendroglial GPC 
which could be independent of the CD133 status. Extensive sialylation which 
tends to characterize tumor invasiveness was found to modify CD133 surface 
expression
39
, implying that CD133 may represent yet another aspect of the 
tumor phenotype as distinct from the tumor-propagating functions specified in 
the gene signature. Nevertheless, our data provide strong evidence that the 
primary tumor phenotype and patient survival outcome are “hardwired” into 
the GPCs, thus underscoring their use as relevant cellular models for further 
investigations. In particular, knowing their regulatory and maintenance 
pathways would aid greatly in therapeutic targeting strategies. 
Our small molecule screen consistently identified known signaling 
pathways promoting the survival of GPCs; namely TGFβ42, 107, Jak/Stat108, 152, 
PI3K/Akt/mTOR
3
, all of which have been shown to be critical for maintaining 
GPCs in vitro, resulting in tumor growth. However, the lack of efficacy of 
Hh/SMO
111
 and γ-secretase153 inhibitors suggests that such screens cannot 
reflect an aspect of tumor biology, that is, paracrine feedback loops. In 
addition, in enabling a greater speed at performing these initial screens with a 
larger number of compounds, viability which was used as an endpoint may not 
reflect the survival of bona fide tumor stem cells. These frequently minority 
cells would be masked by the transiently proliferating progenitors. 
Consequently, candidates from such screens have to be further validated with 
functional assays. GSK3β emerged as a novel regulatory pathway of GPC 
survival. We focused our attention on this pathway as clinical stage candidates 
are in trials and the demonstration of its inhibition efficacy on GPCs would be 
instrumental. Initially thought to have a role only in glycogen metabolism, 
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GSK3 has recently been reported to be an important enzymatic modulator of a 
wide array of cellular functions including cell survival, metabolism and 
structure
154, 155
. The involvement of GSK3 in the regulation of apoptosis is 
controversial. While studies have implicated a role of GSK3 as a pro-survival 
factor, yet others have reported a role of GSK3 as pro-apoptotic. GSK3β 
knockout mice have been shown to develop an embryonic lethal phenotype, 
and the embryonic fibroblasts from these knockout mice are sensitized to 
apoptosis
115
. GSK3 has also been shown to be a pro-survival factor in 
pancreatic tumor cells, through the modulation of NF-κB66. Moreover, reports 
have provided evidence for GSK3β inhibition in the promotion of p53-
dependent apoptosis mediated by Bax in colorectal cancer cells
156
. On the 
other hand, studies have shown that overexpression of catalytically active 
GSK3 induced apoptosis in both Rat-1 and PC12 cells, and dominant-negative 
GSK3 protected cells from apoptosis upon inhibition of phosphatidylinositol 
(PI) 3-kinase, thereby proving a role of GSK3 in the PI 3-kinase/Akt cell 
survival pathway
157. A role of GSK3β has also been reported in neuronal 
apoptosis
158
, and apoptosis of cardiomyocytes using the GSK3 inhibitor 
BIO
159
. These data point to the complex involvement of GSK3 in apoptosis 
and suggest that the biological outcome of GSK3 signaling is tissue and cell 
type context dependent. The complexity of GSK3β is heightened by reports 
implicating its role both as a tumor promoter and tumor suppressor. Studies 
have shown a role of GSK3β as a tumor suppressor in skin tumorigenesis, 
where down-regulation or inactivation of GSK3β would render it oncogenic 
for epidermal cells
62
.   Kinase-inactive GSK3β in mouse mammary glands 
also plays a role in promoting mammary tumorigenesis
63
. However, the 
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function of GSK3β as a tumor promoter has been evident in tumorigenesis of 
ovarian, colon and pancreatic carcinomas
57
. 
Studies have provided an insight into the role of GSK3β in GBM, 
demonstrating that GSK3 inhibition reduced glioma cell survival and 
clonogenicity, through the effects of c-Myc, decrease in NFκB, and alteration 
of glucose metabolism, leading to apoptosis and cytotoxicity
71
. Studies have 
also provided a role for GSK3β inhibition in the promotion of tumor cell 
differentiation, apoptosis and reduction in clonogenicity in serum-grown 
glioma cells
72
. These data point to a pro-survival and tumor promoter 
involvement of GSK3β in GBMs, providing the basis for our investigations in 
GPCs. Specifically, we asked how GSK3β inhibition affected tumor stem cell 
activity defined by complementary means; CD133 expression and sphere 
formation which reflects extended self-renewal potential. Our data suggest that 
GSK3β inhibition induces differentiation of GPCs, accompanied by apoptotic 
responses consistent with cell cycle exit. Interestingly, we noted that while 
CD133
+
 cells were preferentially inhibited, CD133
-
 cells which comprised 
more lineage-committed progenitors generally continued to proliferate. Such 
observations challenge the “cancer stem cell hypothesis” in therapeutic 
targeting, and suggests that equal targeting of other non-stem cells may be 
crucial to fully eradicate tumor growth. Indeed, we had observed that GSK3 
inhibition resulted in elevated β-catenin protein expression in our GPCs (data 
not shown). The Wnt pathway has been shown vital to maintain self-renewing 
stem cells, and hyperactivated Wnt signaling initiates and sustains intestinal 
cancers
15
. It is thus plausible that while GSK3β maintains the CD133+ tumor 
stem cell population, its inhibition may induce differentiation and a 
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concomitant loss of CD133 expression (thus scoring as CD133
-
 cells) which 
then proliferate owing to the self-renewing properties of an activated Wnt 
signaling mechanism. Supporting our hypothesis, we leveraged on 
REMBRANDT and observed that GSK3β mRNA expression was able to 
stratify patient survival. Fig. 40A shows the Kaplan-Meier survival plot for all 
gliomas with differential GSK3β gene expression, where significant difference 
was observed between the GSK3β upregulated versus downregulated samples 
(p = 0.0212). An investigation into the clinical reports of patients with GSK3β 
upregulation revealed that most of the samples belonged to Grades II and III 
astrocytoma and oligodendroglioma, whereas Grade IV GBMs only 
constituted 3 out of 19 of the patient samples. In the group of patients with 
GSK3β downregulation, an increased number of patients belonged to Grade 
IV GBMs, with 11 out of 23 patients. An analysis of the gene expression plot 
in all gliomas indeed shows that GBMs show significant downregulation of 
GSK3β gene expression (p = 0.0224) compared to the insignificant change in 
GSK3β gene expression in other gliomas (p > 0.05) when evaluated against 
the non-tumor samples (Fig. 40B). These observations would be consistent 
with our postulation of GSK3β inhibition at inducing differentiation with 
elevated β-catenin, consistent with GBM being of a mixed cell type tumor. 
From our results in this thesis however, we would have expected a reversed 
trend in which low GSK3β expression correlates with better survival and high 
GSK3β expression portends poorer survival by promoting GPC growth. 
Interestingly, Clement et al. demonstrated that embryonic stem cell-like genes 
tended to be enriched in glioma grades II-III, further strengthening our notion 
that GBM represents a more differentiated state where bona fide stem cell 
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numbers are diluted. GSK3 has been shown to negatively regulate the Wnt, 
Notch and Hh pathways, which exhibit aberrant activation in various 
cancers
160, 161
. This suggests that GSK3 inhibitors could have a therapeutically 
negative, pro-survival impact on tumor cells by activating the Wnt pathway. In 
contrast, although the induction of differentiation by itself has been suggested 
as a therapeutic strategy, the use of morphogens introduces the potential 
problem of interfering with the highly regulated adult stem cell niches, and 







Figure-40. Kaplan-Meier survival plot for gliomas with differential GSK3β gene 
expression and gene expression intensity in gliomas.  (A) Kaplan-Meier plot for all 
gliomas displaying up- and down-regulated GSK3β expression (B) Gene expression 
intensity of GSK3β in gliomas showing significant down-regulation in GBMs versus 











7.1 FUTURE WORK 
Moving forward, the validation of GSK3β inhibition in GPCs requires 
further in vivo work, specifically, populations of cells must be colored to allow 
for single cell tracking. Varnat et al. has recently developed a novel „red/green‟ 
competition assay to test stem cell self-renewal in vivo
162
. This method has the 
advantage in that it does not select cell populations for analysis (e.g. 
implantation), resulting in a biased, expected survival outcome. Instead, mixed, 
colored cell populations are allowed to interact in tumor formation, and the 





Adapting this method, we can isolate CD133
+
 GBM cells from primary tumors 
and transduce these cells with shGSK3β lentiviral vectors expressing RFP 
(TomatoRED). Similarly for CD133
-
 cells, we can sort these cells and 
129ransducer them with shGSK3β lentiviral vectors expressing GFP. We can 
then proceed to inject these cells into immunocompromised mice. Competition 













 cells in vivo in a tumor context is postulated to 




 populations. Compared to xenograft 
models with GPCs transduced with non-silencing control vectors, we can then 
generate a survival Kaplan-Meier curve in which we would expect the 
shGSK3β transduced GPCs to exhibit better survival.  Relative population size 




 cells can then be measured by FACS 
analysis following tumor dissociation where relative expression of RFP- and 
GFP-positive cells can be determined. A greater percentage of RFP
+
 cells 
would suggest that the stem CD133
+
 cells are responsible for tumor growth 





 cells as compared to RFP
+
 cells would suggest a contribution by the 
more differentiated CD133
-
 cells. This would help us validate if GSK3β 
inhibition indeed causes a differentiation in the CD133
+
 population. The 
contribution of proliferation of these sorted GPCs can be determined by IHC 
staining of Ki-67.   
 
7.2 CONCLUSIONS 
In vitro passaged GPCs contribute to molecular heterogeneity and survival 
outcome of glioma patients. GSK3β promotes GPC survival while its 
inhibition abrogates tumor stem cell frequency and induces differentiation. 
However, non-tumor stem cells continue to proliferate, signaling a need for 
caution in determining efficacy of GSK3β inhibition by focusing on only GPC 
activity alone. Better animal models allowing single cell tracking by colors 
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Tissue collection and primary glioma-propagating cell culture 
Graded brain tumor specimens were obtained with informed consent, as part 
of a study protocol approved by the institutional review board. NNI-1, 2, 3, 4 
and 5 were derived from patients with GBM as previously described
28, 84
. 
NNI-8 is a new GPC line derived from a patient with anaplastic 
oligoastrocytoma, and characterized according to previous methods (Fig. 
S2)
28
. "Gunther" lines: GS-1, 3, 4, 5, 6, 7 and 8 are GBM-propagating cells 
while GS-2 was derived from a high grade tumor with oligodendroglial 
features as previously described
73
. "Pollard" lines: G144, 144ED, 166, 179 and 
GliNS2 are GBM-propagating cells while G174 was derived from a patient 




Processing of Microarray Data and Gene Signature Generation 
(Conducted by F.S.L. Ng, Singapore Institute for Clinical Sciences, 
A*STAR)
 
Affymetrix U133 Plus 2.0 CEL files were mas5 processed and quantile 
normalized in the R statistical software using the affy packages
163
.  Probes 





 publications and were processed similarly.  
To obtain a GPC gene signature, a linear model was fitted with batch 
correction using the limma package
169
.  Additionally, the NNI-8 Stemness 
signature was obtained using the limma package by comparing the GPC cells 
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to primary tumor.  For both signatures, probesets with adjusted p-value ≤ 0.05 
were considered significant.   
 
Prediction of Phillips Classification in Rembrandt and Gravendeel 
datasets
 
To classify the Rembrandt and Gravendeel samples according to the Phillips et 
al. classification
10
, Affymetrix U133A probes from the Phillips classification 
signature genes were mapped to U133 Plus 2.0 GeneChip using BioMart 
(http://www.biomart.org/).  Classification of the Rembrandt and Gravendeel 





Rembrandt SNP Array Processing and 1p19q LOH Analysis 
CEL files from the Affymetrix 100K SNP Arrays of Oligodendroglioma and 
Oligoastrocytoma patients were downloaded from the Rembrandt database and 
all samples were normalized in dChip
165, 166
. Chromosome 1p and 19q loss of 












Table-S1. Probesets in the GPC signature. 95 probes were used to generate the oligodendroglial GPC gene signature of oligodendroglial 




Gene Symbol Description Log Fold Change 
212507_at 23505 TMEM131 transmembrane protein 131  -0.931307621 
241612_at 27022 FOXD3 forkhead box D3  1.372986027 
201368_at 678 ZFP36L2 zinc finger protein 36, C3H type-like 2  -1.105289687 
201369_s_at 678 ZFP36L2 zinc finger protein 36, C3H type-like 2  -0.904474969 
201564_s_at 6624 FSCN1 fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus)  -1.072722937 
220231_at 10842 C7orf16 chromosome 7 open reading frame 16  2.645835821 
228035_at 65975 STK33 serine/threonine kinase 33  -1.243243529 
215241_at 63982 ANO3 anoctamin 3  1.090294876 
218163_at 28985 MCTS1 malignant T cell amplified sequence 1  1.017692402 
231840_x_at 90624 LYRM7 Lyrm7 homolog (mouse)  0.891245471 
206067_s_at 7490 WT1 Wilms tumor 1  0.827289917 
218988_at 55508 SLC35E3 solute carrier family 35, member E3  1.67648345 
205386_s_at 4193 MDM2 Mdm2 p53 binding protein homolog (mouse)  1.884030655 
211832_s_at 4193 MDM2 Mdm2 p53 binding protein homolog (mouse)  1.788934315 
1553426_at 285668 C5orf64 chromosome 5 open reading frame 64  -1.147145398 
211138_s_at 8564 KMO kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)  1.260883191 
205306_x_at 8564 KMO kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)  1.335650833 
241765_at 1368 CPM carboxypeptidase M  3.226405764 
243403_x_at 1368 CPM carboxypeptidase M  2.660052824 
225591_at 26260 FBXO25 F-box protein 25  1.023236638 
1557260_a_at 84911 ZNF382 zinc finger protein 382  1.763574339 
209565_at 7737 RNF113A ring finger protein 113A  0.993408597 
235502_at 5515 PPP2CA protein phosphatase 2, catalytic subunit, alpha isozyme  1.026294597 
243282_at 54520 CCDC93 coiled-coil domain containing 93  -0.893187785 
226462_at 29091 STXBP6 syntaxin binding protein 6 (amisyn)  1.408107909 






214440_at 9 NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase)  1.762236745 
50400_at 196743 PAOX polyamine oxidase (exo-N4-amino)  1.059361819 
237029_at 3081 HGD homogentisate 1,2-dioxygenase  0.971522564 
244829_at -- C6orf218 chromosome 6 open reading frame 218  1.411926375 
227109_at 120227 CYP2R1 cytochrome P450, family 2, subfamily R, polypeptide 1  1.414119526 
225846_at 54845 ESRP1 epithelial splicing regulatory protein 1  1.270624793 
219121_s_at 54845 ESRP1 epithelial splicing regulatory protein 1  1.120675543 
213638_at 221692 PHACTR1 phosphatase and actin regulator 1  1.535840464 
215000_s_at 9637 FEZ2 fasciculation and elongation protein zeta 2 (zygin II)  -0.957606762 
242989_at 6801 STRN striatin, calmodulin binding protein  -1.055129989 
204077_x_at 9583 ENTPD4 ectonucleoside triphosphate diphosphohydrolase 4  0.815264939 
218870_at 55843 ARHGAP15 Rho GTPase activating protein 15  1.017607164 
221427_s_at 81669 CCNL2 cyclin L2  -0.850386591 
222999_s_at 81669 CCNL2 cyclin L2  -0.954468271 
205512_s_at 9131 AIFM1 apoptosis-inducing factor, mitochondrion-associated, 1  0.954516011 
207344_at 10566 AKAP3 A kinase (PRKA) anchor protein 3  2.654311598 
244825_at 57477 SHROOM4 shroom family member 4  1.054431061 
205281_s_at 5277 PIGA phosphatidylinositol glycan anchor biosynthesis, class A  0.836793751 
226764_at 152485 ZNF827 zinc finger protein 827  -0.996757033 
1554509_a_at 80013 FAM188A family with sequence similarity 188, member A  1.293780634 
206334_at 8513 LIPF lipase, gastric  1.947198374 
204644_at 10495 ENOX2 ecto-NOX disulfide-thiol exchanger 2  0.879076665 
218807_at 10451 VAV3 vav 3 guanine nucleotide exchange factor  -1.573828653 
223423_at 26996 GPR160 G protein-coupled receptor 160  1.266788929 
215153_at 9722 NOS1AP nitric oxide synthase 1 (neuronal) adaptor protein  -0.882741057 
1563512_at 9722 NOS1AP nitric oxide synthase 1 (neuronal) adaptor protein  -1.07867364 
37512_at 8630 HSD17B6 hydroxysteroid (17-beta) dehydrogenase 6 homolog (mouse)  1.128384226 
212631_at 8417 STX7 syntaxin 7  1.113525058 
225308_s_at 85461 TANC1 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1  -0.854227497 
200665_s_at 6678 SPARC secreted protein, acidic, cysteine-rich (osteonectin)  -1.027737524 
229000_at 58492 ZNF77 zinc finger protein 77  0.944812365 
204759_at 1102 RCBTB2 
regulator of chromosome condensation (RCC1) and BTB (POZ) domain 







221289_at 1750 DLX6 distal-less homeobox 6  1.041848794 
206552_s_at 6863 TAC1 tachykinin, precursor 1  1.705027503 
222767_s_at 79794 C12orf49 chromosome 12 open reading frame 49  0.808709328 
204713_s_at 2153 F5 coagulation factor V (proaccelerin, labile factor)  1.431619627 
204714_s_at 2153 F5 coagulation factor V (proaccelerin, labile factor)  1.504311671 
206426_at 2315 MLANA melan-A  0.890635292 
206427_s_at 2315 MLANA melan-A  1.431212371 
206135_at 9705 ST18 suppression of tumorigenicity 18 (breast carcinoma) (zinc finger protein)  1.131230985 
206058_at 6539 SLC6A12 
solute carrier family 6 (neurotransmitter transporter, betaine/GABA), 
member 12  
1.091850355 
1561969_at 131368 ZPLD1 zona pellucida-like domain containing 1  1.316003453 
224999_at 1956 EGFR epidermal growth factor receptor  -1.990616663 
201983_s_at 1956 EGFR epidermal growth factor receptor  -2.165112816 
204238_s_at 10591 C6orf108 chromosome 6 open reading frame 108  1.111934072 
242727_at 221079 ARL5B ADP-ribosylation factor-like 5B  1.32300753 
235356_at 374354 NHLRC2 NHL repeat containing 2  0.931504627 
231569_at 203562 TMEM31 transmembrane protein 31  1.032880572 
205647_at 5893 RAD52 RAD52 homolog (S. cerevisiae)  -0.833601355 
202746_at 9452 ITM2A integral membrane protein 2A  3.632094429 
202747_s_at 9452 ITM2A integral membrane protein 2A  3.720860606 
228891_at 10507 SEMA4D 
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) 
and short cytoplasmic domain, (semaphorin) 4D  
0.981611103 
207540_s_at 6850 SYK spleen tyrosine kinase  1.381598219 
204011_at 10253 SPRY2 sprouty homolog 2 (Drosophila)  -0.96891126 
221035_s_at 56155 TEX14 testis expressed 14  0.988947099 
209848_s_at 6490 PMEL premelanosome protein  1.830948971 
215643_at 223117 SEMA3D 
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3D  
0.977345169 
203122_at 51112 TTC15 tetratricopeptide repeat domain 15  -1.208989641 
231068_at 146802 SLC47A2 solute carrier family 47, member 2  -1.501602291 
239738_at 117154 DACH2 dachshund homolog 2 (Drosophila)  1.361110621 
225651_at 7325 UBE2E2 ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, yeast)  1.451235296 
244419_at 2487 FRZB frizzled-related protein  1.045474278 
219212_at 51182 HSPA14 heat shock 70kDa protein 14  0.825224502 






219099_at 57103 C12orf5 chromosome 12 open reading frame 5  1.237422609 
222613_at 57102 C12orf4 chromosome 12 open reading frame 4  1.105505079 
212954_at 8798 DYRK4 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4  1.57075808 
226066_at 4286 MITF microphthalmia-associated transcription factor  2.334568409 
208606_s_at 54361 WNT4 wingless-type MMTV integration site family, member 4  0.859407907 
 
Table-S2A. Activation scores, associated p-value and metadata of Rembrandt samples identified as (+) or (-) based on the OA GPC 
signature 
Samples Activation Score Normalized Score p-value Age 
Survival 
(mths) Status Histology Grade 
HF0505 0.749457969 1 0.0271 35 3.2 1 GBM IV 
HF1246 0.732100118 0.976839461 0.003 65 0.2 1 ASTROCYTOMA II 
E08021 0.731966357 0.976660984 0.0097 40 81.5 1 OLIGODENDROGLIOMA III 
HF1269 0.694346941 0.926465486 0.0014 55 13 1 GBM IV 
HF0599 0.688132241 0.918173226 0.0444 70 42.8 1 OLIGODENDROGLIOMA II 
E10193 0.680597094 0.908119098 0.0269 50 34.2 NA GBM IV 
HF1502 0.654386806 0.873146771 0.0595 70 6.4 1 OLIGODENDROGLIOMA III 
HF1032 0.640376005 0.854452194 0.0471 40 28.1 1 ASTROCYTOMA III 
HF1227 0.632969918 0.844570269 0.018 50 251.7 0 OLIGODENDROGLIOMA II 
E09688 0.624472362 0.833232 0.0144 55 50.8 1 MIXED II 
E09787 0.622652421 0.830803657 6.00E-04 55 86.5 0 GBM IV 
HF0180 0.616102353 0.822063916 0.0479 35 0.3 1 GBM IV 
E09956 0.603754355 0.805588012 0.001 70 21 1 GBM IV 
HF1587 0.590356299 0.787711017 0.0511 30 75.3 0 ASTROCYTOMA III 
E10184 0.586292819 0.782289125 0.0947 30 28.3 1 GBM IV 
HF0087 0.586151619 0.782100723 0.0099 60 78.8 1 ASTROCYTOMA III 
E09606 0.584952923 0.780501305 0.0162 30 13.3 1 GBM IV 
E09515 0.584812915 0.780314493 0.0474 35 65.4 0 ASTROCYTOMA II/III 
E09278 0.58381164 0.778978494 0.0363 40 36.6 0 GBM IV 
HF0963 0.575711213 0.768170114 0.04 10 10.6 1 GBM IV 
HF1493 0.57332728 0.764989237 0.0684 65 41.9 1 OLIGODENDROGLIOMA III 






E09670 0.566785165 0.756260108 0.0575 75 14.2 1 GBM IV 
E09454 0.565155368 0.754085474 0.0828 55 18 1 GBM IV 
E09846 0.559234143 0.746184798 0.0508 65 14.3 1 GBM IV 
HF0285 0.558833826 0.745650656 0.0393 80 14.4 1 OLIGODENDROGLIOMA II 
E10312 0.557733116 0.744181981 0.0856 35 37.9 1 GBM IV 
HF1677 0.557606793 0.744013429 0.0491 50 63.5 0 ASTROCYTOMA II 
E09930 0.557353343 0.743675251 0.0686 50 5.1 1 GBM IV 
HF0026 0.554987055 0.740517919 0.0633 60 57.1 1 ASTROCYTOMA II 
HF0252 0.554987055 0.740517919 0.0552 35 123.1 0 ASTROCYTOMA II 
E09938 0.554812915 0.740285564 0.0303 45 25.2 1 GBM IV 
E09893 0.554807183 0.740277916 0.0153 40 111.9 1 OLIGODENDROGLIOMA III 
E10072 0.550695692 0.734791963 0.0179 65 37.2 0 OLIGODENDROGLIOMA II/III 
E09513 0.544168132 0.726082255 0.0911 55 13.4 1 OLIGODENDROGLIOMA II/III 
HF0251 0.5391027 0.719323462 0.0012 65 22.7 1 OLIGODENDROGLIOMA III 
E09920 0.537674994 0.717418476 0.0367 25 59.4 1 ASTROCYTOMA III 
HF1058 0.530737231 0.708161435 0.0242 40 18 1 GBM IV 
HF1511 0.526839197 0.702960298 0.0256 25 56.6 1 ASTROCYTOMA II 
E09262 0.525938162 0.701758049 0 50 13.6 1 MIXED II/III 
HF0434 0.52223726 0.696819944 0.0083 60 6.1 1 ASTROCYTOMA II 
HF1667 0.519023712 0.692532115 0.0019 60 2.5 1 GBM IV 
HF0445 0.515744412 0.688156552 0.0388 40 47.2 1 GBM IV 
E09212 0.507821892 0.677585553 0 40 7.1 1 ASTROCYTOMA II/III 
E09601 0.503894105 0.672344716 0.0034 70 13.2 1 GBM IV 
E09921 0.497126104 0.663314188 0.0602 40 36.4 0 ASTROCYTOMA II/III 
HF1489 0.496517546 0.662502191 0.0539 50 68.3 1 ASTROCYTOMA II 
E10258 0.488339677 0.651590479 0.0539 50 20.6 1 GBM IV 
HF0936 0.488324253 0.651569899 0.0039 55 5.1 1 ASTROCYTOMA II 
E09988 0.484443639 0.646392006 0.0127 70 64.6 1 OLIGODENDROGLIOMA III 
HF0962 0.483030037 0.644505839 0.0278 45 116.5 0 OLIGODENDROGLIOMA II 
E09605 0.480872441 0.641626964 0.0053 45 59.3 1 GBM IV 
HF1492 0.468710079 0.625398754 0.0344 30 2.2 1 GBM IV 
HF0953 0.466790317 0.622837219 0.0829 35 44.6 1 ASTROCYTOMA II 






E09531 0.462403898 0.61698443 8.00E-04 55 19.3 1 ASTROCYTOMA II/III 
E09664 0.461318096 0.615535648 0.0155 40 27.1 1 OLIGODENDROGLIOMA II/III 
HF0022 0.459908744 0.613655152 0.0678 20 133.9 0 ASTROCYTOMA II 
HF0914 0.452628786 0.603941522 0.032 40 146.9 0 ASTROCYTOMA II 
E10551 0.451868661 0.602927288 0.0669 65 12.3 1 GBM IV 
E09907B 0.443791064 0.59214937 0.0024 60 55.2 1 GBM IV 
HF1345 0.433641331 0.578606606 0.0145 15 83.5 0 ASTROCYTOMA II 
HF1588 0.431310239 0.575496235 0.0735 40 75.2 0 ASTROCYTOMA II 
E09802 0.429940365 0.573668415 0.0306 80 32.2 1 GBM IV 
HF1585 0.425210527 0.567357403 0.031 25 19.9 1 GBM IV 
HF0520 0.422798129 0.564138546 0.0122 40 8.7 1 GBM IV 
E09852 0.422437933 0.563657938 0.0288 50 48.3 1 GBM IV 
HF0108 0.420665649 0.561293184 0.0404 35 132 0 ASTROCYTOMA III 
E09192 0.404265925 0.53941107 0.0641 75 13.4 1 GBM IV 
HF0024 0.4034404 0.538309574 0.0562 45 5.8 1 GBM IV 
E09471 0.399568094 0.533142766 0.0065 70 27.2 1 ASTROCYTOMA II 
E10026 0.398363859 0.531535958 0.0281 65 15.4 1 GBM IV 
HF0608 0.398032902 0.531094363 0.0107 50 10.6 1 ASTROCYTOMA II 
E09690 0.389382233 0.519551795 0.0354 75 62.3 0 GBM IV 
E09647 0.382230723 0.510009552 0.0426 55 19.3 1 GBM IV 
E10144 0.380705674 0.507974683 0.0099 50 25.9 1 GBM IV 
HF1409 0.379186615 0.505947806 0.0143 50 12.7 1 ASTROCYTOMA III 
E09661 0.376503249 0.502367397 0.0076 65 48.5 0 OLIGODENDROGLIOMA II 
E09867 0.368241369 0.49134359 0.0267 75 38.7 0 OLIGODENDROGLIOMA II 
HF0778 0.363984009 0.485663005 0.0013 65 8.1 1 ASTROCYTOMA II 
HF1262 0.357766443 0.477366921 0.0163 30 23.7 1 GBM IV 
HF1178 0.356451664 0.475612614 0.0369 35 15.8 1 GBM IV 
HF0152 0.341086864 0.455111398 0.0564 30 131.5 0 ASTROCYTOMA III 
HF0543 0.334896186 0.44685119 0.049 30 67.6 0 GBM IV 
HF0996 0.322142945 0.429834571 0.0493 50 120.5 0 GBM IV 
HF0138 0.306071311 0.408390229 0.0594 60 1.2 1 GBM IV 
HF1509 -0.299523658 -0.386689141 0.0852 40 2.7 1 GBM IV 






HF1078 -0.31280225 -0.403831985 0.0685 50 22.8 1 GBM IV 
HF0790 -0.317019359 -0.40927633 0.0439 45 7.5 1 GBM IV 
HF0855 -0.323567174 -0.417729649 0.0293 55 13.7 1 ASTROCYTOMA II 
HF0510 -0.336784038 -0.434792801 0.0494 45 19.6 1 OLIGODENDROGLIOMA II 
HF0894 -0.337132125 -0.435242187 0.0477 40 14.1 1 GBM IV 
HF0835 -0.34490649 -0.445278998 0.0021 20 45.3 1 OLIGODENDROGLIOMA II 
E10031 -0.352909446 -0.455610923 0.0213 55 27.5 1 GBM IV 
HF0327 -0.362469071 -0.467952531 0.0057 75 19.6 1 OLIGODENDROGLIOMA II 
E09917 -0.367243861 -0.47411685 0.0036 50 6.1 1 GBM IV 
HF0960 -0.383971676 -0.495712688 0.033 45 88.7 1 OLIGODENDROGLIOMA II 
HF0408 -0.387273163 -0.499974953 4.00E-04 30 15.8 1 GBM IV 
HF1090 -0.395275411 -0.510305964 0.0306 50 8.5 1 OLIGODENDROGLIOMA III 
HF0450 -0.407202966 -0.525704601 0.0508 30 29.5 1 ASTROCYTOMA II 
E09791 -0.416213927 -0.537337876 0.0619 60 13.4 1 GBM IV 
E09730 -0.419038557 -0.540984511 0.0168 40 61.7 1 GBM IV 
HF0442.5 -0.422172569 -0.545030563 0.0252 30 19.6 1 GBM IV 
HF1122 -0.440157815 -0.568249762 0.0091 40 7.3 1 GBM IV 
HF1534 -0.445761091 -0.575483669 0.0165 20 7.8 1 GBM IV 
HF1057 -0.450285554 -0.581324812 1.00E-04 55 24.5 1 OLIGODENDROGLIOMA III 
HF1671 -0.453315816 -0.585236922 0.0711 50 13.3 1 GBM IV 
HF0031 -0.462637223 -0.597270985 0.0601 35 0.5 1 GBM IV 
E10300 -0.46358746 -0.598497754 0.0218 60 9.4 1 GBM IV 
HF0702 -0.480207693 -0.619954703 0.0205 50 8.5 1 ASTROCYTOMA III 
E10102 -0.485464009 -0.626740679 0.014 45 38.8 0 GBM IV 
E10271 -0.485974839 -0.627400166 0.0716 30 12.5 1 GBM IV 
HF0460 -0.491378375 -0.634376206 0.0796 45 10.7 1 OLIGODENDROGLIOMA III 
E09348 -0.496743594 -0.641302777 0.0536 35 18.5 1 GBM IV 
E09139 -0.497586056 -0.642390407 0.028 45 36.5 1 GBM IV 
HF1186 -0.500533627 -0.646195762 0.0111 30 20.1 1 ASTROCYTOMA III 
HF1185 -0.506307341 -0.653649705 0.0285 25 95.2 0 ASTROCYTOMA III 
HF1344 -0.506640166 -0.654079386 0.061 60 9 1 ASTROCYTOMA II 
HF0990 -0.508177096 -0.656063585 0 NA 88.3 1 GBM IV 






E10483 -0.513600598 -0.663065399 0.0754 25 66.4 1 ASTROCYTOMA II 
HF1538 -0.521697579 -0.673518713 0.0756 55 3.2 1 GBM IV 
HF1286 -0.530642368 -0.685066558 0.0333 75 13.2 1 ASTROCYTOMA III 
HF1618 -0.537184 -0.693511895 0.022 50 2.4 1 GBM IV 
HF0816 -0.543687185 -0.701907595 0.0361 60 46.7 1 OLIGODENDROGLIOMA III 
E50074 -0.546405102 -0.705416463 0.0368 50 5.4 1 GBM IV 
HF1382 -0.551104735 -0.711483754 0.0141 35 48.3 1 GBM IV 
E09967 -0.574153706 -0.741240291 0.002 45 4.4 1 GBM IV 
E09610 -0.57500937 -0.742344965 0.0061 55 12.5 1 GBM IV 
E10227 -0.601182757 -0.776135166 0.008 45 12.6 1 GBM IV 
HF0066 -0.601470694 -0.776506897 0.0016 50 9.1 1 GBM IV 
HF0986 -0.603858685 -0.779589825 2.00E-04 15 62.4 1 GBM IV 
HF1139 -0.628805522 -0.811796533 0.0117 40 15.8 1 GBM IV 
HF1191 -0.64276171 -0.829814163 7.00E-04 25 0.3 1 GBM IV 
HF1150 -0.651136485 -0.840626112 0 70 21.2 1 ASTROCYTOMA III 
HF0142 -0.6526464 -0.842575432 0.0021 25 0.3 1 GBM IV 
E09833B -0.661856328 -0.854465576 0.0192 45 20.8 1 GBM IV 
HF1297 -0.665978187 -0.859786953 0 60 17.2 1 GBM IV 
E09966 -0.678273537 -0.875660417 0.0042 55 17.7 1 ASTROCYTOMA III 
HF0184 -0.681526594 -0.879860159 0 65 12 1 OLIGODENDROGLIOMA III 
HF1628 -0.684914765 -0.884234334 0.084 70 14.6 1 GBM IV 
E10284 -0.686683443 -0.886517721 0.0026 55 4.8 1 GBM IV 
E10267 -0.686925784 -0.886830587 0.004 75 12 1 GBM IV 
HF1077 -0.702421737 -0.906836074 5.00E-04 45 73.4 1 GBM IV 
HF1490 -0.722523361 -0.932787546 0.073 65 4 1 ASTROCYTOMA III 















Score p-value Age 
Survival 
(yrs) Status Histology Grade CHR1p CHR19q EGFR 
GSM405355 0.801064034 1 0.0074 73 1.19 1 ASTROCYTOMA II NA NA NA 
GSM405256 0.737876569 0.921120582 0.0866 38 4.79 1 ASTROCYTOMA II no LOH no LOH wild type 
GSM405461 0.716299484 0.894185051 0.0947 49 0.76 1 GBM IV LOH LOH wild type 
GSM405246 0.682859857 0.852441038 0.0305 33 6.31 1 GBM IV LOH LOH NA 
GSM405203 0.66280444 0.827405066 0.0025 39 8.92 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405212 0.658658913 0.82223004 0.02 23 17.49 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405370 0.643329952 0.803094291 0.0192 47 1.61 1 GBM IV no LOH no LOH wild type 
GSM405318 0.634974336 0.792663644 0.0118 62 6.21 0 OLIGODENDROGLIOMA III no LOH no LOH NA 
GSM405216 0.615021607 0.76775586 0.0045 52 3.28 1 GBM IV NA no LOH wild type 
GSM405207 0.605455573 0.755814201 0.0052 44 8.12 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405409 0.59181949 0.738791739 0.0477 54 10.36 1 OLIGODENDROGLIOMA III LOH LOH NA 
GSM405324 0.566705887 0.707441431 0.0436 14 0.67 1 GBM IV no LOH no LOH amplification 
GSM405234 0.554016145 0.691600324 4.00E-04 58 0.62 1 GBM IV NA NA NA 
GSM405283 0.538231934 0.671896267 0.0183 38 4.07 1 OLIGOASTROCYTOMA III LOH LOH wild type 
GSM405205 0.533253927 0.665682023 0.0317 48 3.24 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405386 0.521886757 0.651491935 0.0114 54 3.76 1 OLIGODENDROGLIOMA II LOH LOH wild type 
GSM405325 0.519420906 0.648413715 0.0449 43 3.65 1 OLIGOASTROCYTOMA III NA NA wild type 
GSM405441 0.517104497 0.64552205 0.0178 45 3.27 0 OLIGODENDROGLIOMA II LOH LOH wild type 
GSM405204 0.516167462 0.644352312 0.0954 34 8.59 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405320 0.515438603 0.643442448 0.017 70 0.6 1 GBM IV NA NA wild type 
GSM405411 0.507483079 0.633511251 5.00E-04 38 0.05 1 ASTROCYTOMA III LOH no LOH NA 
GSM405217 0.506733901 0.632576024 0.0389 33 6.77 0 GBM IV NA no LOH wild type 
GSM405314 0.504431242 0.629701523 2.00E-04 54 0.65 1 GBM IV no LOH LOH wild type 
GSM405343 0.489292619 0.610803379 0.0816 67 NA 0 GBM IV NA NA wild type 
GSM405457 0.486971348 0.607905645 0.0523 71 0.3 1 OLIGODENDROGLIOMA III no LOH no LOH wild type 
GSM405287 0.486856457 0.607762221 0.0345 44 6.87 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405330 0.483717775 0.603844081 0.0869 33 0.71 1 GBM IV no LOH NA wild type 
GSM405261 0.476668599 0.595044314 0.0015 60 0.98 1 OLIGODENDROGLIOMA III no LOH no LOH NA 






GSM405243 0.470390141 0.587206667 0.0156 61 0.88 1 GBM IV NA NA NA 
GSM405395 0.464586642 0.579961928 0.0425 55 3.76 1 OLIGOASTROCYTOMA II LOH LOH wild type 
GSM405382 0.459041423 0.573039611 0.0015 44 4.86 1 OLIGOASTROCYTOMA III LOH LOH NA 
GSM405420 0.458788616 0.572724023 0.0413 50 3 1 OLIGODENDROGLIOMA III no LOH no LOH wild type 
GSM405278 0.458173812 0.571956538 2.00E-04 58 0.73 1 GBM IV NA NA amplification 
GSM405462 0.454461768 0.567322647 0.0601 50 7.52 1 ASTROCYTOMA II LOH LOH NA 
GSM405415 0.438470443 0.547360042 0.0062 67 0.5 1 GBM IV no LOH no LOH NA 
GSM405301 0.426132041 0.531957526 0.0979 65 0.3 1 GBM IV NA NA NA 
GSM405465 0.420244949 0.524608435 0.0242 69 0.63 1 GBM IV NA no LOH NA 
GSM405211 0.419707136 0.523937062 0.0445 35 1.83 1 OLIGODENDROGLIOMA III LOH LOH NA 
GSM405342 0.417912408 0.521696632 0.0872 47 2.99 1 OLIGODENDROGLIOMA III NA NA wild type 
GSM405396 0.416841065 0.520359231 0.0331 77 0.02 1 GBM IV no LOH no LOH NA 
GSM405403 0.415940255 0.519234715 0.0034 38 0.04 1 ASTROCYTOMA III NA NA NA 
GSM405333 0.40417074 0.504542362 0.0697 58 9.11 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405249 0.40304092 0.503131964 0.002 23 0.04 1 GBM IV NA NA wild type 
GSM405475 0.39505561 0.493163584 0.0501 34 1.05 1 GBM IV NA NA wild type 
GSM405481 0.392048822 0.489410092 0.0018 34 10.37 0 
PILOCYTIC 
ASTROCYTOMA I NA NA NA 
GSM405268 0.385988137 0.481844298 0.0039 48 0.64 1 GBM IV no LOH no LOH amplification 
GSM405311 0.381022431 0.47564541 0.0427 43 7.48 0 ASTROCYTOMA II NA NA NA 
GSM405265 0.377448173 0.471183522 0.0795 32 1.81 1 ASTROCYTOMA III NA NA wild type 
GSM405483 0.373761793 0.466581668 0.0012 32 0.19 0 
PILOCYTIC 
ASTROCYTOMA I NA NA NA 
GSM405334 0.364091978 0.454510454 0.0214 57 1.47 1 OLIGODENDROGLIOMA III no LOH no LOH wild type 
GSM405321 0.363960116 0.454345846 0.0406 34 3.97 1 ASTROCYTOMA III NA NA wild type 
GSM405459 0.36310793 0.453282028 0.0099 64 1.14 1 GBM IV no LOH no LOH NA 
GSM405210 0.348355938 0.434866532 0.0782 39 10.28 1 OLIGODENDROGLIOMA III LOH LOH wild type 
GSM405464 0.340105521 0.424567209 0.0132 55 0.56 1 GBM IV NA NA NA 
GSM405250 0.317464016 0.39630292 0.0848 31 1.48 1 ASTROCYTOMA II NA NA NA 
GSM405466 0.302478925 0.377596437 0.0725 67 0.28 1 GBM IV no LOH no LOH NA 
















GSM405240 -0.351520541 -0.471837164 0.0206 33 6.62 0 GBM IV no LOH no LOH NA 
GSM405391 -0.371763333 -0.499008553 0.0328 56 1.05 1 GBM IV no LOH no LOH NA 
GSM405339 -0.373760087 -0.501688746 0.0043 78 NA 0 GBM IV NA NA amplification 
GSM405436 -0.375071936 -0.503449608 0.0199 79 0.48 1 GBM IV NA NA NA 
GSM405450 -0.379106436 -0.508865015 0.0134 37 13.3 0 OLIGOASTROCYTOMA III NA NA NA 
GSM405372 -0.380450453 -0.510669056 0.0961 37 3.32 1 GBM IV LOH LOH NA 
GSM405439 -0.381414955 -0.511963683 0.0096 33 3.7 0 OLIGOASTROCYTOMA II no LOH NA wild type 
GSM405384 -0.383888277 -0.515283561 0.0174 70 0.02 0 GBM IV no LOH no LOH NA 
GSM405424 -0.401716738 -0.539214255 0.0365 33 3.2 1 ASTROCYTOMA II no LOH no LOH wild type 
GSM405230 -0.430676082 -0.578085652 0.0297 63 0.47 1 GBM IV no LOH no LOH NA 
GSM405438 -0.433696491 -0.582139871 0.0301 43 2.3 1 GBM IV LOH LOH NA 
GSM405388 -0.444215467 -0.596259227 0.0413 79 0.53 1 OLIGOASTROCYTOMA III no LOH no LOH amplification 
GSM405337 -0.445057768 -0.597389827 0.0197 15 0.28 1 GBM IV NA NA amplification 
GSM405440 -0.445411877 -0.597865138 0.0352 70 0.53 1 GBM IV NA NA wild type 
GSM405326 -0.450820952 -0.605125604 0.0235 75 0.27 1 GBM IV NA NA amplification 
GSM405422 -0.459443511 -0.616699447 0.034 71 0.91 1 GBM IV no LOH no LOH NA 





GSM405476 -0.466653593 -0.626377359 0.0131 65 1.31 1 OLIGOASTROCYTOMA III no LOH no LOH amplification 
GSM405443 -0.486639715 -0.653204227 0.0605 57 0.98 1 GBM IV NA NA amplification 
GSM405312 -0.491071311 -0.659152647 0.0293 61 1.02 1 GBM IV NA NA amplification 
GSM405226 -0.512661405 -0.688132486 0.0028 49 0.28 1 OLIGOASTROCYTOMA III no LOH LOH amplification 
GSM405474 -0.524231599 -0.703662865 0.0344 61 0.29 1 GBM IV NA NA amplification 
GSM405390 -0.554141148 -0.743809699 0.0917 70 0.02 1 OLIGOASTROCYTOMA III NA NA NA 
GSM405405 -0.581116167 -0.780017587 0.0126 71 0.61 1 GBM IV no LOH LOH NA 
GSM405267 -0.591581464 -0.794064892 0.0358 53 0.65 1 GBM IV no LOH NA NA 
GSM405292 -0.605376456 -0.812581563 0 66 1.11 1 GBM IV NA NA amplification 
GSM405347 -0.616268217 -0.827201299 0.0143 43 0.19 1 OLIGOASTROCYTOMA III NA NA amplification 
GSM405428 -0.622239739 -0.835216722 0.0052 71 0.79 1 GBM IV no LOH no LOH amplification 
GSM405376 -0.637951306 -0.856305963 0.016 53 1.85 1 GBM IV no LOH NA amplification 
GSM405289 -0.67705098 -0.908788469 0.003 37 0.19 1 ASTROCYTOMA III NA NA amplification 













Description Log Fold Change 
1553635_s_at 200132 TCTEX1D1 Tctex1 domain containing 1  -6.215791136 
209156_s_at 1292 COL6A2 collagen, type VI, alpha 2  -6.493620158 
209448_at 10553 HTATIP2 HIV-1 Tat interactive protein 2, 30kDa  -6.42297587 
222484_s_at 9547 CXCL14 chemokine (C-X-C motif) ligand 14  -8.105582051 
202018_s_at 4057 LTF lactotransferrin  -8.54583883 
230422_at 2359 FPR3 formyl peptide receptor 3  -7.35868863 
203032_s_at 2271 FH fumarate hydratase  6.389162912 
204122_at 7305 TYROBP TYRO protein tyrosine kinase binding protein  -7.451463342 
213975_s_at 4069 LYZ lysozyme  -8.567997622 
204570_at 1346 COX7A1 cytochrome c oxidase subunit VIIa polypeptide 1 (muscle)  -6.10959307 
204158_s_at 10312 TCIRG1 T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3  -6.005341469 
209183_s_at 11067 C10orf10 chromosome 10 open reading frame 10  -6.05532165 
209047_at 358 AQP1 aquaporin 1 (Colton blood group)  -6.969067359 
205572_at 285 ANGPT2 angiopoietin 2  -7.511111563 
236034_at 285 ANGPT2 angiopoietin 2  -6.482834194 
235639_at 28513 CDH19 cadherin 19, type 2  6.235154529 
209901_x_at 199 AIF1 allograft inflammatory factor 1  -6.32542485 
213095_x_at 199 AIF1 allograft inflammatory factor 1  -7.499645133 
215051_x_at 199 AIF1 allograft inflammatory factor 1  -7.64616928 
1555460_a_at 25800 SLC39A6 solute carrier family 39 (zinc transporter), member 6  6.466383357 
220311_at 29104 N6AMT1 N-6 adenine-specific DNA methyltransferase 1 (putative)  6.090119758 
203240_at 8857 FCGBP Fc fragment of IgG binding protein  -6.279670112 
202628_s_at 5054 SERPINE1 
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), 
member 1  
-6.169187776 
201743_at 929 CD14 CD14 molecule  -9.061228844 
225400_at 116461 TSEN15 tRNA splicing endonuclease 15 homolog (S. cerevisiae)  6.564806667 
219386_s_at 56833 SLAMF8 SLAM family member 8  -6.439653705 
218345_at 55365 TMEM176A transmembrane protein 176A  -7.028336131 
219167_at 51285 RASL12 RAS-like, family 12  -7.447403055 






234023_s_at 55835 CENPJ centromere protein J  6.500186173 
209619_at 972 CD74 CD74 molecule, major histocompatibility complex, class II invariant chain  -6.392605538 
223434_at 2635 GBP3 guanylate binding protein 3  -7.428950443 
207054_at 3617 IMPG1 interphotoreceptor matrix proteoglycan 1  -7.236493758 
205374_at 6588 SLN sarcolipin  -6.139099986 
203535_at 6280 S100A9 S100 calcium binding protein A9  -6.508034002 
203571_s_at 10974 C10orf116 chromosome 10 open reading frame 116  -6.322842462 
204128_s_at 5983 RFC3 replication factor C (activator 1) 3, 38kDa  6.363690078 
218559_s_at 9935 MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian)  -6.671432912 
201842_s_at 2202 EFEMP1 EGF containing fibulin-like extracellular matrix protein 1  -6.040243322 
212268_at 1992 SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1  -6.972772922 
209723_at 5272 SERPINB9 serpin peptidase inhibitor, clade B (ovalbumin), member 9  -6.55138368 
223620_at 2857 GPR34 G protein-coupled receptor 34  -7.926594277 
219607_s_at 51338 MS4A4A membrane-spanning 4-domains, subfamily A, member 4  -8.180055654 
226034_at 1846 DUSP4 dual specificity phosphatase 4  6.838468179 
225314_at 132299 OCIAD2 OCIA domain containing 2  -8.275917817 
204990_s_at 3691 ITGB4 integrin, beta 4  -6.364422156 
203854_at 3426 CFI complement factor I  -6.363714998 
202310_s_at 1277 COL1A1 collagen, type I, alpha 1  -7.130038944 
1556499_s_at 1277 COL1A1 collagen, type I, alpha 1  -9.238542552 
213566_at 6039 RNASE6 ribonuclease, RNase A family, k6  -7.823580016 
204482_at 7122 CLDN5 claudin 5  -6.460963571 
221816_s_at 51131 PHF11 PHD finger protein 11  -6.825731298 
239132_at 4842 NOS1 nitric oxide synthase 1 (neuronal)  -6.386282534 
209395_at 1116 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39)  -10.14439331 
209396_s_at 1116 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39)  -9.362700349 
219719_at 51751 HIGD1B HIG1 hypoxia inducible domain family, member 1B  -6.669433848 
203540_at 2670 GFAP glial fibrillary acidic protein  -7.35128303 
201721_s_at 7805 LAPTM5 lysosomal protein transmembrane 5  -6.25877809 
232887_at 644139 PIRT phosphoinositide-interacting regulator of transient receptor potential channels  -6.331567906 
204787_at 11326 VSIG4 V-set and immunoglobulin domain containing 4  -7.189520229 
208161_s_at 8714 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3  -6.929235405 






202859_x_at 3576 IL8 interleukin 8  -8.035544596 
235417_at 90853 SPOCD1 SPOC domain containing 1  -6.444542888 
203835_at 2615 LRRC32 leucine rich repeat containing 32  -6.267902391 
202238_s_at 4837 NNMT nicotinamide N-methyltransferase  -6.6617682 
202237_at 4837 NNMT nicotinamide N-methyltransferase  -7.208303354 
229391_s_at 441168 FAM26F family with sequence similarity 26, member F  -6.297620939 
223467_at 51655 RASD1 RAS, dexamethasone-induced 1  -8.103012345 
239461_at 117248 GALNTL2 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2  
-7.696742518 
228501_at 117248 GALNTL2 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2  
-6.995008809 
205786_s_at 3684 ITGAM integrin, alpha M (complement component 3 receptor 3 subunit)  -6.272756493 
208747_s_at 716 C1S complement component 1, s subcomponent  -8.132346089 
201859_at 5552 SRGN serglycin  -8.765885577 
201858_s_at 5552 SRGN serglycin  -8.111413158 
207397_s_at 3239 HOXD13 homeobox D13  6.35025642 
1568604_a_at 8618 CADPS Ca++-dependent secretion activator  -7.030383795 
231068_at 146802 SLC47A2 solute carrier family 47, member 2  -8.52812485 
215049_x_at 9332 CD163 CD163 molecule  -7.402833043 
218729_at 56925 LXN latexin  -6.457187984 
209875_s_at 6696 SPP1 secreted phosphoprotein 1  -7.285379742 
200986_at 710 SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1  -8.060359753 
225353_s_at 714 C1QC complement component 1, q subcomponent, C chain  -7.877615852 






Table-S4. Results from Pathway Activation Score, Log Rank and Cox Regression analysis (NNI-8 GPC versus primary tumor gene 
signature) 
 (+) represent patients with concordance to GPC signature; (-) represent patients with inverse gene expression relationship to GPC signature 
 
Table-S5A. Activation scores, associated p-value and metadata of Rembrandt samples identified as (+) or (-) based on the NNI-8 GPC 






Score p-value Age 
Survival 
(mths) Status Histology Grade 
E08021 1.522597165 1 0 40 81.5 1 OLIGODENDROGLIOMA III 
E09448 1.422752629 0.934424851 0 60 229.1 1 OLIGODENDROGLIOMA III 
HF0891 1.303831733 0.856320873 0 35 28.8 1 GBM IV 
HF0142 1.288468221 0.84623054 0 25 0.3 1 GBM IV 
HF0066 1.216406036 0.798902076 0 50 9.1 1 GBM IV 
E10110 1.176753544 0.772859408 0 50 23.1 1 GBM IV 
HF0996 1.119487883 0.735248895 0 50 120.5 0 GBM IV 
E09804 1.103850023 0.724978378 0 70 42.4 0 OLIGODENDROGLIOMA II 
HF1136 1.084938272 0.712557659 0 35 45.3 1 ASTROCYTOMA III 
HF0108 1.077128487 0.707428407 0 35 132 0 ASTROCYTOMA III 
HF1227 1.074604481 0.705770709 0 50 251.7 0 OLIGODENDROGLIOMA II 
E10105 1.067544582 0.701133961 0 40 1.1 NA ASTROCYTOMA III 
E09278 1.050937357 0.690226792 0 40 36.6 0 GBM IV 
HF0920 1.049199817 0.689085624 0 40 1 1 OLIGODENDROGLIOMA II 
Dataset 
Connectivity Maps Analysis 
Log Rank 
p-value 





(+) (-) total (+)(-) %(+)(-) Hazard Ratio p-value Hazard Ratio p-value 



















E09867 1.04340192 0.685277724 0 75 38.7 0 OLIGODENDROGLIOMA II 
E09690 1.029117513 0.675896118 0 75 62.3 0 GBM IV 
E09893 1.027983539 0.675151355 0 40 111.9 1 OLIGODENDROGLIOMA III 
E09394 1.019807956 0.669781857 0 30 51.7 1 MIXED III 
HF1628 1.007590306 0.66175764 0 70 14.6 1 GBM IV 
E09802 0.99482396 0.653373054 0 80 32.2 1 GBM IV 
HF0184 0.987032465 0.648255814 0 65 12 1 OLIGODENDROGLIOMA III 
HF0975 0.978033836 0.642345762 0 60 36.5 1 ASTROCYTOMA III 
HF0251 0.974357567 0.63993129 0 65 22.7 1 OLIGODENDROGLIOMA III 
HF1382 0.962780064 0.632327503 0 35 48.3 1 GBM IV 
HF1511 0.960128029 0.63058572 0 25 56.6 1 ASTROCYTOMA II 
E09722 0.958006401 0.629192293 0 50 28.5 1 GBM IV 
HF1587 0.919524463 0.603918412 0 30 75.3 0 ASTROCYTOMA III 
HF0180 0.911165981 0.598428791 0.0105 35 0.3 1 GBM IV 
HF1677 0.903978052 0.593707957 0 50 63.5 0 ASTROCYTOMA II 
E09656 0.891229995 0.585335383 0 65 34.1 1 OLIGODENDROGLIOMA III 
HF1551 0.888523091 0.583557563 0 30 70.9 0 ASTROCYTOMA II 
E10299 0.878079561 0.576698539 0 40 44.6 0 ASTROCYTOMA II/III 
HF1613 0.870233196 0.571545262 0 35 66.8 1 ASTROCYTOMA III 
E10013 0.860045725 0.564854411 5.00E-04 55 4.9 1 GBM IV 
E09855 0.850022862 0.55827167 0.0247 25 38.4 0 ASTROCYTOMA III 
E10252B 0.846566072 0.556001345 0 55 53 1 GBM IV 
E09988 0.84526749 0.555148472 0 70 64.6 1 OLIGODENDROGLIOMA III 
HF0702 0.831184271 0.545899001 0.0011 50 8.5 1 ASTROCYTOMA III 
E09818 0.829263832 0.544637709 0 30 38.1 0 ASTROCYTOMA II/III 
E09997 0.827471422 0.543460504 0 35 46.9 0 ASTROCYTOMA II/III 
E09966 0.822496571 0.540193158 0.002 55 17.7 1 ASTROCYTOMA III 
HF1469 0.821326017 0.539424371 0 25 22.2 1 GBM IV 
HF1640 0.81911294 0.537970882 0 50 5.5 1 GBM IV 
HF1295 0.80175583 0.526571209 0 55 19.1 1 ASTROCYTOMA III 
E09688 0.800877915 0.525994618 0 55 50.8 1 MIXED II 
E10267 0.789062643 0.518234672 0 75 12 1 GBM IV 






E09454 0.760987654 0.499795791 0 55 18 1 GBM IV 
HF1344 0.758536808 0.498186143 0 60 9 1 ASTROCYTOMA II 
E10262 0.755884774 0.496444359 0.0074 50 18 1 GBM IV 
E09569 0.738052126 0.484732366 0 70 37.4 1 GBM IV 
E10211 0.736131687 0.483471074 0 85 28.4 1 GBM IV 
E09920 0.725761317 0.4766601 0.0074 25 59.4 1 ASTROCYTOMA III 
E10271 0.722981253 0.47483423 0.0044 30 12.5 1 GBM IV 
HF1191 0.715116598 0.469668941 6.00E-04 25 0.3 1 GBM IV 
E09959 0.713580247 0.468659908 0 50 46.4 1 ASTROCYTOMA III 
HF0966 0.709958848 0.466281472 2.00E-04 50 137.7 0 ASTROCYTOMA III 
E50123 0.674183813 0.442785412 0 30 17.5 1 GBM IV 
E10001 0.672610882 0.441752354 0 50 8.7 1 OLIGODENDROGLIOMA III 
HF0960 0.669666209 0.439818374 0 45 88.7 1 OLIGODENDROGLIOMA II 
E10252 0.666575217 0.437788295 0 55 53 1 GBM IV 
HF1490 0.665532693 0.437103594 0.0025 65 4 1 ASTROCYTOMA III 
HF0990 0.651906722 0.42815443 0 NA 88.3 1 GBM IV 
E09860 0.621490626 0.408177974 0 40 36.8 0 OLIGODENDROGLIOMA II 
HF1338 0.604572474 0.397066596 0 35 5.9 1 GBM IV 
E09956 0.604444444 0.39698251 0 70 21 1 GBM IV 
HF0963 0.566035665 0.371756679 0.009 10 10.6 1 GBM IV 
E09610 0.565743027 0.371564482 0.0243 55 12.5 1 GBM IV 
HF1057 0.554513032 0.364188929 0.0021 55 24.5 1 OLIGODENDROGLIOMA III 
E09623 0.547379973 0.359504132 3.00E-04 50 20.7 1 GBM IV 
E10184 0.541033379 0.355335864 0 30 28.3 1 GBM IV 
HF1487 0.530132602 0.348176533 0 50 9.9 1 OLIGODENDROGLIOMA II 
E09921 0.511476909 0.335923986 0 40 36.4 0 ASTROCYTOMA II/III 
HF0442.5 0.509044353 0.33432635 0.0137 30 19.6 1 GBM IV 
HF0992 0.496607225 0.326157986 2.00E-04 30 20 1 GBM IV 
E10144 0.477750343 0.313773304 0.0012 50 25.9 1 GBM IV 
E10138 0.459789666 0.301977225 2.00E-04 25 46.9 0 ASTROCYTOMA II/III 
E09801 0.459021491 0.301472708 5.00E-04 30 42.5 1 ASTROCYTOMA III 
HF0654 0.387965249 0.25480492 0.0299 20 14.6 1 GBM IV 






HF0816 -0.432245085 -0.40731102 0.0376 60 46.7 1 OLIGODENDROGLIOMA III 
E09471 -0.454631916 -0.428406467 0.0028 70 27.2 1 ASTROCYTOMA II 
HF1534 -0.478372199 -0.450777291 7.00E-04 20 7.8 1 GBM IV 
E10226 -0.53223594 -0.501533901 0.0285 65 18.7 1 GBM IV 
E10031 -0.545569273 -0.514098101 0.0032 55 27.5 1 GBM IV 
HF0316 -0.551641518 -0.519820068 0 40 73.4 1 ASTROCYTOMA II 
HF0954.2 -0.593379058 -0.559149978 0 70 11 1 ASTROCYTOMA III 
HF0606 -0.612821216 -0.577470615 0 30 76.8 1 ASTROCYTOMA II 
E09451 -0.636707819 -0.599979318 0 60 5.3 1 GBM IV 
HF0024 -0.649272977 -0.611819655 0 45 5.8 1 GBM IV 
E09664 -0.661088249 -0.622953363 0.0094 40 27.1 1 OLIGODENDROGLIOMA II/III 
E09673 -0.665441244 -0.627055255 0 45 213.8 0 ASTROCYTOMA II 
E10158 -0.667142204 -0.628658095 0 70 40.6 0 GBM IV 
HF0844 -0.672281664 -0.633501086 0 30 63.8 1 ASTROCYTOMA II 
HF1538 -0.68349337 -0.644066044 0 55 3.2 1 GBM IV 
E10193 -0.687242798 -0.647599187 0 50 34.2 NA GBM IV 
HF1671 -0.689437586 -0.649667368 0 50 13.3 1 GBM IV 
E10284 -0.691687243 -0.651787253 0 55 4.8 1 GBM IV 
HF1077 -0.697960677 -0.657698804 0 45 73.4 1 GBM IV 
HF1137 -0.711074531 -0.670056186 0 35 18.3 1 GBM IV 
E09430 -0.715354367 -0.674089139 0 45 32 1 GBM IV 
HF0543 -0.715628715 -0.674347661 0 30 67.6 0 GBM IV 
E09483 -0.715829904 -0.674537244 0 65 10.3 1 GBM IV 
E10514 -0.716671239 -0.675330047 0 75 23.7 1 GBM IV 
HF0089 -0.72698674 -0.685050498 0 65 7.9 1 ASTROCYTOMA III 
E10551 -0.734192958 -0.691841026 0 65 12.3 1 GBM IV 
E09661 -0.739515318 -0.696856365 0 65 48.5 0 OLIGODENDROGLIOMA II 
E10488 -0.758774577 -0.715004653 0 55 21.9 1 GBM IV 
E10103 -0.764389575 -0.72029575 0 50 3.3 1 ASTROCYTOMA II/III 
E09930 -0.772565158 -0.727999724 0 50 5.1 1 GBM IV 
E09531 -0.773699131 -0.729068284 0 55 19.3 1 ASTROCYTOMA II/III 
HF1178 -0.788367627 -0.742890628 0 35 15.8 1 GBM IV 






E09649 -0.804773663 -0.758350281 0 70 9.7 1 GBM IV 
HF0757 -0.813644262 -0.766709179 0 40 74.9 1 ASTROCYTOMA II 
HF0460 -0.816899863 -0.769776981 0 45 10.7 1 OLIGODENDROGLIOMA III 
HF1246 -0.829721079 -0.781858605 0 65 0.2 1 ASTROCYTOMA II 
E09602 -0.841481481 -0.792940609 0 60 4.1 1 GBM IV 
E10227 -0.845834476 -0.797042501 0 45 12.6 1 GBM IV 
E09239 -0.849419296 -0.80042053 0 30 63.3 1 ASTROCYTOMA III 
E09331 -0.864618198 -0.814742684 0 55 38.9 0 GBM IV 
E10290 -0.880951075 -0.830133398 0 30 6.9 1 GBM IV 
E10077 -0.88698674 -0.835820896 0 55 25.8 1 GBM IV 
E10300 -0.88870599 -0.837440971 0 60 9.4 1 GBM IV 
E09334 -0.89223594 -0.840767295 0 50 85.2 1 MIXED III 
E10305 -0.90434385 -0.852176761 0 40 10.1 1 GBM IV 
HF1585 -0.910068587 -0.857571266 0 25 19.9 1 GBM IV 
HF0953 -0.940283493 -0.886043225 0 35 44.6 1 ASTROCYTOMA II 
E09348 -0.942075903 -0.887732239 0 35 18.5 1 GBM IV 
E10002 -0.944691358 -0.890196822 0 55 8.4 1 GBM IV 
HF1356 -1.01733882 -0.958653614 0 50 13.5 1 GBM IV 
HF0608 -1.035354367 -0.975629933 0 50 10.6 1 ASTROCYTOMA II 
HF1220 -1.039433013 -0.979473303 0 35 10.4 1 GBM IV 
E09759 -1.061216278 -1 0 45 20.1 1 GBM IV 
  
Table-S5B. Activation scores, associated p-value and metadata of Gravendeel samples identified as (+) or (-) based on the NNI-8 GPC 










(yrs) Status Histology Grade CHR1p CHR19q IDH1 EGFR 
GSM405467 1.226995885 1 0 43.9 1.34 1 OLIGODENDROGLIOMA III no LOH no LOH mutation wild type 
GSM405476 1.216186557 0.991190412 0 64.97 1.31 1 OLIGOASTROCYTOMA III no LOH no LOH 
no 
mutation amplification 
GSM405475 1.200091449 0.978072921 0 33.74 1.05 1 GBM IV NA NA 
no 






GSM405431 1.147946959 0.935575232 0 80.65 0.92 1 GBM IV no LOH no LOH 
no 
mutation wild type 
GSM405210 1.13399177 0.924201771 0 38.53 10.28 1 OLIGODENDROGLIOMA III LOH LOH mutation wild type 
GSM405399 1.132766347 0.923203053 0 52.07 1.18 1 OLIGOASTROCYTOMA III no LOH NA 
no 
mutation amplification 
GSM405349 1.128376772 0.919625555 0 24.42 2.41 1 GBM IV NA NA 
no 
mutation wild type 
GSM405246 1.126127115 0.917792088 0 32.59 6.31 1 GBM IV LOH LOH mutation NA 
GSM405369 1.106776406 0.902021286 0 50.34 4.13 1 GBM IV LOH LOH mutation wild type 
GSM405201 1.089437586 0.887890171 0 44.57 9.82 1 OLIGODENDROGLIOMA III LOH LOH mutation NA 
GSM405208 1.088834019 0.887398265 0 51.4 3.04 1 OLIGODENDROGLIOMA III LOH LOH mutation wild type 
GSM405338 1.064581619 0.867632591 0 50.23 7.96 1 OLIGODENDROGLIOMA II LOH LOH mutation wild type 
GSM405370 1.054485597 0.859404347 0 46.52 1.61 1 GBM IV no LOH no LOH 
no 
mutation wild type 
GSM405323 1.005102881 0.819157499 0 58.78 0.62 1 GBM IV NA NA 
no 
mutation amplification 
GSM405319 1.003950617 0.818218406 0 53.65 5.62 1 OLIGODENDROGLIOMA III LOH LOH mutation NA 
GSM405257 1.000164609 0.815132815 0 46.04 10.86 0 OLIGODENDROGLIOMA III LOH LOH mutation wild type 
GSM405437 0.981545496 0.799958263 0 51.63 3.44 0 OLIGODENDROGLIOMA II NA NA mutation NA 
GSM405378 0.975290352 0.794860329 0 57.22 0 1 OLIGODENDROGLIOMA II NA NA 
no 
mutation wild type 
GSM405382 0.972491998 0.792579674 0 44.15 4.86 1 OLIGOASTROCYTOMA III LOH LOH NA NA 
GSM405227 0.967773205 0.788733864 0 48.1 4.77 1 OLIGODENDROGLIOMA III NA NA NA NA 
GSM405449 0.95820759 0.780937901 0 45.39 2.02 1 OLIGODENDROGLIOMA III LOH LOH 
no 
mutation wild type 
GSM405247 0.941362597 0.767209254 0 39.36 1.59 1 GBM IV no LOH no LOH 
no 
mutation NA 
GSM405420 0.939899406 0.766016755 0 49.94 3 1 OLIGODENDROGLIOMA III no LOH no LOH mutation wild type 
GSM405327 0.937796068 0.764302537 0 66.86 3.3 1 OLIGODENDROGLIOMA III LOH LOH mutation wild type 
GSM405329 0.936406036 0.763169663 0 60.33 5.02 1 OLIGODENDROGLIOMA III LOH LOH mutation NA 
GSM405212 0.936296296 0.763080225 0 23.33 17.49 1 OLIGODENDROGLIOMA III LOH LOH 
no 
mutation wild type 
GSM405204 0.929382716 0.757445667 0 33.89 8.59 1 OLIGODENDROGLIOMA III LOH LOH 
no 
mutation wild type 






GSM405234 0.882725194 0.719419849 0 57.68 0.62 1 GBM IV NA NA NA NA 
GSM405347 0.875793324 0.713770384 0 43.11 0.19 1 OLIGOASTROCYTOMA III NA NA mutation amplification 
GSM405441 0.871568358 0.710327043 0 44.74 3.27 0 OLIGODENDROGLIOMA II LOH LOH 
no 
mutation wild type 
GSM405308 0.868696845 0.707986763 0 47.4 3.1 0 GBM IV NA NA mutation NA 
GSM405377 0.859625057 0.700593268 
0.007
1 41.98 0.6 1 OLIGODENDROGLIOMA III LOH LOH 
no 
mutation NA 
GSM405434 0.848870599 0.691828399 0 67.01 0.24 1 GBM IV NA NA NA NA 
GSM405386 0.84528578 0.688906776 0 53.85 3.76 1 OLIGODENDROGLIOMA II LOH LOH mutation wild type 
GSM405232 0.844078647 0.687922965 0 35.7 0.98 1 GBM IV no LOH no LOH mutation wild type 
GSM405223 0.839561043 0.684241123 0 53.26 1.92 1 GBM IV NA NA 
no 
mutation amplification 
GSM405207 0.835976223 0.6813195 0 44.41 8.12 1 OLIGODENDROGLIOMA III LOH LOH 
no 
mutation wild type 
GSM405366 0.833836305 0.67957547 0 75.13 2.21 1 OLIGODENDROGLIOMA III LOH LOH mutation wild type 
GSM405388 0.817704618 0.666428167 0 78.52 0.53 1 OLIGOASTROCYTOMA III no LOH no LOH 
no 
mutation amplification 
GSM405337 0.816479195 0.665429449 0 15.02 0.28 1 GBM IV NA NA 
no 
mutation amplification 
GSM405344 0.81571102 0.664803387 0 34.71 1.19 1 OLIGODENDROGLIOMA II 
partial 
LOH no LOH 
no 
mutation wild type 
GSM405253 0.794549611 0.647556867 
4.00E
-04 34.84 12.56 0 GBM IV no LOH no LOH 
no 
mutation NA 
GSM405330 0.794494742 0.647512149 0 33.12 0.71 1 GBM IV no LOH NA mutation wild type 
GSM405380 0.786465478 0.640968309 0 39.99 6.04 1 OLIGODENDROGLIOMA III LOH LOH mutation wild type 
GSM405289 0.767480567 0.625495632 0 37.44 0.19 1 ASTROCYTOMA III NA NA 
no 
mutation amplification 
GSM405341 0.766620942 0.624795039 0.072 71.11 0.63 1 OLIGOASTROCYTOMA III NA NA mutation amplification 
GSM405316 0.742386831 0.605044272 0 40.06 10.34 1 OLIGOASTROCYTOMA III NA NA 
no 
mutation wild type 
GSM405461 0.737997257 0.601466774 0 49.14 0.76 1 GBM IV LOH LOH 
no 
mutation wild type 
GSM405318 0.725358939 0.591166562 0 62.46 6.21 0 OLIGODENDROGLIOMA III no LOH no LOH mutation NA 
GSM405383 0.711970736 0.580255195 0.029 37.6 1.32 1 ASTROCYTOMA II no LOH no LOH 
no 






GSM405231 0.707599451 0.576692604 0.0017 62.96 1.26 1 GBM IV no LOH no LOH NA NA 
GSM405312 0.697082762 0.568121516 0 61.31 1.02 1 GBM IV NA NA 
no 
mutation amplification 
GSM405292 0.685980796 0.559073428 0 65.52 1.11 1 GBM IV NA NA 
no 
mutation amplification 
GSM405396 0.682414266 0.556166711 
2.00E-
04 77.31 0.02 1 GBM IV no LOH no LOH mutation NA 
GSM405309 0.682359396 0.556121993 0.004 54.6 0.26 1 GBM IV NA NA mutation NA 
GSM405220 0.668971193 0.545210625 0 54.12 1.27 1 GBM IV NA NA 
no 
mutation wild type 
GSM405225 0.667636031 0.54412247 0 31.56 3.47 1 OLIGOASTROCYTOMA III no LOH no LOH NA wild type 
GSM405249 0.660027435 0.537921474 0 23.02 0.04 1 GBM IV NA NA mutation wild type 
GSM405468 0.65395519 0.532972602 0 33.48 7.04 0 
PILOCYTIC 
ASTROCYTOMA I NA NA 
no 
mutation NA 
GSM405215 0.651083676 0.530632323 0.0056 51.44 2.3 1 GBM IV no LOH no LOH 
no 
mutation NA 
GSM405460 0.644554184 0.525310795 0 52.52 0.48 1 OLIGODENDROGLIOMA III no LOH no LOH 
no 
mutation amplification 
GSM405303 0.643219021 0.52422264 0.0055 56.64 0.55 1 GBM IV NA NA 
no 
mutation NA 
GSM405352 0.638372199 0.520272486 0 69.95 0.4 1 GBM IV NA NA 
no 
mutation amplification 
GSM405427 0.633763146 0.516516114 0.0014 50.83 1.53 1 GBM IV NA NA NA NA 
GSM405262 0.63122085 0.514444146 0.0062 43.26 2.89 1 GBM IV NA NA 
no 
mutation amplification 
GSM405392 0.616680384 0.502593686 0.0161 48.35 0.47 1 GBM IV NA no LOH NA NA 
GSM405284 0.613260174 0.499806219 0 57.7 1.6 1 OLIGOASTROCYTOMA III no LOH no LOH NA amplification 
GSM405242 0.60696845 0.494678472 0.0119 30.33 0.18 1 GBM IV NA NA NA NA 
GSM405363 0.605724737 0.493664848 
2.00E-
04 48.84 9.79 1 GBM IV no LOH no LOH mutation wild type 
GSM405385 0.602487426 0.491026444 0 34.78 1.26 0 GBM IV no LOH NA mutation NA 
GSM405391 0.599725652 0.488775601 0.0071 55.55 1.05 1 GBM IV no LOH no LOH NA NA 
GSM405355 0.598171011 0.487508571 0.013 73.19 1.19 1 ASTROCYTOMA II NA NA 
no 
mutation NA 






GSM405372 0.572748057 0.466788898 0 37.12 3.32 1 GBM IV LOH LOH NA NA 







GSM405281 0.561847279 0.457904779 0 37.12 3.32 1 ASTROCYTOMA III NA NA 
no 
mutation NA 
GSM405205 0.557274806 0.454178219 0.006 48.03 3.24 1 OLIGODENDROGLIOMA III LOH LOH mutation wild type 
GSM405302 0.543557385 0.442998539 0.0107 41.39 0.74 1 GBM IV NA NA 
no 
mutation amplification 
GSM405339 0.53907636 0.43934651 
9.00E-
04 78.08 NA 0 GBM IV NA NA 
no 
mutation amplification 
GSM405419 0.518829447 0.422845303 0.0073 36.27 2.93 1 GBM IV NA NA mutation wild type 
GSM405483 0.50780064 0.41385684 
6.00E-
04 32.35 0.19 0 
PILOCYTIC 
ASTROCYTOMA I NA NA 
no 
mutation NA 
GSM405362 0.507123914 0.41330531 
4.00E-
04 38.11 1.06 1 GBM IV no LOH no LOH 
no 
mutation NA 
GSM405422 0.494759945 0.403228692 
1.00E-
04 70.67 0.91 1 GBM IV no LOH no LOH 
no 
mutation NA 
GSM405325 0.468020119 0.381435769 
4.00E-
04 42.98 3.65 1 OLIGOASTROCYTOMA III NA NA mutation wild type 
GSM405203 0.458655693 0.373803774 0 38.58 8.92 1 OLIGODENDROGLIOMA III LOH LOH 
no 





0.352486153 0.0119 71.02 0.35 1 GBM IV NA NA 
no 

































0.462118801 0 79.19 1.64 1 OLIGODENDROGLIOMA III no LOH no LOH 
no 
mutation wild type 
GSM405368 -0.55473251 
-















0.485945757 0.0111 68.18 0.73 1 GBM IV NA no LOH mutation NA 
GSM405470 -0.56354824 
-

























































0.532055771 0 61.74 1.55 1 GBM IV NA NA 
no 










0.614302698 -0.53458649 0.0168 41.09 0.29 1 GBM IV no LOH no LOH 
no 





0.548990896 0.0028 49.64 0.45 1 ASTROCYTOMA III no LOH NA 
no 



















0.560339339 0 69.89 0.3 1 GBM IV NA NA NA NA 
GSM405365 -0.66085048 
-

















0.578054371 0 37.84 1.5 1 GBM IV no LOH no LOH 
no 





0.587110842 0.0011 11.72 0.03 0 
PILOCYTIC 

















0.609537149 0 57.01 1.47 1 OLIGODENDROGLIOMA III no LOH no LOH NA wild type 
GSM405393 
-



















0.618720952 0 65.53 2.22 1 GBM IV NA no LOH 
no 
mutation wild type 
GSM405261 -0.71303155 
-
0.620503597 0 60.46 0.98 1 OLIGODENDROGLIOMA III no LOH no LOH mutation NA 
GSM405477 -0.71478738 
-















































0.683819316 0 65.35 0.3 1 GBM IV NA NA NA NA 
GSM405233 -0.79310471 
-
0.690185904 0 51.64 0.86 1 GBM IV NA NA 
no 




































0.754281531 0 63.61 0.3 1 GBM IV NA NA 
no 















0.759549882 0 38.4 6.08 0 ASTROCYTOMA III no LOH no LOH 
no 





0.764977399 0 70.98 0.3 1 OLIGODENDROGLIOMA III no LOH no LOH 
no 



















0.784984402 0 70.28 0.6 1 GBM IV NA NA 
no 






























0.940448102 -0.81840899 0 58.58 1.21 1 GBM IV LOH LOH 
no 
mutation wild type 
GSM405456 -0.94083219 
-







































0.916327115 0 61.1 0.35 1 GBM IV no LOH no LOH 
no 





0.942048131 0 32.14 1.81 1 ASTROCYTOMA III NA NA 
no 
mutation wild type 
GSM405459 
-







0.959699497 0 63.3 0.38 1 GBM IV NA NA mutation amplification 
 
Table-S6. Confusion Matrix for cross validation of Phillips Classification signature 
 Predicted  
Mesenchymal Proneural Proliferative Class Error Rate 
Actual 
Mesenchymal 30 0 5 0.14285714 
Proneural 2 34 1 0.08108108 
Proliferative 4 0 24 0.14285714 
 Overall Error Rate 0.12 
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Table-S7. 50 compounds from Eli Lilly targets common oncologic pathways. 
Table of 50 small molecules from Eli Lilly, showing the targeting of common 
oncologic pathways in our GPCs.  
 




3 PPARα, PPARγ 
16 PPARα, PPARγ 
4 PI3Kα 
31 mTOR, PI3Kα 
42 mTOR, PI3Kα 
43 mTOR, PI3Kα 
46 mTOR, PI3Kα 
7 mTOR 
5 GSK3β, CDK2, CDK4 
8 GSK3β, CDK1, CDK2 
6 GSK3β > PKCβ (~ 10×) 
9 GSK3β, CDK2, CDK4, PKCα/β 
12 GSK3β > IKKα (~ 10×) 
14 GSK3β 
24 CDK1, CDK2, CDK4, CDK6 
37 CDK1, CDK4, CDK9 
39 CDK1, TAK1 
40 CDK1, CDK9, TAK1 
44 CDK9 > CDK7 (~ 10×) 
45 CDK9 
48 CDK9 
19 AurA, TAK1 
11 p70s6, PKAα, AKT 
41 p70s6, PKA, PKCβ2, PKCε 
33 p70s6, PLK1, FLT3 
22 PLK1, PLK3 
35 PLK1, PLK3 
50 PLK1, PLK3 
25 ABL1, FLT3 
23 ABL1, EphB4, FLT3, DDR2, FGFR1, KDR 
27 ABL1, EphB2 > EphB4 (~ 10×) 
36 EphB4, EphB2, FGFR1/3 
32 JAK2 >> AurA/B, FGFR1/3, JAK3 (~ 20-40×) 
13 TGFβR1 
29 TGFβR1 





38 MMP2, 3, 12, 13 
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Figure-S1A. Top 10 process networks generated from oligodendroglial GPC 
gene signature using GeneGo analysis. The “oligodendroglial GPC gene signature” 














Figure-S1B. Notch signaling identified from GeneGo Process Network.   Red circles indicate the 4 key genes (JNK, SFRP3, WNT, 
Skp2/TrCP/FBXW) up-regulated while blue circles indicate the key gene (EGFR) down-regulated in the OA GPC signature. All other genes 






   
Figure-S1C. TGF, GDF and Activin signaling identified from GeneGo Process Network.   Red circles indicate the 3 key genes (PKC, 
PP2A, JNK) up-regulated while blue circles indicate the key gene (EGFR) down-regulated in the OA GPC signature. All other genes shown 








Figure-S1D. WNT signaling identified from GeneGo Process Network.   Red circles indicate the 4 key genes (JNK, PP2A, WNT, WNT4) 
up-regulated while blue circles indicate the key gene (EGFR) down-regulated in the OA GPC signature. All other genes shown depict the 




Figure-S2. “NNI-8 GPC versus primary tumor” gene signature stratifies patient 
survival. Patient survival is shown in all glioma patients. Tumor grade (“Grade”) and 
molecular classification (“Phillips”10) distribution corresponding to (+) and (-) classes 







Figure-S3. Oligodendroglial GPCs express OPC markers. Oligodendroglial tumor 
GPCs (OA) of NNI-8 and Pollard reflect higher immature OPC marker expression
167
, 
Olig2, Nkx2.2 and GalC, in comparison to GBM GPCs (GBM). The Gunther line 
expresses mature oligodendrocyte marker, GalC, and may reflect its diagnosis as a 
GBM with oligodendroglial features 
